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Abstract 
Herbal medicine is getting popular worldwide in treating various diseases/conditions.  
Danshen (dried root of Salvia miltiorrhiza) is a traditional Chinese herbal medicine and has 
long been used for relieving symptoms of cardiovascular disorders like angina and 
hypertension. Tanshinone IIA (TIIA) and cryptotanshinone (CT) are major bioactive 
compounds isolated from Danshen and have been reported with actions against inflammation, 
oxidative stress, and myocardial ischemia reperfusion injury. However, the mechanisms of 
these compounds on chronic hypoxia induced apoptosis have not been fully understood. The 
objective of this study is to investigate cytoprotective effects of tanshinones and relevant 
molecular mechanisms involved against hypoxia injury.  
 
Firstly, an in vitro chronic hypoxia injury model was set out in H9c2 cell, which is derived 
from rat cardiomyocytes with similar characteristic to primary cardiomyocyte cells. Cells 
were subjected to a 8 hr hypoxia period and then various markers for cell apoptosis 
(cytochrome c, Bcl-2 proteins and membrane potential) and oxidative stress (O2
-
, H2O2, 
superoxide dismutase and NO) were measured in the presence and absence of TIIA, CT or 
Compound 1 (Com1: a synthetic compound derived from TIIA) which were treated for 2 hr 
pre and during 8 hr hypoxia period. 
 
H9c2 cells in hypoxia condition exhibited a significant decrease in cell viability (35% cell 
death rate). This was accompanied with significant increase in LDH enzyme release (2.2 fold 
increase) and HIF-1α expression (1.7 fold increase). The chronic hypoxia induced cell death 
was characterized with late stage of apoptosis (6.6 fold higher than normoxia group), increase 
in caspase 3 activity and cytochrome c release, hyperpolarization of mitochondria membrane 
potential and expression of pro-apoptosis proteins (Bax and Bak). This chronic hypoxia 
- 3 - 
 
induced cell apoptosis was also associated with increased mitochondrial superoxide and 
intracellular NO productions and inhibited mitochondrial superoxide dismutase activity. 
Additionally, ATP depletion and elevation of intracellular calcium were also observed.  
 
TIIA and CT (0.3 and 3 μΜ), in concentrations without affecting the cell viability, 
significantly inhibited the late apoptosis rate (2.4 and 1.8 fold decrease by 3 μM TIIA and CT, 
repectively, compared to hypoxia control). These compounds also significantly inhibited 
caspase 3 activity, cytochrome c release, and hyperpolarization of mitochondrial membrane 
potential. The hypoxia-induced overexpression of Bax was significantly suppressed by 3 μM 
TIIA and 3 μM CT (103.4% and 109.3%, respectively, compared to hypoxia control), 
resulting a decreased ratio of Bax/Bcl-2. TIIA showed a slightly higher inhibition of 
cytochrome c release than CT. In addition, the hypoxia-induced increase in mitochondrial 
superoxide production, but not hydrogen peroxide/peroxinitrite production, was inhibited by 
TIIA and CT. TIIA and CT markedly enhanced mitochondria superoxide dismutase activity 
compared to hypoxia and normoxia group. Excess production of nitric oxide by hypoxia was 
inhibited by TIIA and CT. TIIA also inhibited the increase in [Ca
2+
]i and restored hypoxia 
induced ATP depletion.   
 
Com1 (0.3 μΜ and 3 μΜ) inhibited the hypoxia-induced increase in late apoptosis by 2.8 and 
2.4 fold, respectively, compared to the hypoxia control. It also markedly inhibited 
hyperpolarization of mitochondrial membrane potential (52.2% and 97.8%), cytochrome c 
release (84.0% and 102.1%) and reduced Bax/Bcl-2 ratio. Com1 also inhibited hypoxia-
induced productions of mitochondrial superoxide hydrogen peroxide/peroxinitrite. Excess 
production of nitric oxide, increase in [Ca
2+
]i and ATP depletion induced by hypoxia was 
- 4 - 
 
inhibited or restored by Com1.  Com1 was more effective in increase in Bcl-2 protein 
expression than TIIA.  
The results indicate that TIIA, CT and Com1 all protect against chronic hypoxia induced cell 
injury and apoptosis. These compounds acts on mitochondrial apoptosis signaling pathway by 
multiple mechanisms, by reducing mitochondria hyperpolarization, inhibiting cytochrome c 
release and caspase 3 activity, and balancing anti- and pro-apoptotic proteins in Bcl-2 family 
proteins. They also have antioxidant effects by reducing mitochondrial superoxide production, 
NO production and enhancing MnSOD activity, as well as effects of regulating cellular ATP 
content and intracellular calcium level. These findings provide evidence for molecular 
mechanisms involved in the cardioprotective actions of tanshinones against hypoxia induced 
cell injury. As hypoxia is an important contributor of ischemia cardiac injury, preventing 
hypoxia induced cell damages may minimize ischemia reperfusion injury. In this regard, 
understanding the mechanism of actions of tanshinones and related compounds may help to 
develop new therapeutic agents to treat hypoxia/ischemia injury and heart disease.  
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HIF-1α Hypoxia Inducible Factor-1α 
I/R Ischemia Reperfusion 
ICAM-1  IntraCellular AdhesionMolecule-1 
IHD Ischemia Heart Disease 
IL-1β  Interleukein-1β 
IL-6  Interleukin-6 
iNOS inducible  Nitric Oxide Synthases 
LDH  Lactate Dehydrogenase 
LDL Low-Density Lipoproteins  
L-NAME L-NG-Nitroarginine Methyl Ester 
MAPKs Mitogen-activated protein kinases 
MCP-1 Monocyte Chemoattractant Protein-1 
MDA Malondialdehyde 
MDA  Malondialdehyde 
MI Myocardial Infarction 
MMP-9 Matrix Metallo Proteinases-9 
mNOS Mitochondrial  Nitric Oxide Synthases 
MnSOD Manganese superoxide dismutase 
MPO Myeloperoxidase 
MPO Myeloperoxidase 
MPTP Mitochondria Permeability Transition Pore  
NCX Sodium Calcium Exchanger  
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NF-kB Nuclear Factor-κB 
NO Nitric Oxide 
Nrf2  Nuclear-factor-E2-related factor  
O2
-
 Superoxide radical 
ONOO
-
 Peroxinitrite 
PCNA Proliferating cell nuclear antigen 
PI Propidium Iodide 
PI3K  Phosphatidylinositol-3-kinase 
PPARγ Peroxisome Proliferator Activated Receptor gamma 
RNS Reactive Nitrogen species 
ROS Reactive Oxygen species 
RT  Room Temperature 
SD  Standard Deviation 
SfA Sanglipherin A  
SOD Superoxide dismutase 
SRA Scavenger receptor A 
TGF-β1 Transforming growth factor beta β1 
TIIA Tanshinone IIA 
TMRM Tetramethyl Rhodamine Methyl Ester 
TNFR Tumor necrosis factor receptor  
TNF-α  Tumour Necrosis Factor α 
TUNEL Terminal deoxynucleotide transferase-mediated dUTP nick end labelling 
VCAM-1 Vascular Cell AdhesionMolecule-1 
VSMCs Vascular smooth muscle cells  
Δψ Mitochondrial membrane potential  
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1.1 Ischemic heart diseases 
Ischemia heart disease (IHD) is the most common cause of death worldwide [1]. It has been 
the leading cause of death over last 10 years in Australia[2]. IHD is a disease characterized 
by ischemia (reduced blood/oxygen supply) of the heart, usually due to thrombosis, spasms 
or alterations of coronary vessel activity and atherosclerotic plaques. IHD is classified into 
stable and unstable forms. Stable IHD includes angina (characteristic chest pain on exertion) 
and decreased exercise tolerance. Unstable IHD presents itself as chest pain or other 
symptoms at rest or rapidly worsening angina that attributes to plaque rupture and form of 
adherent blood clot.  Diagnosis of IHD is through examination of an electrocardiogram, 
cardiac markers, cardiac stress testing or a coronary angiogram.  
General risk factors of IHD are smoking, high cholesterol, genetic factors and diabetes 
complication as result of building plaques in cardiac vessel [2]. The risk of IHD increases 
with age and more prevalent in men then woman. Lifestyle factors (e.g., smoking, poor 
dietary intake) can result in hypercholesterolemia (high cholesterol levels), diabetes, and 
hypertension (high blood pressure) [3-4]. The general development of IHD is illustrated in 
Figure 1.1. In order to reduce the risks of IHD, it is important to understand the underlying 
cellular mechanisms of IHD.  
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Figure 1.1 Development of IHD. The risk of IHD increases with ischemia, atherosclerosis 
diabetes and hypertension. Chronic inflammation response and oxidative stress also 
contribute to promote IHD. With the onset of IHD, cardiomyocytes undergo hypoxia and in 
turn induces cell apoptosis when hypoxia condition persists [5]. 
 
1.2 Molecular mechanisms of IHD 
IHD is influenced by various factors, in particular, chronic inflammation and oxidative stress 
[5]. Inflammation is a key factor of coronary disease including the initiation and progression 
of atherosclerotic plaque, plaque rupture, and thrombosis. Major signalling molecules of 
inflammation response in IHD includes inducible NO synthase (iNOS), cyclooxygenase-2 
(COX-2), and interleukein-1β (IL-1β) and NF-kB, a transcription factor that up-regulates the 
production of downstream inflammatory mediators such as tumor necrosis factor-α [6]. 
Oxidative stress is known to contribute to pathophysiology of atherosclerosis and acute 
thrombotic events [7]. The role of oxidative stress in IHD pathophysiology includes the 
oxidation of low-density lipoprotein, endothelial dysfunction, plaque rupture, and myocardial 
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ischemic injury [8]. The cardiac oxidative stress is mainly originated from mitochondria 
derived reactive oxygen and reactive nitrogen species (ROS/RNS) [8]. A recent study has 
reported the importance of mitochondrial redox signalling and other factors such as hypoxia 
inducible factor-1α (HIF-1α) and nitric oxide (NO) in IHD [9]. Therefore, one of main 
strategies of eliminating IHD related cardiac injury is through regulating mitochondrial 
function that control ROS generation and in turn reducing ROS-mediated inflammatory 
response. 
 
1.3 Treatments of IHD 
General treatments of IHD include medication, percutaneous coronary intervention 
(angioplasty) or coronary artery bypass surgery [10]. Current medications for treating mild 
IHD symptoms are β-blockers, calcium channel antagonists, and nitrates. These drugs have 
minor to severe side effects such as tolerance and hypotension (Table 1.1) [11]. Patients with 
severe IHD require bypass coronary arteries surgery or heart transplant that is highly 
effective but often has a high risk of infections and heart attack after surgery (Table 1.2) [12]. 
These surgery therapies are effective procedures that allow the rapid return of blood flow to 
the ischemic zone of the myocardium, i.e., reperfusion. However, reperfusion can also cause 
cell damages (reperfusion injury) which may lead to further complications such as diminished 
cardiac contractile function (stunning) and arrhythmia [13]. Reperfusion injury after severe 
myocardial ischemic is associated with oxidative stress and inflammatory responses as result 
of sudden oxygen supply [14]. For these reasons, new therapeutic approaches have been 
considered, including gene therapy [15], and pre/post conditions in ischemia and reperfusion 
(I/R) injuries [16] as well as developing new detection technique of I/R [17]. Among these, 
pre- and post-conditions has been extensively studied and applied to treat I/R injury. There 
have been efforts in searching new agents with properties of eliminating I/R injuries. For 
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example, superoxide dismutase (an antioxidant enzyme) has been demonstrated their 
pharmacological efficacy in preclinical studies on ischemic reperfusion injury [18], but it fail 
in subsequent clinical trial [19] partially due to impermeable to cells and complex 
mechanisms of I/R. Adenosine (an anti-inflammatory agent) is  another example to failed in 
clinical trial with strong pre-clinical effects on reperfusion injury [20]. Therefore, it is 
necessary to conduct further research to identify new effective agents to treat 
ischemia/hypoxia and reperfusion injuries. In this regard, studying mechanisms of actions of 
effective natural products may provide an opportunity for identifying and developing novel 
therapeutic drugs.    
 
  Table 1.1 Drug therapy for IHD  
Drugs Mechanisms of actions Adverse effects Ref 
β-blockers  Smooth muscle spasm 
 Reduce blood pressure 
 Bronchospasm 
 Fatigue 
[21-22] 
Nitrates  Redistribute blood flow 
 Antiplatelet action 
 Hypotension 
 Nitrate tolerance 
[23-24] 
Calcium channel  
antagonists 
 Relaxes heart muscle  
 Relaxes blood vessels 
 Hepatotoxicity 
 Palpitations 
[25] 
 
  Table 1.2 Surgical therapy for IHD 
Surgery types Mechanisms of actions Adverse effects Ref 
Coronary 
angioplasty 
 Treatment for 
obstructed arteries 
 Damage to blood vessels 
 Heart attack, Stroke 
[26-27] 
Bypass coronary 
arteries 
 Improve blood flow to 
the heart (for severe 
cases) 
 Wound infection 
 Stroke, Heart attack 
 
[28-30] 
 
 
Heart transplant 
 Replaces diseased heart 
with a donor heart 
 Rejection of the donor heart 
 Infections 
 Clogging of the arteries 
 
 
[31] 
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1.4 Hypoxia  
Hypoxia is a condition caused by reduction in oxygen supply due to a respiratory 
insufficiency or to a defective vasculature [32]. This is a main driver of cardiac cell injury 
and death (apoptosis or/and necrosis) in diseases like IHD and hypertension [33]. Comparing 
with other organs, heart is extremely sensitive to hypoxia condition because it requires a high 
level of metabolism for its function [34].  
Short time exposure of hypoxia in cardiac cells (up to 15 minutes in clinical condition or 
experimental condition) has certain cell protective effects without causing cardiomyocytes 
death due to activation of cell self-defence mechanisms which will leads to enhance cell 
survival factors such as extracellular signal-regulated kinase [19, 35]. However, prolonged 
hypoxia (more than 15 min) can cause irreversible tissue damage by initiating apoptosis. 
Apoptosis due to chronic hypoxia is a complex process (Figure 1.2) involving various cellular 
mechanisms from mitochondrial function, intracellular calcium, and pH homeostasis to 
oxidative stress [33]. Hypoxia also affects cell signalling mechanisms, such as the increase 
levels of hypoxia inducible factor (HIF-1α) which has a cascading effect of downstream 
glycolytic enzymes, glucose transporters (GLUT 1 and 3) and lactic dehydrogenase A [34, 
36]. Specific mechanisms involved in chronic hypoxia induced apoptosis such as 
mitochondria regulated apoptosis, ROS, and NO will be discussed in detail below.   
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Figure 1.2 Possible pathways of chronic hypoxia induced apoptosis. Chronic hypoxia 
stimulates cell apoptosis through three pathways. Top pathway: Activation of hypoxia 
inducible factor-1α (HIF-1α) by hypoxia can activate pro-apoptotic proteins in Bcl-2 family 
proteins which leads more pro-apoptotic proteins than anti-apoptotic (less) proteins in 
mitochondria. This event can contribute to mitochondria permeability transition pore (MPTP) 
opening. Middle pathway: Hypoxia causes ATP depletion resulting in a decrease in cellular 
pH due to anaerobic glycolysis, increase in proton stimulates Na
+
-H
+
 exchange and Na
+
-Ca
2+
 
exchange, results in an increase in intracellular Ca
2+
([Ca]i). Changes in mitochondrial 
membrane potential (Δψ) during hypoxia can lead uptake of [Ca]i into mitochondria. The 
increase in mitochondrial Ca
2+
 contributes to MPTP opening. Bottom pathway: Hypoxia also 
causes increase production of intracellular nitric oxide (NO) and mitochondrial reactive 
oxygen species, which affect on MPTP opening. All three apoptosis mechanisms lead to the 
activation of MPTP, and this activation leads to cytochrome c release and caspase 3 
activation [34, 37-38]. 
 
1.5 Apoptosis 
Cardiac cells are terminally differentiated and non-splitting cells. This unique characteristics 
makes them vulnerable to apoptosis [39]. Clinical studies have reported that myocardial 
infarction can occur after revascularization (surgical procedure restoring blood supply to the 
tissue/organ), fibrinolytic therapy and anti-arrhythmic drugs [40]. Thus, it is important to 
minimize not only vascular dysfunction but also cardiomyocytes apoptosis in IHD.  
There are two major forms of myocardial cell death which are necrosis and apoptosis [41-42]. 
Necrosis is regarded as an event occurred by excessively toxic stimulus or massive cell 
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injury. It leads to a massive cell swelling due to accumulation of water and electrolytes, 
resulting in plasma membrane rupture, and inflammatory responses. Apoptosis is a 
programmed energy-dependent cell death process accompanying with DNA 
fragmentation/shrinkage of the cell without triggering an inflammatory response (     Table 
1.3) [41, 43-45]. Apoptosis of cardiac cells is a key factor in developing ischemia heart 
disease, heart failure and myocardial infarction [44, 46]. In the past, it was assumed that 
myocardial cell damage is largely caused by necrosis, however the current understanding is 
that apoptosis is also a contributing factor [41, 47].  Recent researches have been focused on 
developing new ways to reduce cell apoptosis and related cell mechanisms such as cell death 
receptors, extrinsic pathway, and intrinsic (mitochondria) pathway [47-49].  
Apoptosis process involves extrinsic and/or intrinsic pathway. Extrinsic pathway is 
stimulated by death receptors such as tumor necrosis factor receptor (TNFR) family, i.e., 
TNFR1, Fas ligand and activation of caspase-8. [43, 45, 50]. Intrinsic pathway or 
mitochondrial death pathway is mediated by MPTP opening that regulated by factors such as 
Bcl-2 family proteins, ROS, intracellular Ca
2+
. As a result of MPTP opening, cytochrome c 
and pro-apoptotic proteins such as Smac/Diablo are released/activated which promote cell 
apoptosis [51-52]. There is a possible link between extrinsic and intrinsic pathways via 
caspase-8 and Bid (a pro-apoptotic protein in Bcl-2 family proteins) (Figure 1.3) [50-51]. 
Once Bid protein is activated, it translocates into mitochondria, affecting balancing of Bcl-2 
proteins and MPTP opening. Among both cell apoptosis pathways, intrinsic pathway is the 
vital apoptosis form in vertebrate cells [43].   
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     Table 1.3 Characteristics of cellular apoptosis and necrosis 
Type of cell death 
 
Morphology of cells 
Ref 
 
Apoptosis 
 Cell shrinkage 
 DNA fragmentation 
 Chromatin condensation/ fragmentation 
 Cytochrome c release into the cytoplasm 
 Activation of the caspase family of proteases 
[53] 
Necrosis 
 Cytoplasmic swelling 
 Postlytic random DNA digestion (smear pattern on gel 
electrophoresis) 
 Dilatation of cytoplasmic organelles 
 Irreversible plasma membrane damage 
 Inflammatory response 
[54] 
 
 
1.6  Intrinsic pathway 
It has been known that mitochondria functions are important for Intrinsic pathway of 
apoptosis [55]. It is one of the important therapeutic targets due to its role in MPTP opening 
and regulation of pro-apoptotic proteins [56]. Factors activating MPTP opening include high 
level of intracellular Ca
2+
, excessive ROS and ATP depletion [57]. Under a stress condition, 
the opening of MPTP leads to a transient hyperpolarization and then depolarization of 
mitochondria membrane, resulting in releasing apoptotic proteins such as cytochrome c, smac, 
and apoptosis inducing factor (AIF) that in turn stimulate caspase 3 and apoptosis (Figure 
1.3). One of important contributors on MPTP opening is the Bcl-2 family proteins which are 
categorised as anti- (Bcl-2, Bcl-xl) and pro-apoptotic (Bax, Bak, and Bad) proteins [43].  
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Figure 1.3 Schematic diagram of the intrinsic (mitochondria) pathway. During hypoxia, the 
cell responses to the stress by activating p53 protein, 14-3-3, and caspase 8 which lead to free 
of pro-apoptotic proteins (Bax, Bad and Bid). The unbounded pro-apoptotic proteins 
translocate to mitochondria and cause an imbalance of anti- and pro-apoptotic Bcl-2 family 
proteins (increase pro-apoptotic proteins). MPTP is then opened and causes the release of 
cytochrome c from mitochondria. Cytochrome c translocates to the cytoplasm where forms 
apoptosome by assembling with apoptotic protease activating factor-1 (Apaf-1) and 
procaspase-9 leading to caspase-9 activation, which causes caspase-3 activation and 
ultimately induces apoptosis [58]. 
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1.6.1  Mitochondrial permeability transition pore  
Mitochondrial permeability transition pore (MPTP) is a polyprotein complex located between 
the inner and outer mitochondrial membrane. It is involved in the regulation of the 
mitochondrial matrix homeostasis [59]. The major subunit of MPTP is the adenine nucleotide 
transporter (ANT: responsible for maintaining the proton gradient required for energy 
production), Cyclophilin D (key regulator of MPTP and interact with Bcl-2 proteins) and the 
mitochondrial phosphate carrier (essential for ATP synthesis) [60]. MPTP opening is 
increased by elevated intracellular Ca
2+
 levels, depletion of adenine nucleotide, high 
inorganic phosphate (Pi) and oxidative stress [61]. Opening of the MPTP leads to dissipation 
of the proton motive force, the pH gradient and the permeabilization of the inner 
mitochondrial membrane, resulting in changes Δψ (mitochondria membrane potential). The 
dissipation of Δψ interrupts oxidative phosphorylation. In addition, levels of ATP hydrolysis 
are increased as the F1F0 ATPase attempts to re-establish Δψ via reverse proton pumping. 
Finally, MPTP opening leads to cytochrome c release from the mitochondria to the cytosol 
and the event of apoptosis process [43]. Some direct inhibitors of MPTP opening include 
cyclosporin A (CsA) and sanglipherin A (SfA). Indirect inhibitors of MPTP opening include 
mitochondrial targeted antioxidants (MitoQ and HO-3538: Superoxide dismutase mimetic 
compounds), Bic1 (Bax channel inhibitor) and translocator protein ligands (RO5-4864 and 
SSR180575). CsA and SfA inhibit opening of the MPTP by blocking the association between 
cyclophilin D and ANT [62].  
 
1.6.2 Bcl-2 family proteins 
Bcl-2 family proteins consist of both anti- and pro-apoptotic proteins. Balancing these 
proteins are important in regulation of MPTP opening [63]. Bcl-2 family proteins are 
classified into three different groups with the different Bcl-2 homology domains (BH1, BH2, 
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BH3 and BH4) [64]. Bcl-2 anti-apoptotic proteins (such as Bcl-2, Bcl-xl or Bcl-w) have four 
BH domains (BH1 to BH4). Bax like pro-apoptotic proteins (Bax, Bak or Bok/Mtd) contain 
BH1, BH2 and BH3. Another group of pro-apoptotic proteins contents BH3 only (Bid, Bad, 
Bim/Bod, MAP-1 and Bmf) (Table 1.4) [65]. Anti-apoptotic proteins (Bcl-2 and Bcl-xl) are 
localized on the outer mitochondria membrane and are involved in regulating cell survival by 
restraining cytochrome c release [64, 66]. In addition, Bcl-xl inhibits activation of caspases 
and formation of apoptosome by inhibiting cytochrome c release [67-68] . In healthy cells, 
pro-apoptotic proteins (Bak and Bax) exist as a non-active monomer. In stressed cells, 
however, these pro-apoptotic proteins form dimerization complexes and lead to release of 
other pro-apoptogenic proteins (Cytochrome c) that promote MPTP opening [69]. Bad is 
sequestered by 14-3-3 protein in normal cell, but it translocates to mitochondria and 
neutralizes action of anti-apoptotic proteins (Bcl-2, Bcl-xl and Bcl-w) in stressed cells. This 
leads to activation of Bax by insufficient proportion of anti-apoptotic proteins in the 
mitochondria [70-72]. Another well-recognised BH3 only protein is tBid (Bid cleavage). It 
has been shown to induce the oligomerization of Bak as well as activation of Bax which 
results in predominant proportion of pro-apoptotic proteins in mitochondria (Figure 1.4) [58, 
73].  
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Table 1.4 The composition of Bcl-2 family proteins 
 
 
 
Figure 1.4 Role of balance of anti- and pro-apoptotic proteins in MPTP opening. In normal 
cells, pro-apoptotic proteins are sequestered by anti-apoptotic proteins or cytosolic proteins 
leading to conserved mitochondrial membrane integrity. When cells undergo stress such as 
under hypoxia, pro-apoptotic proteins are freed from the sequestered proteins and this 
ultimately contributes to MPTP opening [74]. 
 
Type Subfamily Proteins 
Anti-apoptosis Bcl-2 subfamily 
Bcl-2 
Bcl-xl 
Bcl-w 
Mcl-1 
A1/Bfl-1 
Pro-apoptosis 
Bax subfamily 
Bax 
Bak 
Bok/Mtd 
BH3 subfamily 
Bik/Nbk/BIK 
Hrk/DP5 
Bim 
Noxa 
Bad 
Puma/Bbc3 
Bmf 
EGL-1 
Bid 
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1.6.3 Calcium homeostasis 
Calcium plays an important role as a secondary messenger in cellular processes such as 
muscle contraction, secretion, cell division, cell cycle progression, energy production and 
gene transcription [75]. A consequence of hypoxia/ischemia is the elevated levels of 
intracellular Ca
2+
 caused by imbalanced Sodium Calcium Exchanger (NCX) action [37]. 
Recent findings suggest that increased cytosolic calcium is a potent inducer of mitochondrial 
injury and apoptosis [76]. Mitochondrial calcium ([Ca
2+
]m) uptake is driven by Δψ. A 
gradual increase in cytosolic Ca
2+
 and/or increased Ca
2+
 oscillation frequency then can lead to 
the build-up of [Ca
2+
]m (Figure 1.5) [37]. Additionally, intracellular Ca
2+
 regulates NO 
production through Ca
2+
/calmodulin dependent nitric oxide synthases (eNOS and nNOS) [77]. 
Recent studies have shown that overproduction of NO by hypoxia disrupt mitochondrial 
electron transport chain and increases superoxide generation and produce peroxinitrite and 
stimulates apoptosis [78]. More detailed role of NO in apoptosis will be discussed in Section 
1.6.4. 
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Figure 1.5 Changes in ion and metabolites during ischemia [37]. During ischemia, ATP 
depletion results in a decrease in cellular pH due to anaerobic glycolysis. This result in 
increases in proton stimulates Na
+
-H
+
 exchange and Na
+
-Ca
2+
 exchange and elevates 
cytosolic Ca
2+
. Much of the ATP generated by glycolysis is consumed by the mitochondrial 
ATP synthase (F1F0-ATPase) that uses the energy to generate mitochondrial membrane 
potential (Δψ). Changes in intracellular Ca2+ affect mitochondrial Ca2+ levels, which in turn 
regulate MPTP opening. 
 
1.6.4 Nitric oxide  
Nitric oxide (NO) is an important mediator of apoptosis during hypoxia through four distinct 
modes of actions. 1) Reversible inhibition of mitochondrial respiration at cytochrome oxidase 
reducing intracellular ATP, 2) Stimulation of mitochondrial superoxide production and 
increase in hydrogen peroxide, 3) Increase in peroxynitrite formation, and 4) Regulating HIF-
1α stabilization (Figure 1.6) [33, 38].  
NO is synthesized from L-arginine by three isoforms of NO synthases (eNOS, nNOS, and 
iNOS). eNOS and nNOS are regulated by calcium/calmodulin and phosphorylation, while 
iNOS is induced during inflammation, producing higher levels of NO for prolonged period 
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[79]. Previous studies have reported that eNOS dependent NO increase is involved in 
peroxinitrite formation, inhibiting Electron Transport Chain (ETC) and respiration in 
mitochondria [78, 80]. Moderate increase in NO levels can facilitate superoxide radical 
production by inhibiting ETC and in turn increase H2O2. Higher levels of NO inhibits H2O2 
production by scavenging the precursor superoxide, resulting in higher peroxinitrite 
production [38]. Peroxinitrite, resulted from elevated NO and superoxide radicals can damage 
DNA repair mechanisms, inducing MPTP opening as results of impairing complex I to IV, 
mitochondrial membrane, and antioxidant enzyme [81].  
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Figure 1.6 Schematic diagram of the interactions between NO, RNS, ROS and the 
mitochondrial respiratory chain. Chronic hypoxia increases NO production by stimulating 
NOS synthases (eNOS by up regulation of Hsp90 protein and calcium; nNOS by calcium; 
iNOS by inflammatory response and HIF-1α). This elevated NO blocks complexes III and IV, 
resulting in mitochondrial superoxide production and formation of peroxynitrite (ONOO
−
), 
further inhibiting the respiratory chain and antioxidant enzymes (aconitase and the 
Manganese superoxide dismutase (MnSOD)) [82-83].  
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1.6.5 Reactive oxygen species  
Reactive oxygen species (ROS) contribute to a number of pathological process including 
aging, apoptosis and cellular injury. Apoptosis in IHD and heart failure can be induced by 
ROS via interacting with various cellular signalling [33]. During hypoxia, the main source of 
ROS is from electron transport chain in mitochondria (Figure 1.6), not from cytosolic 
NADPH oxidase derived ROS [84-85]. This is different from blood vessels where main 
source of ROS is derived NADPH oxidase and xanthine oxidase [86]. The rate of ROS 
production from mitochondria is increased in various of pathological conditions, including 
hypoxia, ischemia and reperfusion [87]. This mitochondrial ROS generation is regulated by 
electron transport chain (ETC: composite to four complexes, Complex I: NADH 
dehydrogenase, Complex II: succinate dehydrogenase, Complex III: cytochrome c reductase, 
Complex IV: cytochrome c oxidase), especially in complex I and III (Figure 1.7) [88]. 
Normally, superoxide is detoxified by the combined activity of the mitochondrial antioxidant 
enzymes mainly manganese superoxide dismutase (MnSOD), catalase, and glutathione 
peroxidise. However, the function of these antioxidant enzymes can be suppressed by excess 
NO and peroxinitrite leading to increased level of superoxide in mitochondria. Mitochondrial 
superoxide spontaneously undergoes dismutation to form H2O2 by MnSOD. H2O2 is further 
catalysed into hydroxyl radical by Fenton reaction [89]. In addition, H2O2 generated by 
complex III can attribute on stabilization of HIF-1α protein during hypoxia and activated 
HIF-1α protein can cause cell damage [32]. Mitochondrial NO synthase (mNOS) also 
contributes to superoxide generation by blocking ETC, specifically, complex IV function and 
cause ATP depletion [90]. Mitochondrial ROS production also depends on a high Δψ (over 
140 mV) that may be regulated by dephosphorylation of cytochrome c oxidase in ETC by 
increased calcium level during hypoxia [91-92].   
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Figure 1.7 Physiology of the respiratory electron transport chain in mitochondria [93]. Heavy 
curved arrows indicate the normal flow of electrons through the ETC. Substrates, such as 
NADH and succinate, normally enter at complex I and II where they are oxidized. The 
electrons are then transported to complex III by ubiquinol. Cytochrome c transfers electrons 
from complex III to complex IV, which reduces O2 to form H2O. In the process, electrons are 
pumped from the matrix into the intermembrane space at complex I, III, and IV generating an 
electrochemical gradient, the mitochondria membrane potential. This gradient is then used by 
ATP synthase (ATPase), to power the production of ATP from ADP. H
+
 leak is the re-entry 
of protons into the mitochondrial matrix independent of ATPase. ATPase is normally the 
point of re-entry for H
+
 back into the matrix, with only minimal H
+
 leak. In the setting of 
ischemic injury, the respiratory complexes are damaged, and electrons leak from complex I 
and III (indicated by broken arrows). These electrons bind to O2 to produce O2
·¯
, which is 
dismutated to form H2O2 by the enzyme superoxide dismutase (SOD). H2O2 inside the matrix 
crosses the inner mitochondrial membrane to the intermembrane space. In the setting of 
ischemic injury H
+
 leak increases. Additionally, freely diffused H2O2 oxidize iron and form 
hydroxyl radicals. (Cyt c: cytochrome c).  
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1.6.6 Hypoxia inducible factor-1α 
Hypoxia inducible factor-1 (HIF-1) is a transcriptional factor responsible for the induction of 
genes that regulates adaptation/survival of cells in decreased oxygen condition [94]. HIF-1 is 
a heterodimer composed of the rate limiting factor HIF1α and the constitutively expressed 
HIF-1β. HIF1α subunit accumulation in nucleus is oxygen sensitive. HIF-1β is also called the 
aryl hydrocarbon receptor nuclear translocator and is not influenced by oxygen [9, 95]. In 
normal condition, HIF-1α is degraded in the proteasome by prolyl hydroxylation, but it is 
highly activated during hypoxia as a result of inhibition of prolyl hydroxylation activity by 
excess NO or ROS [96-97]. Activated HIF-1α during hypoxia is closely associated with 
mitochondrial function. Bnip3 (a pro-apoptotic protein in Bcl-2 family proteins) expression is 
controlled by HIF-1α [98]. Activation of Bnip3 leads to heterodimerization with Bcl-xl or 
Bcl-2 with reduced anti-apoptotic actions [99]. Additionally, pro-apoptotic proteins (Bax, 
NOXA, and PUMA in Bcl-2 family proteins) can be activated by HIF-1α dependent p53 
protein activation, which contributes to an imbalance of anti- and pro-apoptotic proteins 
(Figure 1.8) [100-101].   
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Figure 1.8 Possible pathway of HIF-1α dependent cell apoptosis [95]. Hypoxia elicits 
activation of HIF-1α that activates p53 and BNIP3 (BCL-2/adenovirus E1B 19 kDa 
interacting protein 3) proteins. Subsequently, pro-apoptotic proteins (Bax/Puma/NOXA) are 
freed to translocate to mitochondria leading to the imbalance of anti- and pro-apoptotic 
proteins which activates MPTP opening and apoptosis.  
  
- 29 - 
 
1.7 Danshen  
Danshen, also called red sage root, is dried roots of Salvia miltiorrhiza which is cultivated 
widely in Asian countries like Korea, Japan and China (Figure 1.9). Danshen has long been 
used as traditional Chinese medicine to relieve symptoms of cardiovascular dysfunctions like 
angina and hypertension [102]. The earliest medicinal use of Danshen can be traced back 
more than 2000 year ago. The use of Danshen in clinical condition for the treatment of 
ischemic stroke was largely documented in the 1970s in China [103]. The current commercial 
products derived from Danshen include Fu fang Danshen, Danshen dripping pills etc. [102]. 
Early clinical studies in China showed that Danshen is effective in relieving angina pectoris 
by oral administration [104]. Other clinical studies have demonstrated Danshen effects on 
patients with stroke, angina and hypertension [105]. Its clinical trials in China have indicated 
that Danshen products are safe with minor side effects such as headache, thirsty and mild 
gastrointestinal reaction [102]. Based on clinical efficacy of Danshen, pharmacological 
studies have been carried on in vitro and in vivo to elucidate its mechanisms of actions. 
 
 
                                 Figure 1.9 Danshen plant (left) and its roots (right). 
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1.7.1 Chemical constitutes of Danshen 
Compounds derived from Danshen are classified into two categories, hydrophilic and 
lipophilic compounds. Hydrophilic compounds of Danshen include phenolic acids, 
danshensu, magnesium lithospermate B, salvianolic acids, protocatechuic acid and 
protocatechuic aldehyde. The lipophilic compounds of Danshen include mainly tanshinones 
such as tanshinone I, IIA, IIB and cryptotanshinone [102]. Tanshinones are lipophilic 
compounds found in Danshen, its chemical structure is identified to diterpene quinone. Since 
1930s, more than 40 tanshinones and their compounds have been isolated [106]. The 
chemical structures of these compounds are illustrated in Figure 1.10 and 1.11 respectively. 
These compounds have various pharmacological activities including cardioprotective actions 
against ischemia reperfusion (I/R) injury [107-108].  
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Figure 1.10 Chemical structure of main hydrophilic compounds from Danshen. 
 
          Figure 1.11 Chemical structure of main lipophilic compounds from Danshen. 
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1.8 Pharmacological actions of Tanshinones 
It has been shown that tanshinones possess various pharmacological activities such as 
antibacterial, antioxidant, anti-inflammatory, and antineoplastic effects [109]. The two major 
bioactive compound of tahsnones is tanshinone IIA (TIIA) and cryptotanshinone (CT), both 
having similar chemical structures as shown above. Studies have shown that TIIA can 
improve ischemia reperfusion injuries [110], atherosclerosis[111], cardio complications [112] 
and myocardial infarction [113], possibly by vasodilatation [114], anti-apoptosis [110], anti-
oxidant, and anti-inflammatory actions [113]. Similarly, studies have revealed that CT has the 
capacity to prevent atherosclerosis and I/R induced cardiac injuries [115-116] by its 
vasodilator activity [117]  and anti-inflammatory actions [118]. Table 1.5 and 1.6 shows 
pharmacological actions of tanshinones on in vitro and in in vivo respectively.  
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Table 1.5 Pharmacological actions of tanshinones in vitro. 
Compound       Cell      Effect   Mechanism Ref 
Dihydro-
tanshinone 
Rat coronary 
blood vessels 
Vasorelaxation action Calcium influx ↓ [119] 
Crypto-
tanshinone 
HUVECs Anti-inflammation 
activity 
ET-1 ↓, NF-kB ↓ 
NO/eNOS ↑ 
[118] 
Rat coronary 
blood vessels 
Vasodilator action Calcium influx ↓ [117] 
HASMCs 
 
Anti-atherosclerosis 
 
MMP-9 ↓ 
NF-kB/ AP-1↓ 
ERK/p38/ JNK↓ 
[115] 
 
HUVECs Anti-inflammation 
activity 
ET-1 ↓, NF-kB ↓ 
NO/eNOS ↑ 
[118] 
 
Tanshinone 
IIA 
HUVECs  Vasodilator action NO ↑ [114] 
HASMCs 
 
Cytoprotective effects 
against TNF-α, 
ANGП, H2O2 induced 
cell damage 
GSH//NADPH ↑ 
 Nrf2 ↑ 
ERK1/2 ↑, PKB ↑ 
[120] 
Neonatal rat 
ventricular 
myocytes 
Cytoprotective effects 
against H2O2  
DNA 
fragmentation↓ 
[110] 
 
Neonatal rat 
cardiomyocytes 
Cytoprotective effects 
against Doxorubicin  
H2O2 ↓, 
 .
O2
- ↓ 
Bcl-2/Bax ratio↑ 
[121] 
J774 mouse 
macrophage cells 
Cytoprotective against 
H2O2 induced cell 
damage 
GPx ↑ [122] 
Human umbilical 
vein endothelial 
cells 
 
Vasodilatation action NO ↑ 
AMPK /PI3K/Akt 
↑ 
[123] 
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Neonatal 
cardiomyocytes 
 
Cytoprotective effects 
on Doxorubicin  
 
 
ROS ↓ 
Bcl-xl↑,Caspase 3↓ 
p-Akt ↑ 
 
[112] 
HUVECs Cytoprotective effects 
against H2O2  
SOD ↑, CD40 ↓ 
NO ↑ 
[124] 
Neonatal 
cardiomyocytes 
Anti-oxidant action 
against H2O2  
[Ca
2+]i ↓ 
MMP ↑ 
[125] 
Neonatal 
cardiomyocytes/c
ardiac fibroblasts 
Anti-inflammatory 
effects 
MCP-1 ↓ 
TGF-β1 secretion ↓ 
[113] 
VSMCs Inhibition of 
proliferation 
p-ERK1/2 ↓ 
c-fos↓ 
[126] 
Tanshinone 
VI 
Neonatal 
cardiomyocytes 
Anti-hypertrophy 
action 
p-ERK ↓ [127] 
Sodium 
tanshinoneII 
sulfonate 
Rat 
cardiomyocytes 
Anti-hypertrophy 
action 
[Ca
2+]i  ↓ 
c-jun expression↓ 
[40] 
Porcine coronary 
artery smooth 
muscle cells 
Vasodilatation action BKCa [128] 
Rat heart 
mitochondria 
fraction 
Protecting I/R injury 
 
ROS↓ 
NADP oxidation↑ 
[129] 
 BKCa: High conductance Ca
2+
 activated K
+
 channels, CD40: Cluster of differentiation40,        [Ca
2+
]i: 
intracellular calcium, ET-1: Endothelin-1, G6PDH: Glucose 6-phosphate  dehydrogenase, GSH: Glutathione, 
GPx: Glutathione peroxidise, ICAM-1: Intracellular adhesionmolecule-1, I/R: Ischemia Reperfusion, MMP: 
mitochondrial membrane potential, MMP-9: Matrix metalloproteinases-9, NF-kB: Nuclear factor kB, Nrf2: 
Nuclear-factor-E2-related factor , NO: Nitric Oxide, HUVECs: Human umbilical vein endothelial cells, 
HASMC: Human aortic smooth muscle cells, ROS: Reactive Oxygen Species, SOD: Superoxide dismutase, 
VCAM-1: Vascular cell adhesionmolecule-1, VSMCs: Vascular smooth muscle cells   
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Table 1.6 Pharmacological actions of tanshinones in vivo. 
Compound Animals/Tissue  Effect Mechanism Ref 
Tanshinone Mouse carotid 
artery  
Suppressing 
intimal 
hyperplasia 
Intimal thickening↓ 
PCNA↓ 
[130] 
Rat heart  Improving 
acute 
myocardial 
infarction 
[Ca
2+]i ↓ 
Cell adhesion ↓ 
[131] 
Tanshinone IIA Rat coronary 
artery 
Protection of 
I/R injury 
Bcl-2 ↑ 
Caspase 3↓ 
SOD ↑, MDA ↓ 
[110] 
Male C57BL/6 
mice 
Amelioration 
of myocardial 
I/R 
eNOS/NO ↑ 
AMPK/PI3K/Akt ↑ 
[123] 
Rat aorta Attenuation of 
atherosclerotic 
calcification 
oxLDL production↓ 
.
O2
- ↓ , Cu/Zn SOD↑ 
MDA ↓ 
[132] 
Rat heart Improvement 
of myocardial 
infarction 
TNF-α level ↓ 
MCP-1↓/TGF-β1↓ 
CD68↓ 
[113] 
Mice aorta Anti-
atherosclerotic 
action 
Cholesterol level↓ 
CD36 and SRA ↓ 
PPARγ↓ 
[111] 
Rabbit aorta Anti-
atherosclerotic 
action 
CD40 ↓, MMP-2 ↓ 
SOD ↑ 
[133] 
Rat coronary 
arterioles 
Vasodilator 
action 
NO  ↑ 
Cytochrome P450 ↑ 
BKca ↑ 
[134] 
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Sodium 
tanshinoneII- 
sulfonate 
Mouse heart Protection of 
Dox induced 
cell injury 
Free radical ↓ 
Mitochondrial lipid 
peroxidation ↓ 
[135] 
Rat heart  Anti-apoptotic, 
antioxidant 
actions 
Scavenging lipid free 
radicals 
[136] 
Crypto- 
tanshinone 
Rat heart  Ameliorating 
I/R injury  
 
NF-kB↓ 
TNF-α, IL-1β↓ 
Neutrophil infiltration↓ 
MPO↓ 
[116] 
 BKCa: High conductance Ca
2+
 activated K+ channels, CD36: Cluster of Differentiation 36, CD68: Cluster of 
Differentiation 68, Dox: Doxorubicin, IL1β:Interleukin-1 beta, IL-6:  Interleukin-6, I/R: Ischemia Reperfusion, 
MDA: Malondialdehyde, MMP-2: Matrix  metalloproteinases-2, MPO: Myeloperoxidase, NF-kB: Nuclear 
Factor-KappaB, PPARγ: peroxisome proliferator activated receptor gamma, PCNA: Proliferating cell nuclear 
antigen, ROS: Reactive oxygen species, SOD: Superoxide dismutase, SRA: Scavenger receptor A, VSMC: 
Vascular Smooth Muscle Cell 
 
1.9 Tanshinone IIA  
1.9.1 Effects of Tanshinone IIA on myocardial infarction 
Myocardial infarction (MI) caused by disruption of blood supply to heart can lead to cell 
death. Cardiomyoctyes apoptosis is important factor in MI pathology and it is associated with 
diseases such as atherosclerosis, diabetic and cardiomyopathy [137]. An in vitro study has 
shown that TIIA (8 μM) inhibited tumor necrosis factor-α (TNF-α) induced monocyte 
chemoattractant protein-1 (MCP-1) and transforming growth factor β1 (TGF-β1) expression 
(50% reduction compared to disease group) in cardiac fibroblasts [113].  In vivo studies have 
shown that TIIA was effective in attenuating MI, the effect was associated with its anti-
inflammatory and vasodilator actions [113, 123]. For example, TIIA (60 mg/kg) was shown 
to reduce MI size induced by TNF-α by 26% in rats [113]. In a rat model of I/R injury, TIIA 
(20 mg/kg) was shown to be effective in reducing MI size (21% compared to I/R model). 
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TIIA may act through up regulating eNOS/NO pathway and AMPK/PI3K/Akt pathway [123].  
Studies have proposed reperfusion injuries to be the main cause of MI and subsequently heart 
failure [138]. Modulating redox signalling during reperfusion may reduce or minimize MI 
through up regulating eNOS/NO pathway and AMPK/PI3K/Akt pathway [123].  Studies have 
proposed reperfusion injuries to be the main cause of MI and subsequently heart failure [138]. 
Modulating redox signalling during reperfusion may reduce or minimize MI damage in heart 
failure [139]. TIIA have been shown with antioxidant actions by enhancing SOD, glutathione 
peroxidise and decreasing free radicals (H2O2 and O2
-
) [110, 121-122]. It has been reported 
that cardiomyocyte glutathione peroxidase may be more important than superoxide dismutase 
as antioxidant mechanisms due to their permeability to membranes.  [19]. Thus, TIIA may a 
promising agent to treat MI and reperfusion injuries due to its better permeability to 
membrane.  
 
1.9.2 Effects of Tanshinone IIA on ischemia reperfusion injuries 
Myocardial ischemia reperfusion (I/R) injury is caused by insufficient oxygen supply to the 
tissue commonly caused by thrombosis, coronary atherosclerotic plaques, diabetes 
complication [4]. Major regulators of prolonged ischemia/hypoxia induced cell damages are 
calcium, pH, ROS, and mitochondrial function. Sudden oxygen supply during reperfusion 
after prolonged ischemia impairs myocardial cells by ROS dependent mechanisms [37]. 
Mitochondria, especially, mitochondrial membrane transition pore (MPTP) opening, have 
been a major therapeutic target [140]. In in vitro studies, TIIA (10 μM) inhibited hydrogen 
peroxide induced cell apoptosis in neonatal cardiomyocytes by 40% reduction of cell death as 
evidenced by decreased Hoechst 33342 staining (a probe for identifying apoptosis) and DNA 
fragmentation [110]. Similar findings were reported in H2O2 induced cardiomyocytes cell 
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apoptosis (60% inhibition), with a reduction H2O2 induced intracellular calcium increase by 
52% by TIIA [125]. However, it is not clear about the exact role this antioxidant action of 
TIIA in I/R injury due to complex interactions of H2O2 with other signalling pathways. In in 
vivo study, 30 mg/kg TIIA significantly inhibited apoptosis induced by I/R (about 50% 
reduction of terminal deoxynucleotide transferase-mediated dUTP nick end-labelling 
(TUNEL) staining: a probe for indentifying apoptosis). Also this anti-apoptosis action of 
TIIA was accompanied with reduction of caspase 3 activity, increased SOD level and Bcl-
2/Bax ratio [110]. Additionally, TIIA restored I/R induced diminished eNOS/NO production 
and coronary dysfunction in mice [123]. Recent studies have reported similar protective 
effects of TIIA on cerebral I/R injury via inhibiting intrinsic death pathway, inflammatory 
response and ROS [141-142]. In summary, the capacity of TIIA on myocardial I/R injuries is 
associated with inhibition of intrinsic pathway (mitochondrial membrane potential, Bcl-2 
proteins expression, and caspase 3 activity), anti-inflammatory actions and antioxidant 
activities.  
 
1.9.3 Effects of Tanshinone IIA on atherosclerosis  
Atherosclerosis is an endothelial dysfunction (artery wall thickens) that caused by 
inflammatory process promoted by low-density lipoproteins (LDL) (plasma proteins that 
carry cholesterol and triglycerides) [143].  Additionally, atherogenic stimuli, including 
diabetes, and oxidative stress, induce vascular dysfunction, leading to atherosclerosis [144]. 
Main targets of reducing atherosclerosis has been focused on anti-inflammatory, anti-oxidant 
and vasodilator (calcium and NO) pathways [145]. The effects of TIIA on atherosclerosis 
have been reported [146]. In in vitro studies, it have been shown that TIIA treatment 
enhanced nitric oxide generation, inhibits platelet aggregation/leukocyte adhesion [147] and 
inhibited endothelial dysfunction (TIIA (30 μg/ml)) caused by H2O2   by enhancing SOD 
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activity in vascular endothelial cells [124]. TIIA has been shown anti-inflammatory activity 
by inhibition of cluster of differentiation 40 (CD40) [124]. More evidences of the anti-
atherosclerosis effects of TIIA have been demonstrated in animal models (Aorta from 
rats/mice fed with high fat or cholesterol). TIIA (35 mg/kg) reduced the thickness of the 
intima, and calcification by 40% in rat. Additionally, TIIA suppressed oxidized LDL protein 
production and superoxide production by enhancing Cu/Zn SOD [132]. Further, TIIA (30 
mg/kg) inhibited atherosclerosis in apolipoprotein E deficient (ApoE−/−) mice by reducing 
cholesterol content by 25% and oxLDL by 37%. [111].  Rabbit with atherosclerosis on a high 
fat diet was shown to have an over expression of inflammatory regulator (CD40 and matrix 
metalloproteinase-2 (MMP-2)), addition of TIIA to their dietsignificantly suppressed these 
factors [148]. Further study is required to elucidate the role of NO synthesis and redox 
signaling in actions of TIIA.   
 
1.9.4 Effects of Tanshinone IIA on adriamycin induced cardiomyopathy 
Adriamycin (ADR), also called doxorubicin, is an effective anti-cancer drug. However, its 
clinical usage is greatly limited by cardiomyopathy which may lead to heart failure [149]. 
Cardiomyopathy is a weakening of the heart tissue, which can be caused by increased 
oxidative stress. In a cascading effect, increasing ROS may reduce mitochondria oxidative 
phosphorylation, which in turn depletes ATP, resulting in cardiac cell impairment. Other 
mechanisms that induce cardiomyopathy are through activation mitogen-activated protein 
kinases  (MAPKs) and necrosis and extrinsic pathways [150]. TIIA significantly prevented 
ADR induced cardiomyocytes in animal models by preventing DNA fragmentation (60% 
compared to positive control), suppressing ROS production (lowering hydrogen peroxide by 
60 % and superoxide anion by 16% compared to positive control) and increasing Bcl-2/Bax 
ratio by 90% above the disease group. [151]. Other studies showed that TIIA (3 μM) 
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prevented ADR induced cell apoptosis and ROS production by 33% and 37% respectively. It 
enhanced Bcl-xl protein (anti-apoptosis protein) expression and inhibited cytochrome c 
release and caspase 3 activity. It also restored Akt phosphorylation (a growth factor-mediated 
cell survival protein) which was decreased by ADR [112].  
1.10  Cryptotanshinone  
1.10.1 Effects of Cryptotanshinone on ischemia reperfusion injury 
In an animal study, CT reduced myocardial infarction by 35% in I/R rat model [116]. This 
effect may be related with its anti-inflammatory actions by inhibiting pro-inflammatory 
cytokines such as TNF-α, IL-1β (Interleukin-1beta), IL-6 (Interleukin-6) production, NF-kB 
translocation, and neutrophil infiltration. CT (2 μM) inhibited damage induced by H2O2  and 
TNF-α in human umbilical vein endothelial cells via inhibition of NF-kB activation and 
vascular cell adhesionmolecule-1 (VCAM-1)/intracellular adhesionmolecule-1 (ICAM-1) 
expressions [116].  
 
1.10.2 Effects of Cryptotanshinone on atherosclerosis 
As mentioned earlier (section 1.9.3), atherosclerosis are regulated by ROS, NO and 
inflammatory responses. In vitro studies have reported that CT (9 μM) attenuated endothelial 
dysfunction elicited by TNF-α in human umbilical vein endothelial cells by reducing 
endothelin-1 (ET-1: a potent vasoconstrictor) accumulation, enhancing eNOS/NO and 
inhibiting of NF-kB pathways [118]. In in vitro studies using human aortic smooth muscle 
cells, 10 μM of CT inhibited TNF-α induced activation of matrix metalloproteinases-9 
(MMP-9: responsible for proliferation and migration into the intima), NF-kB and activator 
protein1 (AP1: a transcriptional factor that regulates genes of cytokines and growth 
factors)[115]. In vivo study has elucidated mechanisms involved in vasodilator actions of CT 
- 41 - 
 
(30 μg/ml) reduced calcium flux  (59% reduction compare to contraction model) and calcium 
induced contraction in rat coronary artery [117]. Additionally, CT reduced thromboxane A2 
analogue, U46619 (a stable synthetic analog of the prostaglandin) in induced constriction of 
the porcine coronary artery [152].  
1.11 Outline and scope of thesis 
As highlighted previously, TIIA and CT have demonstrated multiple actions against 
inflammation, oxidative stress, myocardial infarction and ischemia reperfusion injury. 
However, the actions of these compounds on chronic hypoxia induced cell injury and via 
mitochondrial apoptosis have not been fully understood. Therefore, the main objective of this 
study is to elucidate the molecular mechanisms involved in cytoprotective action of 
tanshinones against hypoxia induced cardiac cell injury and apoptosis. Based on current 
understanding of mechanisms involved in ischemia/hypoxia induced injury and apoptosis, the 
project has been focused on intrinsic pathway and oxidative stress related mechanisms. In 
order to achieve this, an in vitro cell model needs to be developed first and used to test of 
effects of two main tanshinones, tanshinone IIA and cryptotanshinone. In addition, a 
synthetic analog of tanshinone IIA, Com1 needs also to be tested in an effort to develop new 
compound, which has similar or better actions than natural tanshinones. The main research 
questions include how tanshinones and synthetic compound may regulate intrinsic pathway 
signalling, in particular, Bcl-2 family proteins, mitochondrial membrane potential, 
cytochrome c release, caspase 3 activation and HIF-1α as well as the role of ROS, NO and 
calcium in the actions of these compounds.   
 
Aims of the project: 
 Establish a chronic hypoxia induced apoptosis model in H9c2 cells. 
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 Investigate the effects of TIIA, CT, and synthetic compound on hypoxia induced cell 
injury and apoptosis 
 Investigate the effects of TIIA, CT, and synthetic compound on the HIF-1α protein 
expression  
 Investigate the effects of TIIA, CT, and synthetic compound on mitochondrial membrane 
potential; cytochrome c release; Caspase 3 activity  
 Investigate the effects of TIIA, CT, and synthetic compound on the expression of Bcl-2 
family proteins  
 Investigate the effects of TIIA, CT, and synthetic compound on ROS, NO and calcium  
 
The finding of these studies may enhance our understanding of mechanisms involved in 
cardioprotective effects of tanshinones and promote the development of potential new 
therapeutic agents for treating ischemia/hypoxia related cardiovascular diseases.  
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3 Chapter 2 MATERIALS AND 
METHODS 
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3.1 Materials 
The following chemicals and biochemicals were used: High glucose DMEM (Dulbecco's 
Modified Eagle Medium) medium, No glucose DMEM medium, Penicillin-Streptomycin, 
FBS (Foetal Bovine Serum) were obtained from Invitrogen (Melbourne, Australia); BSA 
(Bovine Serum Albumin), PBS (Phosphate-Buffered Saline), Trypsin-EDTA solution, 0.4% 
(w/v) Trypan Blue solution, TMRM (Tetramethylrhodamine methyl ester perchlorate ), 
Bichinchoninic Assay Kit, N,N,N′,N′-Tetramethylethylenediamine, Ammonium Persulfate, 
Tween 20, Tris, Triton X-100, Complete Protease inhibitor cocktail, Glycine, Sodium 
Dodecyl Sulfate (SDS) and NaCl, Ethylaminediaminetetraacetic acid (EDTA), Ethylene 
glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), adenosine 5′-diphosphate 
sodium salt (ADP), 2',7'-dichlorodihydrofluorescein diacetate, propidium iodide, 
bisBenzimide H33342 trihydrochloride, Capase 3 assay kit, 4% paraformaldehyde, 
Superoxide dismutase assay kit and formalin solution were purchased from Sigma Aldrich 
(Sydney, Australia); Ethanol were from Merck (Melbourne, Australia); RIPA lysate buffer 
system, methanol, and Bcl-xl mouse monoclonal antibody and Bcl-2 mouse monoclonal 
antibody, cytochrome c mouse monoclonal antibody, β-Actin mouse monoclonal antibody, 
HIF-1α rabbit polyclonal antibody, Hsp90 mouse monoclonal antibody, Phospho-eNOS 
rabbit polyclonal antibody, goat anti-mouse IgG-HRP and goat anti-rabbit IgG-HRP  were 
from Santa Cruz (Queensland, Australia); Bax rabbit polyclonal antibody, and Bax rabbit 
polyclonal antibody were from Genesearch (Gold Coast, Australia); DAF-2 was purchased 
from Sapphire Bioscience Biochemicals (Sydney, Australia); Double colour Prestained 
Standards  were from Biorad (Sydney, Australia); MitoSOX™ Red, MitoTracker® Orange 
CMTMRos, YO-PRO®-1 iodide, fura-2 AM were from Molecular Probes (Melbourne, 
Australia); SuperSignal West Pico Chemiluminescent Substrate, Restore Western Blot 
Stripping Buffer, Ponceau S stain, Mitochondria Isolation Kit for Cultured Cells and NE-PER 
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Nuclear and Cytoplasmic Protein Extraction Reagents were from ThermoFisher Scientific 
(Melbourne, Australia); ENLITEN® ATP Assay System Bioluminescence Detection Kit and 
CytoTox 96® NonRadioactive Cytotoxicity Assay kit were from Promega (Sydney, 
Australia); Tanshinon IIA and cryptotanshinone were purchased from National Institute for 
the Control of Pharmaceutical and Biological Products (Beijing, China).    
 
The following lab-ware were used: 75 cm2 angled-neck tissue culture flask, 96-wells clear 
tissue culture-treated microplates, 24-wells clear tissue culture-treated microplates, 15 ml 
centrifuge tubes, 50ml centrifuge tubes, 100 × 15 mm tissue culture-treated petri dishes were 
obtained from Greiner (Sydney, Australia); 25 cm2 angled-neck tissue culture flask and 6-
well clear tissue culture-treated microplates from Nunc (Sydney, Australia); white opti 
96well plate was from PerkinElmer (Melbourne, Australia); 1.5 ml and 2ml microcentrifuge 
tubes were from Axygen Biosciences (Melbourne, Australia); Nitrocellulose Membrane was 
from Biorad (Sydney, Australia); GasPak™ EZ Anaerobe Container System Sachets with 
Indicator  and GasPak™ EZ Standard Incubation Container were from Becton Dickinson and 
company (Sydney, Australia). 
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3.2 Cell culture 
H9c2 (Rat embryonic myoblasts) cells were obtained from American Type Culture 
Collection (Sydney, Australia). H9c2 cells were cultured with Dulbecco's Modified Eagle's 
Medium (DMEM) with 10% (v/v) FBS and 1% (v/v) Penicillin/Streptomycin (Appendix 
A.1.1). The spent culture media was discarded and replaced with fresh media every two to 
three days. The cells were grown in 75 cm2 tissue culture flasks which were placed in a 5% 
CO2 incubator that was maintained at 37°C. 
H9c2 cultures normally reached confluency between two to three days. Confluence was 
monitored visually using an inverted microscope (Olympus CK30). Once confluent, the spent 
culture media was aspirated and the cells washed with Trypsin-EDTA solution (Appendix 
A.1.1). Cells were incubated with 3ml of Trypsin-EDTA solution for 3 min. Cells were 
dissociated by gentle tapping the flask. The trypsinised cell suspension was collected in a 15 
ml centrifuge tube containing 4 ml of 10% (v/v) Trypsin Neutraliser (Appendix A.1.1) and 
centrifuged (700 rmp for 5 min at 20°C) in Allegra X-22R centrifuge (Beckmam Coulter, 
Sydney, Australia). The supernatant was discarded and the cell pellet resuspended in 1 ml of 
their respective media. Approximately 250 μl of the cell suspension was added to a 75 cm2 
tissue culture flask containing 20 ml tissue culture media. The flask was capped and sprayed 
with 70% (v/v) ethanol before being placed in the incubator as described in Section 2.3.1.1 
For the purpose of experiments, once the cultures in the flask reached 70% confluency, the 
cells were trypsinised and added to 10 ml of tissue culture media. This cell suspension was 
counted with haemocytometer and seeded into 96-wells plates for MTT assay, 6wells plates 
and petri dishes for western blot well plates, 24-wells plates for immunofluorescence assay 
and LDH assay using pipette. 
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3.3 Hypoxia condition 
Hypoxia was achieved using GasPak™ EZ Anaerobe Container System Sachets with 
Indicator (Becton Dickinson and company, Sydney, Australia). After culturing cells for two 
days, cells were placed in a GasPak EZ Gas generating Pouch System (Becton-Dickinson) 
that achieves an O2 concentration of 1 % within 2.5 hr of incubation at 37°C by CO2 
generating sachet, for 8 hr (Figure 2.1). Cells in hypoxia groups were added with no glucose 
DMEM. Cells in normoxic control were added with serum free medium for same duration as 
hypoxia. In experiments for Time-course study of cell viability by MTT assay (described in 
2.6) the hypoxia duration was 2, 4, 8, and 10 hr. The optimum duration of 8 hr was chosen as 
the standard condition for subsequent studies. 
 
 
 
Figure 3.1 Image of GasPak EZ Gas generating Pouch System (Becton Dickinson and 
company) 
 
3.4 Preparation of test Compounds  
All the compounds and signalling pathway inhibitors were dissolved in DMSO. TIIA, CT and 
Compound 1 (Com1) were reconsited into a stock solution of 10 mM. Com1, a new synthetic 
compound, was provided by Department of Chemistry in RMIT University (Melbourne, 
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Australia). All compounds stock solutions were stored at -20°C until use. On the day of 
experiment, 3 and 30 μM of compounds working solution were freshly diluted in media (10x) 
and added 2 hr before and also during the 8 hr hypoxia period. 0.1 μM Cyclosporin A (MPTP 
opening inhibitor, Stock solution: 1 mM in DMSO), 10 μM rotenone (Complex I inhibitor in 
mitochondria electron transport chain, Stock solution: 10 mM in DMSO), 10 μM antimycin 
A (Complex III inhibitor in mitochondria ETC, Stock solution: 10 mM in DMSO), 10 mM 
TEMPOL (SOD mimic that can penetrate in membrane, Stock solution: 100 mM in H2O), 1 
μM MnTBAP (peroxinitrite inhibitor: Stock solution: 10 mM in H2O), 5 μM diphenylene 
iodonium (NAD(P)H oxidase inhibitor, Stock solution:10 mM in DMSO) and 1mM N 
ω
-
nitro-L-arginine-methyl-ester (NO synthase inhibitor, Stock solution: 100 mM in H2O) were 
added 1 hr before also during the 8 hr hypoxia period. The maximum concentration of DMSO 
in final samples was limited to 0.1% in all experiments. 
 
3.5 MTT assay 
Cell viability was determined by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay as described previously with a modification [153]. Cells (1×10
4
 cells/well) 
were seed in 96-wells. At the end of hypoxia period, MTT solution was added into plates at a 
final concentration of 0.5 mg/ml and incubated for 2 hr in 37°C. Then, the culture medium 
was discarded and 150 μl DMSO was added to each well to dissolve dark blue formazan 
crystals. The absorbance was read at 570 nm using PoLARstar OPTIMA plate reader (BMG 
LabTech, Melbourne, Australia) (Figure 2.2). The percentage of cell viability was calculated 
as a ratio of each group over normoxia control. The cell viability of normoxia control cells 
was set as  100% (Normoxia= 100%).  
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Figure 3.2 Image of PoLARstar OPTIMA plate reader (top), filters (bottom left) and measure 
mode instruction (bottom right)(BMG Lab Tech). 
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3.6 Lactate Dehydrogenase assay 
LDH release was measured by using CytoTox 96® NonRadioactive Cytotoxicity Assay kit as 
per the manufacturer’s instructions (Promega). Briefly, after induction of 8 hr hypoxia, 
supernatant was collected in 1.5 ml microfuge tube. Then, the supernatant were diluted with 
media and 50 μl of the dilution was placed in 96-wells. 50 μl of reconstitute substrate mixture 
was added in each wells and incubated for 30 mins at room temperature. After the incubation, 
50 μl of stop solution was added and measured absorbance at 490 nm using Flexstation 
multiplate reader (Molecular device, Melbourne, Australia). The percentage of LDH release 
was calculated as a ratio of each group over normoxia control. The LDH release of normoxia 
control cells was set as 100% (Normoxia= 100%). 
 
3.7 Apoptosis and necrosis assay 
Cell apoptosis and necrosis were assessed by using a combined fluorescent staining with 
Hoechst 33342, YO-PRO-1and propidium iodide (PI) as previously described [154] . Briefly, 
at the end of hypoxia period, Hoechst 33342 (0.5 μg/ml), Yo-Pro-1 (0.1 μM), and PI (0.1 
μg/ml) were added to each well and incubated for 30 mins at 37°C.  The cell images were 
obtained using Image Xpress MICRO system (IMX) (Molecular Devices) at 20X 
magnification with binning of 1 and gain of 2 using laser-based focusing. Images were 
captured using a DAPI filter (350/70 nm Ex, 470/50 nm Em for Hoechst 33342), GFP filter 
(490/40 nm Ex, 510/50 nm Em for YO-PRO-1) and Cy3 filter (550/35 nm Ex, 570/30 nm Em 
for PI). The viable cells were stained with Hoechst only (Hoechst+), the early apoptotic cells 
were stained with Hoechst and YO-PRO-1 (Hoechst+ and YO-PRO-1+), the late apoptotic 
cells were stained with Hoechst 33342, YO-PRO-1 and PI (Hoechst+, YO-PRO-1+, PI+), and 
the necrotic cells were stained with Hoechst 33342 and PI (Hoechst+ and PI+). The cell 
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images were analysed by using Meta express software (Molecular Devices). The percentage 
of each group was calculated as a ratio of each group cell number over total cells number. 
 
3.8 Caspase-3 activity 
Caspase 3 activity was measured by Caspase 3 assay Kit followed by manufacture’s 
instruction with minor modification (Promega). Briefly, cells were scrapped with lysis buffer 
(1x10
7 
cells/100 μl) (Appendix A.1.2) after 8 hr hypoxia. After 30 mins incubation in lysate 
buffer, the lysate were centrifuged at 10,000 g for 5 mins. Supernatant containing cytosolic 
fraction were determined protein concentration by Bradford assay (Section 2.10.2). 50 μl of 
cell lysate containing 100 μg/50 μl protein were incubated with 50 μl assay buffer (Appendix 
A.1.2) including 200 μM caspase 3 substrate (N-acetyl-Asp-Glu-Val-Asp-p-nitroaniline(Ac-
DEVD-pNA))  for 4 hr at 37°C. Free pNA produces a yellow colour that is monitored by 
PoLARstar OPTIMA plate reader at 405 nm. The amount of yellow colour produced upon 
cleavage is proportional to the amount of DEVDase (caspase-3) activity present in the sample. 
The caspase 3 activity was calculated as a ratio of each sample treated group over normoxia 
control.  The caspase 3 activity of normoxia control cells was set as  1 (Normoxia= 1). 
 
3.9  Western Blotting 
3.9.1  Protein Extraction  
For preparing whole cell lysate, the cells in 100 mm petri dishes were harvested following 
hypoxia. At the end of hypoxia, the media was removed from the petri dish. The attached 
cells were washed twice with PBS (4°C) prior to the addition of 200 μl of ice-cold (4°C) 
RIPA lysis buffer (Appendix A.1.3). The cells were dislodged using a cell scraper and the 
lysates collected in a 1.5 ml microfuge tube. Then, the lysates was homogenised by 20 time 
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pipetting and incubated on ice on for 20 mins at 4°C. The lysates were then centrifuged 
(13,000 g for 10 min at 4°C) and the supernatant (cell protein lysate) collected and placed in 
a fresh microfuge tube. A 6 μl of the supernatant with was used to determine the protein level 
utilising the bichinchoninic (BCA) assay (section 2.7.2). In a microfuge tube, 20-80 μg of 
supernatant (cell protein lysate) was added to 14 μl of Laemmli’s sample buffer (Appendix 
A.1.3) at a ratio of 4:1 and boiled for 5 mins at 95°C. These samples were stored at -80°C 
until they were used for SDS PAGE gel electrophoresis (Section 2.10.3).  
Isolation of mitochondria was performed by manufacture’s instruction using isolation kit 
from Thermo fisher. After isolation, 5 μl aliquot of the supernatant of each fraction was used 
to measure protein contents by Bradford assay (section 2.7.2). Briefly, 1×10
7
 cells were 
seeded in 100 mm plates and cultured for 2 days before inducing hypoxia. Cells were 
harvested and centrifuged at 850 g at 4°C for 2 mins and discarded supernatant. 800 μl 
mitochondria isolation reagent A with protease inhibitors was added in cell pellets, vortexed 
and incubated on ice for 2 mins. 10 μl mitochondria isolation reagent B was added and 
incubated for 5 mins on ice with several vortexing. Next, 800 μl mitochondria isolation 
reagent C with protease inhibitors was added and inverted several times. Then, the cell 
suspensions were centrifuged at 750 g at 4°C for 10 mins, collected supernatant and 
centrifuged at 12,000 g at 4°C for 15 mins. After the centrifuge, the supernatant (cytosolic 
fractions) were transferred to microfuge tube and pellets were resuspended with 500 μl 
mitochondria isolation reagent C and centrifuged at 12,000 g at 4°C for 15mins. Then, the 
supernatant was removed and the pellets containing mitochondria were stored at -80°C till 
use. Nuclear fractionation was prepared by manufacture’s instruction using isolation kit from 
Thermo fisher. After trypsinising cells, CER II buffer was added and homogenized by 
vigorous vortex for 1 min. The cell suspension was centrifuged at 16,000 g at 4°C for 5 mins. 
The supernatant (cytoplasm extracts) were collected and stored at -80 °C. The pellet was 
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resuspended with NER buffer and incubated 40 mins on ice with several vortexing. End of 
incubation, the cells suspension was centrifuged at 16,000 g at 4°C for 5 mins. The 
supernatant was transferred to microfuge tube and stored at -80 °C until use.  Protein content 
of these fractions was determined by Bradford assay. 
 
3.9.2  Protein concentration determination 
The bichinchoninic Assay (BCA) was used to determine protein levels (Section 2.8.1) as per 
the manufacturer’s instructions (Sigma Aldrich). BSA was used as the protein standard. 
Briefly, protein standards were added to a 96-well plate in increasing order of concentration 
(0-2 mg of BSA). In each well, 25 μl of supernatant was added in duplicates. After this, 200 
μl of BCA working reagent was added to each well and the samples incubated at 37°C for 30 
mins. After incubation, the plates were read at 560 nm using a PoLARstar OPTIMA plate 
reader (BMG LabTech, Melbourne, Australia). The concentration of cell protein in each well 
was calculated against the protein standards on each plate (Appendix A.2). 
Bradford assay was applied to determine protein contents (Section 2.9, 2.13.2, and 2.15-17) 
as per the manufacturer’s instructions (Sigma Aldrich). BSA was used as the protein standard.  
Protein standards were added to a 96-well plate in increasing order of concentration (0-2 mg 
of BSA). In each well, 5 μl of supernatant was added in duplicates. After this, 250 μl of 
Bradford working reagent was added to each well and the samples incubated at room 
temperature for 10 mins. After incubation, the plates were read at 595 nm using a PoLARstar 
OPTIMA plate reader (BMG LabTech, Melbourne, Australia). The concentration of cell 
protein in each well was calculated against the protein standards on each plate (Appendix 
A.2). 
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3.9.3  SDS PAGE gels 
The SDS PAGE gel was set in a Mini Protean II Multicasting Chamber system (BioRad) 
(Figure 2.3) and consisted of a 7 and 10 % running gel (Appendix A.1.4). Once the running 
gel had set, the stacking gel (Appendix A.1.4) was laid on top with a sample comb. Once the 
stacking gel had set, the sample comb was removed and the gel was immersed in a tank 
containing running buffer [25 mM Tris, 192 mM Glycine, 3.5 mM SDS, (pH8.8)]. In each 
gel, 5 μl of Dual colour Prestained Standards (Figure 2.4) was added to the first lane while 
cell lysates (20-80 μg) were added to each subsequent lane. The gel was run for 90 mins at a 
constant voltage of 100V.  
 
 
Figure 3.3 Mini Protean II Multicasting Chamber system (Bio-Rad). 
 
 
Figure 3.4 Dual colour Prestained Standards (Bio-Rad). 
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3.9.4  Immunoblotting 
Once the gel electrophoresis was completed, the proteins were electro-transferred onto a pre-
wet nitrocellulose membrane, which had been pre-soaked (10 mins) in cold (4°C) transfer 
buffer [25 mM Tris, 192 mM Glycine, 20% (v/v) Methanol], using a transfer unit (BioRad) at 
a constant voltage of 100 V for 1 hr. At the end of this time, the efficiency of transfer was 
determined by soaking the nitrocellulose membrane in Ponceau S solution for 2 mins and 
rinsing with water. The membrane was stained with Ponceau S solution to ensure that the 
transfer of protein had taken place successfully. The nitrocellulose membrane was then 
placed in blocking buffer [5% (w/v) BSA in TBST (Tris-buffered saline tween-20)] and left 
on an orbital shaker for 1 hr at RT. After which the membrane was incubated in a dish with 
10 ml of 5% (w/v) BSA containing the relevant primary antibody [1:1000 Bax rabbit 
polyclonal antibody, 1:1000 Bak rabbit polyclonal antibody, 1:500 HIF-1α rabbit polyclonal 
antibody, 1:500 Phospho-eNOS rabbit polyclonal antibody 1:500 Hsp90 mouse monoclonal 
antibody, 1:500 Bcl-2 mouse monoclonal antibody, 1:500 Bcl-xl mouse monoclonal antibody,  
1:1000 β-actin (loading control)] overnight with gentle agitation on a rocker at 4°C. The β-
actin was used as a loading control to ensure that a constant mass of cell lysate was loaded 
into each lane. The next day, the membrane was washed thrice (10 mins per wash) with 
TBST [20 mM Tris, 138 mM NaCl, 0.05% (v/v) Tween 20, pH 7.6] (RT). After this, it was 
placed in a dish containing 3 ml of 5% (w/v) BSA containing the appropriate secondary 
antibody (1:1000 goat HRP conjugated anti rabbit immunoglobin or anti-mouse 
immunoglobin) and left on an orbital shaker for 1 hr at RT. At the end of this time, the 
membrane was washed again thrice (10 min per wash) with TBST (RT). 
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3.9.5  Protein detection 
After the final TBST wash, the membrane was exposed to 1 ml SuperSignal West Pico 
Chemiluminescent Substrate solution (peroxide solution: peroxide buffer: luminol/enhancer 
solution, 1:1000:1000) for 30 s. The membrane was then placed in a Chemidox XRS unit 
(BioRad) (Figure 2.5) and the chemiluminescence was detected by a CCD camera connected 
to the Chemidox XRS unit and a digital output was obtained. The digital image was analysed 
for densitometry using Image Lab™ Software, Version 3.0 (BioRad). The protein levels in 
normoxia control were expressed as 1, while those in the treated samples were expressed as a 
ratio of this value. 
 
 
Figure 3.5 Chemidox XRS unit (Bio-Rad). 
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3.10  Mitochondria membrane potential  
After one day culturing, the cells were added with serum free media and incubated for 24 hr. 
End of hypoxia, cells were incubated with 150 nM TMRM (tetramethylrhodamine methyl 
ester: cell-permeant and cationic fluorescent dye that is mitochondria selective probe) 
solution for 15 mins at 37C [155]. After the incubation, the cells were washed 3 times with 
PBS gently and 150 μl of PBS was left in plates after the last wash. Then, TMRM 
fluorescence intensity was read immediately on PoLARstar OPTIMA plate reader with an 
excitation wavelength of 544 nm and an emission wavelength of 590 nm. Cell number was 
counted after the reading. Final results were obtained from total cell number divided by 
fluorescence intensity. The fluorescence intensity of membrane potential was normalized by 
cell number left in the plates after fluorescence measurements. To visualise membrane 
potential, cells were incubated with 100 nM TMRM for 30 mins at 37C and washed with 
media gently twice. Then cells were taken in Image Xpress MICRO (Molecular Devices). 
 
3.11  Cytochrome c translocation  
Cytochrome c release was measured by immunofluorescence assay. After exposing hypoxia, 
cells were incubated with 200 nM MitoTracker Orange CMRMRos to localize the 
mitochondria. Then cells were fixed in 4% paraformaldehyde for 10 mins followed by 
permeabilization in 1% Triton X-100. After washing in PBS, Cells were blocked in 20% goat 
serum for 30 mins at 37°C and then incubated with cytochrome c antibody (1:200) for 1 hr at 
37°C. Finally, cells were incubated with Alexa 488 conjugated goat anti-mouse IgG (1:1000) 
for 1 hr at 37°C. After further washing, images were observed on Image Xpress MICRO 
(Molecular Devices). Images were captured using a DAPI filter (350/70 nm Ex, 470/50 nm 
Em for DAPI), GFP filter (490/40 nm Ex, 510/50 nm Em for cytochrome c) and Cy3 filter 
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(550/35 nm Ex, 570/30 nm Em for MitoTracker orange CMRMRos). After visualization, 
cells were scored as having cytochrome c in mitochondria defined by punctuate (no 
cytochrome c release) or cytochrome c release to cytosolic distinguished by diffused staining 
and overtaking mitochondrial staining. The percentage of diffused cytochrome c was 
calculated by translocated cell number over total cell number.   
 
3.12  Superoxide in intracellular and mitochondria  
Dihydroethidium (DHE), which reacts with superoxide anion radical to produce 2-hydroxy 
ethidium (2OH-E), was used to measure changes of intracellular superoxide level by hypoxia. 
End of hypoxia, 20 μM dihydroethidium was added, incubated for 30 mins at room 
temperature, and washed with PBS. Dihydroethidium fluorescence was visualized by Image 
Xpress MICRO (Molecular Devices). Changes superoxide production in mitochondria after 
hypoxia was assessed by labelling with 5 μM MitoSOXRed at 37°C for 30 mins. After the 
incubations, cells were washed and visualised by Image Xpress MICRO (Molecular Devices). 
Images were captured using a DAPI filter (350/70 nm Ex, 470/50 nm Em for DAPI), and Cy3 
filter (550/35 nm Ex, 570/30 nm Em for DHE and MitoSOXRed). Mean fluorescence 
intensity of labelled cells was quantified using Meta express software among 400 cells 
(Molecular Devices). 
 
3.13  Intracellular hydrogen peroxide/peroxinitrite  
To determine intracellular hydrogen peroxide/peroxinitrite (H2O2/ONOO
-
) production, 2′, 7′-
dichlorofluorescein diacetate (DCFH-DA) were used. The nonfluorescent DCFH-DA readily 
diffuses into the cells, where it is hydrolysed to the polar derivative DCFH, which is oxidized 
in the presence of H2O2 or ONOO
- 
to the highly fluorescent DCF. End of hypoxia, cells were 
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incubated with 20 μM DCFH-DA for 20 mins at 37°C. The assay was performed at an 
excitation wavelength of 488 nm and emission at 530 nm in Flexstation multiplate reader 
(Molecular devices, Melbourne, Australia). The fluorescence intensity was normalized to 
total protein content and expressed as arbitrary units per mg protein. 
 
3.14  Intracellular nitric oxide 
Direct measurement of intracellular nitric oxide production was performed on cells loaded 
with the fluorescent nitric oxide-sensitive dye 4,5-diaminofluorescein (DAF-2) [156]. Cells 
were incubated with 5 μΜ DAF-2 for 1 hr after hypoxia. Following the incubation, cells were 
washed twice with PBS and visualized in Image Xpress MICRO (Molecular Devices). 
Images were captured using a DAPI filter (350/70 nm Ex, 470/50 nm Em for DAPI) and GFP 
filter (490/40 nm Ex, 510/50 nm Em for DAF-2).  Mean fluorescence intensity of labelled 
cells was quantified using Meta express software among 400 cells (Molecular Devices). 
 
3.15  SOD activity  
Superoxide dismutase (SOD) assay kit was used and followed the manufacturer’s instructions 
(Sigma-Aldrich). Briefly, cytosolic and mitochondria fractions were prepared as described in 
section 2.10.1. Protein amount was measured by Bradford assay (Section 2.10.2). Twenty  μg 
of protein was added in 96-well plates and then reaction was initiated by adding enzyme 
solution.  Absorbance was measured at 450 nm with PoLARstar OPTIMA microplate reader. 
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3.16 NADPH oxidase activity  
NADPH oxidase activity was measured by lucigenin chemiluminescence based method in the 
presence of superoxide anion [157]. After 8 hr hypoxia, media was discarded and washed 
twice with ice cold PBS. Then, cells were scrapped from plate in 100 μl of PBS. Cells were 
then transferred to tubes and centrifuged at 750 g at 4 C for 10 mins. The supernatant was 
discarded and the pellet was resuspended in lysis buffer (Appendix A.1.5). Next, the cells 
were homogenized by quick freeze and thaw twice. Protein content was measured in 5 μl of 
the cell supernatant by the method of Bradford assay (Section 2.10.2). 10 μg of proteins were 
added in optic white 96-well plates with the100 μl assay buffer (Appendix A.1.5). Then, 
reaction was started by 5 μΜ lucigenin. 5 μΜ DPI was added as an inhibitor before readings. 
Chemiluminescence was measured with PoLARstar OPTIMA microplate reader.   
 
3.17  Intracellular calcium  
Intracellular calcium level was measured by fluorescence assay by loading with Fura-2AM as 
previously described with minor modification [158]. After hypoxia, cells were rinsed twice 
with PBS and detached by trypsinization. The detached cells were centrifuged and washed 
with PBS once. Then, extracellular medium (ECM) buffer (Appendix A1.6) with Ca
2+
 
supplemented with 2 μM Fura-2 were added in the cells and incubated for 30 mins at 37C. 
After end of the initial incubation, cells were allowed the Ca
2+
 probe de-esterification after 
resuspended to ECM buffer only. 1×10
5
 cells were transferred to 96-well plates and then 
Fura-2 fluorescence was obtained by alternate excitation at 340 nm and 380 nm and emission 
at 510 nm. The fluorescence maximum was determined by lysing cells with 0.2% Triton X-
100 and fluorescence minimum was obtained by recording fluorescence following addition of 
40 mM EDTA. The calcium concentration was calculated by equation (Appendix A.3). 
- 61 - 
 
3.18  Cellular ATP contents  
ATP content was determined by ENLITEN® ATP Assay System Bioluminescence Detection 
Kit as per the manufacturer’s instructions (Promega). Briefly, cells seeded in 6-well plates 
were washed with PBS, lysated and collect supernatant by centrifugation.  Protein contents 
were determined by Bradford assay (Section 2.10.2). Proteins (10 μg/20 μl) were added in 
white opti plate and initiated action by adding reconstituted reagent. Then, luminescence was 
measured in PoLARstar OPTIMA microplate reader. The cellular ATP contents of normoxia 
control cells was adjusted to 1 (Normoxia= 1). 
 
3.19  Statistical analysis 
In this study, the Graphpad Prism 5 program (Version 2011, GraphPad Software, Inc.) was 
used to perform statistical analysis. For all studies which include cell viability, western 
blotting, colorimetric assay, chemiluminescence and immunofluorescence assays, the results 
were expressed as the means ± Standard Deviation (SD) from triplicate samples. All data are 
representative of 3-6 independent experiments. Results of the experiments were expressed as 
means ± SEM. The comparisons among groups were conducted with one-way analysis of 
variance (ANOVA) or Paired t-test. Differences of P value less than 0.05 were considered 
significant (note some figures use a Paired t-test).  
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4 Chapter 3 CHRONIC HYPOXIA 
INDUCES APOPTOSIS IN H9C2 
CELLS 
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4.1  Introduction 
As mentioned Chapter 1, myocardial hypoxia is closely associated with cardiac dysfunctions, 
in particular myocardial infarction (MI), ischemia reperfusion injury, and hypertrophy [34]. 
Hypoxia can cause changes of important cell signalling mechanisms involved in regulation of 
mitochondrial function, intracellular calcium and pH homeostasis, resulting in oxidative 
stress which subsequently induce cell death via apoptosis or/and necrosis [33].  
The mitochondria dependent intrinsic apoptosis pathway plays an important role in cardiac 
cell injury under various pathological conditions [159]. For example, there is strong evidence 
that mitochondria transition pore opening (MPTP) is involved in stress induced cardiac cell 
damage and cell death [56]. The event of MPTP opening is affected by various factors 
including elevated intracellular Ca
2+
, excess oxidative radicals, ATP depletion and Bcl-2 
family proteins [37]. MPTP opening causes a transient hyperpolarization, followed by 
depolarization, of the mitochondria membrane, which in turn causes the release of apoptotic 
proteins such as cytochrome c, smac and apoptosis inducing factor (AIF), resulting in caspase 
3 activation and apoptosis. Other drivers of MPTP opening include Bcl-2 family proteins, in 
particular pro-apoptotic (Bax, Bak and Bad) proteins but also involving anti-apoptotic (Bcl-2, 
Bcl-xl) proteins [160-161]. Cardiac cells under prolonged hypoxia condition have been 
shown with mitochondrial damage and apoptosis, including changes in cytochrome c release, 
caspase 3 activation and Bcl-2 family proteins [162]. It has been known that Bcl-2 family 
proteins are regulated by hypoxia inducible factor 1α (HIF-1α), a protein highly activated in 
low oxygen condition [95]. A previous study has reported that increased expression of HIF-
1α and its regulated genes by hypoxia was associated with cell apoptosis and Bax and Bcl-xl 
proteins via stimulation of Bnip3 protein and p-53 protein [100]. 
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Oxidative stress is another key factor in chronic hypoxia-induced cell apoptosis [32]. It has 
known that the source of oxidative stress in hypoxia is from mitochondria, not from cytosolic 
[84-85].  Studies have reported that excess NO production during prolonged hypoxia can 
increase mitochondrial ROS production by inhibiting mitochondrial electron transport chain 
function. Increased NO and superoxide productions by hypoxia promote the formation of 
peroxinitrite, which in turn cause cell apoptosis [78]. Overproduce of NO affects not only 
mitochondrial ROS production, but also HIF-1α accumulation by HIF prolyl hydroxylase 
inactivation. In addition, studies have shown that ROS derived from mitochondria and 
NADPH oxidases can activate HIF-1α accumulation [33, 163]. Increased NO production was 
regulated by NO synthase (eNOS) in hypoxia and heat shock conditions [164]. As eNOS is 
Ca
2+
/calmodulin dependent, changes of intracellular Ca
2+ 
by hypoxia may modulate NO 
production [165]. This indicates that hypoxia induced mitochondrial apoptotic pathway is 
closely associated with interactions of mitochondrial ROS, NO and calcium. Understanding 
the interplay of these factors and their involvements in actions of therapeutic agents may help 
to identify new agents to treat cardiac diseases [166-167]. 
In this study, the main focus was to identify chronic hypoxia induced changes in 
mitochondrial death pathway, including Bcl-2 proteins expression, membrane potential, 
cytochrome c translocation, caspase 3 activity and HIF-1α protein expression. Additionally, 
the relationship of ROS, NO and calcium in chronic hypoxia induced apoptosis in H9c2 cells 
was also examined.  
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4.2  Methods 
See Chapter 2.  
 
4.3  Results 
4.3.1 Hypoxia time course study 
In order to establish the optimal condition of hypoxia model in H9c2 cells, a time course 
study was firstly conducted by MTT assay. A significant reduction of cell viability was 
observed in cell exposed to 2 hr hypoxia (1% O2) group to 82.0 ± 1.8%, while normoxia 
showed 100%. Different hypoxia times (2-10 hr) were tested and result is shown in Figure 
3.1. The percent of cell death increased to 34.8 ± 2.2% (Figure 3.1) in 8 hr hypoxia group and 
38.3 ± 2.8% in 10 hr hypoxia group. It was decided to use 8 hr hypoxia period as the standard 
condition for the subsequent experiments. This condition is similar to a previous study in the 
same cell line, which showed 8 hr hypoxia exposure caused significant cell damages and 
activation of mitochondrial death pathway [168]. 
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Figure 4.1 Time course study of hypoxia on H9c2 cells. H9c2 cells were cultured and 
exposed to hypoxia for 2-10 hr. After end of hypoxia, MTT assay was conducted as described 
in materials and method. The cell viability of normoxia control cells (0 hr) was set as 100%. 
Results expressed as the means ± SD from n=4. Statistical analysis was performed using a 
Paired t-test where significance was recorded, *** P < 0.001 vs. normoxia.  
 
4.3.2 Effects of chronic hypoxia on HIF-1α expression 
To specify HIF-1α translocation, cell nuclear fractions were isolated and subjected to western 
blot.  Figure 3.2A shows a representative western blot of nuclear extract probed for HIF-1α 
and corresponding β-actin. Figure 3.2B presents quantitative values of HIF-1α expression. In 
the 8 hr hypoxia control group, a significant HIF-1α accumulation was detected with a 1.7 
fold increase than that of the normoxia group.  
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Figure 4.2 Effects of chronic hypoxia on HIF-1α expression. After hypoxia, nuclear fractions 
were isolated and equal amounts (25 μg) of the lysates were used for western blotting as 
described in materials and methods. (A) A representative western blot probed for HFI-1α and 
corresponding β-actin. (B) Quantitative western blot band intensity. The HIF-1α expression 
of normoxia control cells was set as 1. Results expressed as the means ± SD from n=4. 
Statistical analysis was performed using a Paired t-test where significance was recorded as * 
P < 0.05 vs. normoxia. 
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4.3.3 Effects of chronic hypoxia on lactate dehydrogenase release 
To examine chronic hypoxia induced cell injury, we measured lactate dehydrogenase (LDH: 
an enzyme that is released by cell death caused by apoptosis or necrosis) release. A 
significant increase in LDH release was observed in hypoxia group to 220.2±15.9%, while 
normoxia present 100% (Figure 3.3).  
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Figure 4.3 Effects of chronic hypoxia on LDH release. After 8 hr hypoxia, cell media 
collected and measured LDH release content by colorimetric assay as described in materials 
and methods. The percentage of LDH release of normoxia cells was set as 100%. Results 
expressed as the means ± SD from n=3. Statistical analysis was performed using a Paired t-
test where significance was recorded, ** P < 0.01 vs. normoxia.  
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4.3.4 Effects of chronic hypoxia on apoptosis and necrosis 
To examine chronic hypoxia induced cellular morphological changes and the characterise 
types of cell death, we assessed the cell apoptosis/necrosis by immunofluorescence assay. 
Figure 3.4A shows images of cells staining with three fluorescence probes (Hoechst 33342: 
an indicator of apoptosis and DNA fragmentation/condensation, YO-PRO-1: an indicator of 
membrane damages, and PI: an indicator of necrosis and membrane damages). Analysed 
images of viable (green), early apoptotic (blue), late apoptotic (pink), and necrotic cells (red) 
are shown in Figure 3.4A. In normoxia cells, a high cell viable rate (92.5 ± 3.1%) was 
observed, with 4.9 ± 4.1% of early apoptosis, 2.7 ± 1.6% of late apoptosis, and no necrosis. 
In contrast, hypoxia cells showed a significant decrease in cell viability (77.1 ± 2.2%) and 
increase in late apoptosis (17.9 ± 3.5%), although the changes of early apoptosis and necrosis 
rate were not significant (Figure 3.4B-3.4E). 
 
A. Images of morphological changes in hypoxia induced H9c2 cells 
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Figure 4.4 Effects of chronic hypoxia on apoptosis and necrosis.  After 8 hr hypoxia, cells 
were stained with Hoechst 33342(HC), YO-PRO-1 and PI probes and visualised as described 
in method. (A) Images of cells staining with three probes and analysed images in normoxia, 
hypoxia and 0.1 μM CsA (Cyclosporin A: a mitochondrial permeability transition pore 
opening inhibitor). Analysed images show viable (green), early apoptosis (blue), late 
apoptosis (pink) and necrosis (red) cells respectively. (B-E) Mean data show subpopulations 
of viable cells (dimly stained HC+ (yellow arrow)), early apoptotic cells (brightly stained 
HC+ (red arrow) and YO-PRO-1+), late apoptotic cells (HC+, YO-PRO-1+, PI+) and 
necrotic cells (HC+ and PI+) respectively. Values shown are mean ± SEM from n=5.  
Statistical analysis was performed using a One way ANOVA where significance was 
recorded *** P < 0.001 vs. normoxia, ### P < 0.001 vs. hypoxia.  
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4.3.5 Effects of chronic hypoxia on caspase 3 activity 
To further investigate mechanisms involvement of this late apoptosis, the changes of caspase 
3 activity, a key stimulator of cell apoptosis in intrinsic pathway, was measured. As shown in 
Figure 3.5, hypoxia significantly increased caspase 3 activity by 1.6 fold compared to 
normoxia group. This activation markedly inhibited by Ac-DEVD-CHO, a caspase 3 
inhibitor, compared to hypoxia and normoxia groups.  
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Figure 4.5 Effects of chronic hypoxia on caspase 3 activity. Changes of caspase 3 activation 
were determined by colorimetric assay as described in method. The caspase 3 activity of 
normoxia cells was set as 1. Values are mean ± SE from n=4. Statistical analysis was 
performed using a One way ANOVA where significance was recorded ** P < 0.01 vs. 
normoxia, ### P < 0.001 vs. hypoxia.   
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4.3.6 Effects of chronic hypoxia on cytochrome c translocation 
Cytochrome c translocation rate was examined by immunofluorescence assay. Figure 3.6A 
illustrates image of three combined fluorescence probes, MitoTracker (for mitochondria 
localization: red), cytochrome c (green) and DAPI (for nuclear staining (viable cell staining): 
blue). In normoxia, cytochrome c displayed punctuates cytoplasmic staining, which is in 
agreement with its localization in mitochondria. Cells underwent hypoxia illustrated diffused 
cytoplasmic staining as results of mitochondrial integrity loss. In hypoxia group, there was 
significant increase in cytochrome c translocation rate by 1.72 fold compared to normoxia 
group (Figure 3.6B). 1 hr pre-treatment with CsA, mitochondria permeability transition pore 
opening inhibitor, significantly inhibited cytochrome c release induced by hypoxia.  
. 
A. Images of cytochrome c translocation 
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Figure 4.6 Effects of chronic hypoxia on cytochrome c translocation. After 8 hr hypoxia, 
cells were stained and visualised as described in materials and methods. (A) Cell images 
stained with cytochrome c (green) and MitoTracker (red) and DAPI (blue) labellings in 
normoxia, hypoxia and 0.1 μM CsA treatments. (B) H9c2 cells were scored as having 
cytochrome c in mitochondria defined by punctuate (no cytochrome c release) or cytochrome 
c release to cytosolic distinguished by diffused staining and overtaking mitochondrial 
staining. Mean data from 500 cells per group in 3 independent experiments. Statistical 
analysis was performed using a One way ANOVA where significance was recorded * P < 
0.05 vs. normoxia control cells, ## P < 0.01 vs. hypoxia. 
 
4.3.7 Effects of chronic hypoxia on mitochondrial membrane potential 
To determine mitochondrial membrane potential, an indicator of MPTP opening, H9c2 cells 
were loaded with TMRM probe. Figure 3.7A illustrates the fluorescence images of normoxia 
and hypoxia group. In normoxia cells, TMRM staining displayed punctuates which is in 
agreement with intact mitochondria integrity. Cells underwent hypoxia illustrated diffused 
TMRM staining (loss of mitochondria integrity) with increased fluorescence intensity. Cells 
exposed to 8 hr hypoxia exhibited a significant increase in membrane potential (2.1 fold 
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increase), compared to normoxia, indicating a hyperpolarization of mitochondria membrane. 
Mitochondrial permeability transition pore opening inhibitor (CsA 0.1 μM) significantly 
inhibited the hyperpolarization by 92.9% compared to hypoxia group (Figure 3.7B).  
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Figure 4.7 Effects of chronic hypoxia on mitochondrial membrane potential. After 8 hr 
hypoxia, cells were stained with TMRM and measured fluorescence assay as described in 
materials and methods. (A) Visualised cells are images stained with TMRM. In normoxia 
cells, TMRM staining displayed punctuates form. Cells underwent hypoxia illustrated 
diffused TMRM staining (yellow arrow) and increased fluorescence intensity. (B) TMRM 
intensity measured by microplate reader as described in materials and methods. The 
quantitative data is calculated by fluorescence intensity over cell number left in the plates 
after fluorescence measurements. Values shown are mean ± SEM from n=3. Statistical 
analysis was performed using a One way ANOVA where significance was recorded *** P < 
0.001 vs. normoxia, ### P < 0.001 vs. hypoxia. 
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4.3.8 Effects of chronic hypoxia on Bcl-2 proteins expression  
4.3.8.1 Anti-apoptosis proteins 
Figure 3.8A shows a representative western blot probed for Bcl-2 and corresponding β-actin. 
In hypoxia group, significant reduction of Bcl-2 protein expression was observed by 24% 
compared to normoxia group (Figure 3.8B).  
Figure 3.9A shows a representative western blot probed for Bcl-xl and corresponding β-actin. 
Figure 3.9B shows quantitative results of Bcl-xl blot density. No significant decrease in Bcl-
xl protein expression was observed in hypoxia group compared to normoxia group (p > 0.05).  
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Figure 4.8 Effects of chronic hypoxia on Bcl-2 protein expression. Whole cell lysates were 
isolated after 8 hr hypoxia and used for western blotting as described in materials and 
methods. (A) Protein (50 μg) was loaded to evaluate Bcl-2 protein expression. (B) 
Quantitative western blot band intensity.  The Bcl-2 protein expression of normoxia control 
cells was set as 1. Results expressed as the means ± SD from n=4. Statistical analysis was 
performed using a Paired t-test where significance was recorded as ** P < 0.01 vs. normoxia. 
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Figure 4.9 Effects of chronic hypoxia on Bcl-xl protein expression. Whole cell lysates were 
isolated after 8 hr hypoxia and used for western blotting as described in materials and 
methods.  (A) Protein (20 μg) was loaded to evaluate Bcl-xl protein expression. (B) 
Quantitative western blot band intensity. The Bcl-xl protein expression of normoxia control 
cells was set as 1. Results expressed as the means ± SD, from n=4.   
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4.3.8.2 Pro-apoptotic proteins  
Figure 3.10A shows a representative western blot probed for Bak and corresponding β-actin. 
In hypoxia induced cells, Bak protein levels were significantly elevated by 52% compared to 
normoxia group (Figure 3.10B). 
Figure 3.11A shows a representative western blot probed for Bax and corresponding β-actin. 
After 8hr hypoxia, Bax protein expression was significantly increased by 98% compared to 
normoxia group (Figure 3.11B) 
 
4.3.8.3 Bax/Bcl-2 ratio 
Compared with normoxia group, hypoxia exposed group showed distinguishable changes by 
162% increase (Figure 3.12) as results of reduction of anti-apoptotic protein and elevation of 
pro-apoptotic protein levels. 
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Figure 4.10 Effects of chronic hypoxia on Bak protein expression. Whole cell lysates were 
isolated after 8 hr hypoxia and used for western blotting as described in materials and 
methods.  (A) Protein (80 μg) was loaded to test Bak protein expression. (B) Quantitative 
western blot band intensity. The Bak protein expression of normoxia control cells was set as 
1. Results expressed as the means ± SD from n=5. Statistical analysis was performed using a 
Paired t-test where significance was recorded as * P < 0.05 vs. normoxia. 
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Figure 4.11 Effects of chronic hypoxia on Bax protein expression. Whole cell lysates were 
isolated after 8 hr hypoxia and conducted western blot described in materials and methods. 
(A) Protein (80 μg) was loaded to test Bax protein levels. (B) Quantitative western blot band 
intensity. The Bax protein expression of normoxia control cells was set as 1. Results 
expressed as the means ± SD from n=4. Statistical analysis was performed using a Paired t-
test where significance was recorded as * P < 0.05 vs. normoxia. 
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Figure 4.12 Effects of chronic hypoxia on Bax/Bcl-2 proteins ratio. The Bax/Bcl-2 ratio of 
normoxia control cells was set as 1. Results expressed as the means ± SD, from n=4. 
Statistical analysis was performed using a Paired t-test where significance was recorded as ** 
P < 0.01 vs. normoxia. 
 
4.3.9 Effects of chronic hypoxia on cytosolic ROS production  
4.3.9.1  NADPH oxidase activity  
To evaluate the changes of NADPH oxidase activity by chronic hypoxia, NADPH oxidase 
activity was measured by chemoluminescence assay. Significant decrease of relative light 
unit (RLU) observed in 8 hr hypoxia group to 6529.7 ± 1524.9 RLU, presenting 36.0% fall 
compared to normoxia group.  DPI (NADPH oxidase inhibitor) treatment significantly 
reduced NADPH oxidase activity by 58.7% and 35.0% compared to normoxia and hypoxia 
groups respectively (Figure 3.13).  
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Figure 4.13 Effects of chronic hypoxia on intracellular NADPH oxidase activity. H9c2 cells 
were incubated with 5 μΜ diphenyliodonium (DPI: NADPH oxidase inhibitor) for 1 hr 
before hypoxia. After hypoxia, whole cell lysates were prepared and NADPH oxidase activity 
was measured by chemiluminoscence assay as described in materials and methods. Values 
shown are mean ± SEM from n=4.  Statistical analysis was performed using a One way 
ANOVA where significance was recorded # P < 0.05 vs. hypoxia, ** P < 0.01 vs. normoxia, 
*** P < 0.001vs. normoxia. 
 
4.3.9.2 Cytosolic superoxide production and SOD activity 
To evaluate the effects of hypoxia on intracellular superoxide generation, cells were loaded 
with DHE probe. Changes of cytosolic SOD activity were measured by colorimetric assay. 
Figure 3.14 shows the quantitative mean value of DHE florescence intensity. 8 hr hypoxia 
significantly decreased the DHE fluorescence intensity to 83.7 ± 18.9 a.u, presenting 61% 
decrease compared to normoxia group. 1 hr pre-treatment with 5 μM DPI reduced superoxide 
production significantly by 73% compared to normoxia group.   
Figure 3.15 shows the quantitative mean value of SOD activity. Cells underwent 8 hypoxia 
treatment did not show statistical difference compared to normoxia group (p > 0.05).   
- 83 - 
 
F
lu
o
re
sc
en
c
e 
in
te
n
si
ty
 (
a.
u
)
Nomoxia Hypoxia DPI  5 M
0
100
200
300
***
***
Hypoxia+DPI
 
Figure 4.14 Effects of chronic hypoxia on intracellular superoxide production. H9c2 cells 
were incubated with 5 μΜ DPI for 1hr before hypoxia. Then cells were labelled with DHE 
probe and visualised as described in materials and methods. The quantified value of 
fluorescence intensity were calculated per image and averaged. Values shown are mean ± 
SEM from n=4. Statistical analysis was performed using a One way ANOVA where 
significance was recorded *** P < 0.001 vs. normoxia. 
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Figure 4.15 Effects of chronic hypoxia on cytosolic SOD enzyme activity. Cytosolic 
fractions were lysated after 8 hr hypoxia and 20 μg of proteins was used to determine 
colorimetric SOD activity as described in materials and methods. Data shown are 
representative of mean ± SEM from n=4. Statistical analysis was performed using a Paired t-
test. 
 
4.3.10 Effects of hypoxia on hydrogen peroxide/peroxinitrite production 
To further examine other sources of ROS (hydrogen peroxide: H2O2 and peroxinitrite: 
ONOO
-
) in intracellular, cells were stained with DCFH-DA probe. 
Figure 3.16 shows the quantitative data DCFH-DA fluorescence intensity. Hypoxia 
significantly elevated DCF fluorescence intensity to 9.57 ± 0.50 a.u/mg protein, presenting 59% 
increase compared to normoxia group. When H9c2 cells were pre-treated with inhibitors, the 
hypoxia induced increase in DCF fluorescence was abolished by 1 μM MnTBAP (ONOO- 
inhibitor but not NO) and 10 μM rotenone (Complex I inhibitor) and antimycin A (AA) 
(Complex III inhibitor) by presenting 70.1%, 79.2% and 91.4% inhibition compared to 
hypoxia group respectively.  
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Figure 4.16 Effects of chronic hypoxia on intercellular H2O2 and ONOO
-
 production. Cells 
were treated with 1 μM MnTBAP (ONOO- inhibitor), 10 μM rotenone (Complex I inhibitor) 
and 10 μM antimycinA (AA) (Complex III inhibitor) for 1 hr before hypoxia. After hypoxia, 
H9c2 cells were stained with 20 μM DCFH-DA and measured fluorescence intensity as 
described in materials and methods. The data shown are representative of fluorescence 
intensity normalized to total protein content and expressed as arbitrary units per mg protein. 
Data shown are representative of mean ± SEM from n=4. Statistical analysis was performed 
using a One way ANOVA where significance was recorded *** P < 0.001 vs. normoxia, ### 
P < 0.001 vs. hypoxia.  
 
4.3.11 Effects of chronic hypoxia on mitochondrial ROS production  
4.3.11.1  Mitochondrial superoxide generation and SOD activity 
As shown in Figure 3.16, increased intracellular ONOO
-
 and H2O2 productions by hypoxia 
are originated from mitochondrial ROS demonstrated by inhibitors (Complex I and Complex 
III inhibitors). To examine the effects of hypoxia on mitochondrial superoxide generation, 
cells were labelled with MitoSOX. The changes of mitochondrial SOD activity by hypoxia 
were measured by colorimetric assay.   
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Figure 3.17A illustrates the images of cells staining with MitoSOX. When compared to 
normoxia group, distinctive MitoSOX fluorescence intensity was observed in hypoxia group. 
Figure 3.17B shows the quantitative mean data of MitoSOX fluorescence intensity. Cells 
exposed to hypoxia exhibited significant increase in MitoSOX fluorescence intensity to 154.3 
± 19.9 a.u, presenting 74% elevation compared to normoxia group. 
1 hr pre-treatment with 10 mM TEMPOL (superoxide dismuatse mimic) significantly 
reduced mitochondrial superoxide production to 86.4 ± 14.8 a.u (102.7% reduction compared 
to hypoxia group). Also, 1 hr pre-treated with 10 μM rotenone (Complex I inhibitor) and 10 
μM antimycin A (Complex III inhibitor) significantly reduced mitochondrial superoxide 
production to 93.4 ± 14.0 a.u and 109.8 ± 11.4 a.u (92.1% and 67.3% fall compared to 
hypoxia group) respectively. Furthermore, 1 hr pre-treatment with 1 mM L-NAME 
significantly decreased the mitochondrial superoxide production to 102.5 ± 8.1 a.u (78.4% 
decrease compared to hypoxia).  
 
Figure 3.18 presents the quantitative mean value of SOD activity. Chronic hypoxia 
significantly reduced MnSOD activity to 71.2 ± 2.2%, presenting 13% reduction compared to 
normoxia group. 
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Figure 4.17 Effects of chronic hypoxia on mitochondrial superoxide production. 1 hr before 
inducing hypoxia, cells were pre-treated with 10 mM TEMPOL (SOD mimic), 10 μM 
rotenone (Complex I inhibitor), 10 μM AA (Complex III inhibitor) and 1 mM L-NAME 
(Nitric oxide synthases inhibitor). After hypoxia, cells were stained with MitoSOX and 
visualised as described in materials and methods. (A) Images of cells labelled with MitoSOX 
(for mitochondrial superoxide staining) and DAPI (for viable cell staining). (B) Quantitative 
fluorescence image intensity. The quantified value of fluorescence intensity were calculated 
per image and averaged. Represented data are mean value of 500 each cells with 4 
independent experiments. Statistical analysis was performed using a One way ANOVA 
where significance was recorded *** P < 0.001 vs. normoxia, ### P < 0.001 vs. hypoxia. 
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Figure 4.18 Effects of chronic hypoxia on mitochondrial SOD enzyme activity. 
Mitochondria fractions were lysated and 20 μg of proteins was used to determine colorimetric 
SOD activity as described in materials and methods. Results expressed as the means ± SD 
from n=4. Statistical analysis was performed using a Paired t-test where significance was 
recorded as ** P < 0.01 vs. normoxia. 
 
4.3.12 Effects of chronic hypoxia on intracellular nitric oxide production 
To determine the effects of chronic hypoxia on intracellular NO production, 
immunofluorescence assay was conducted using DAF-2 probe.  
Figure 3.19A illustrate images of cells staining with DAF-2 in normoxia, hypoxia and L-
NAME. When compared to normoxia group, distinctive DAF-2 fluorescence intensity was 
observed in hypoxia group. The quantitative values of the florescence intensity of images are 
presented in Figure 3.19B. The fluorescence intensity in hypoxia group was 155.9 ± 14.2 a.u, 
whereas the normoxia group showed an average fluorescence intensity of 81.2 ± 5.2 a.u, 
presenting a 92.0 % increase in hypoxia group. Additionally, the enhanced fluorescence 
intensity by hypoxia was significantly reduced in cells treated with L-NAME (1 mM, NO 
synthase inhibitor) to 93.3 ± 8.6 a.u, presenting 92.5% reduction compared to hypoxia group. 
The value presented approximate with normoxia group (81.2 ± 5.2 a.u). 
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Figure 4.19 Effects of chronic hypoxia on intracellular nitric oxide production. (A) H9c2 
cells were treated with 1 mM L-NAME (NOS inhibitor) for 1 hr before hypoxia. Then, 5 μM 
DAF-2 were labelled after hypoxia and visualised as described in materials and methods. (B) 
Quantitative fluorescence image intensity. The quantified value of fluorescence intensity 
were calculated per image and averaged. Represented data are mean value of 500 each cells 
with 3 independent experiments. Statistical analysis was performed using a One way 
ANOVA where significance was recorded *** P < 0.001 vs. normoxia, ### P < 0.001 vs. 
hypoxia. 
 
4.3.13 Effects of chronic hypoxia on Hsp90 and eNOS proteins expression  
Changes in Hsp90 and eNOS proteins expression by hypoxia were determined by western 
blot. 
Figure 3.20A shows a representative western blot of whole cell extract probed for Hsp90 and 
corresponding β-actin. H9c2 cells exposed to hypoxia showed 1.5 fold increases in Hsp90 
expression compared to normoxia group (Figure 3.20B).  
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Figure 3.21A shows a representative western blot of whole cell extract probed for p-eNOS 
and corresponding t-eNOS. Prolonged hypoxia increased eNOS phosphorylation by 1.57 fold 
compared to normoxia group (Figure 3.21B).  
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Figure 4.20 Effects of chronic hypoxia on Hsp90 protein expression. Whole cell lysates were 
isolated after 8 hr hypoxia and used for western blot assay as described in materials and 
methods. (A) Protein (50 μg) was loaded to evaluate Hsp90 protein expression. (B) 
Quantitative western blot band intensity. The Hsp90 protein expression of normoxia control 
cells was set as 1. Results expressed as the means ± SD from n=4. Statistical analysis was 
performed using a Paired t-test where significance was recorded as * P < 0.05 vs. normoxia. 
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Figure 4.21 Effects of chronic hypoxia on eNOS phosphorylation. Whole cell lysates were 
isolated after 8 hr hypoxia and used for western blot assay as described in materials and 
methods. (A) Protein (50 μg) was loaded to evaluate p-eNOS and t-eNOS expression. (B) 
Quantitative western blot band intensity. The p-eNOS/t-eNOS proteins ratio of normoxia 
control cells was set as 1. Results expressed as the means ± SD from n=4. Statistical analysis 
was performed using a Paired t-test where significance was recorded as * P < 0.05 vs. 
normoxia. 
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4.3.14 Effects of chronic hypoxia on intracellular calcium levels 
To examine changes in intracellular calcium ([Ca
2+
]i ) levels after chronic hypoxia, cells were 
loaded with Fura 2-AM probe. Figure 3.22 shows the quantitative intracellular calcium levels. 
[Ca
2+
]i was greatly elevated in hypoxia group to 144.7 ± 22.5 nM while normoxia group 
presented 77.5 ± 8.4 nM, presenting a 86.5% increase in hypoxia group.  
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Figure 4.22 Effects of chronic hypoxia on intracellular calcium levels. After hypoxia, cells 
were loaded with 2 μM of Fura-2AM and measured fluoresce intensity as described in 
materials and methods. The data shown are calculated by equation described in appendix 
(Appendix A.3). Results expressed as the means ± SD from n=4. Statistical analysis was 
performed using a Paired t-test where significance was recorded as ** P < 0.01 vs. normoxia. 
 
4.3.15 Effects of chronic hypoxia on cellular ATP contents 
To examine the effects of chronic hypoxia on cellular ATP contents, luminescence assay was 
conducted. Figure 3.24 shows the quantitative result of cellular ATP contents. After 8 hr 
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hypoxia, a significant reduction of the cellular ATP contents was observed by presenting 20.9% 
decrease compared to normoxia (Figure 3.24).  
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Figure 4.23 Effects of chronic hypoxia on cellular ATP contents. After hypoxia, cell lysates 
were collected and 10 μg of protein used for detecting ATP contents. Cellular ATP contents 
were measured by luminescence assay as described in materials and methods. The ATP 
contents of normoxia cells were set as 1. Results expressed as the means ± SD from n=5. 
Statistical analysis was performed using a Paired t-test where significance was recorded as * 
* P < 0.01 vs. normoxia. 
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4.4   Discussion 
The main objective of the studies described in this Chapter is to establish a suitable hypoxia 
cell model to investigate actions of tanshinones. Based on the result from time course study, 
it was found that 8 hr hypoxia exposure induced a significant cell damage and activation of 
cell death signalling. This is similar to a previous study showing that the same hypoxia 
condition caused significant cell death and activation of mitochondrial death pathway [168]. 
The establishment of the hypoxia cell model makes it possible for subsequent studies to 
analyse the mechanisms of cardioprotective actions of tanshinones.  
 
4.4.1 Chronic hypoxia on cell injury and intrinsic pathway 
H9c2 cells exposed to the chronic hypoxia at the present experimental condition exhibited a 
significant cell injury, with increased LDH enzyme release and decreased cell viability or 
increased cell death rate.  
LDH enzyme is located cytosolically, thus, the increase of LHD release indicates an 
impairment of cell membrane by hypoxia [169]. This is consistent with the cell viability 
result, which showed a significant increase in cell death rate caused by hypoxia. The finding 
is similar to previous studies in prolonged/chronic hypoxia conditions [170-171]. In order to 
characterise the stages of cell injury caused by hypoxia, experiments were conducted using 
three different fluorescence probes for apoptosis and necrosis. The results indicate that main 
type of cells damage caused by 8 hr hypoxia is late apoptosis, as characterised by condensed 
chromatin and nuclear, and changes in permeability of cell membrane which causes 
mitochondrial membrane disturbance (Figure 3.4A).  
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It is most likely that cell injury and apoptosis observed in this cell model is due to 
mitochondrial dysfunction and activation of intrinsic pathway as hypoxia significantly 
increased the mitochondrial membrane potential, and changes in caspase 3 activation, 
cytochrome c translocation, and imbalancing in anti- and pro-apoptotic proteins in Bcl-2 
family proteins. This is consistent with previous observations on apoptosis signalling 
pathways in H9c2 cells under hypoxia conditions [172-173] 
It has been established that mitochondria membrane potential is an indicator of MPTP 
opening and increasing MPTP opening subsequently causes cell apoptosis [174]. The 
disturbance in membrane potential may be resulted from altered mitochondria transport of 
proton in electron transport chain and manifested as de- and hyper-polarization [175]. Thus, 
the mitochondria membrane hyperpolarization may link directly to mitochondria apoptosis 
signalling pathway.  
It has been well established that Bcl-2 family proteins play an important role in maintaining 
mitochondrial function and are involved in cardiac protection mechanisms of various 
therapeutic agents [176]. Overexpression of Bcl-2 has been linked to protection of cell 
apoptosis by inhibition of cytochrome c releases [177], while depletion of Bax protein has 
been shown to reduce cell death in ischemia reperfusion injury in mice [178]. In the present 
study, the increased cell death by hypoxia is most likely due to increased pro-apoptotic 
proteins (Bak and Bax) expression and decreased anti-apoptotic protein (Bcl-2) expression. 
Interestingly, under the hypoxia condition, the Bak expression was markedly elevated, while 
that of Bcl-xl was not significantly changed.  Previous studies showed that Bak protein could 
be sequestered not only by Bcl-xl but also by Mcl-l (a member of anti-apoptotic proteins of 
Bcl-2 family proteins) [179]. Recent studies showed that NO production was increased in 
chronic hypoxia [180-181]. NO could induce Mcl-1 protein inactivation which led to Bak and 
Bax proteins activation and cytochrome c release [182]. Thus, it is possible that the Bak 
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protein activation in the present study may involve inactivation of Mcl-1 protein by chronic 
hypoxia. 
Previous studies have reported that increased HIF-1α and HIF-regulated gene expressions by 
hypoxia are associated with cell apoptosis, possibly by stimulation of Bnip3 protein and p53 
protein which subsequently affect Bax and Bcl-xl proteins in mitochondria [98]. The elevated 
Bax and HIF-1α expressions as observed in the present study support a possible link between 
these signalling molecules.  
 
4.4.2  Chronic hypoxia on cytosolic and mitochondrial ROS production 
Previous studies on hypoxia induced ROS generation have shown conflicting results. This 
could be due to a confusion of ROS examined (cytosolic and mitochondria).  It has been 
shown that hypoxia decreased cytosolic superoxide generation but increased mitochondrial 
superoxide generation [183]. Consistent with this, a significant decrease in cytosolic 
superoxide generation and but increase in mitochondrial superoxide generation after hypoxia 
were observed in the present study (Figures 3.14 and 3.17). Decreased cytosolic superoxide 
generation may be resulted from lower oxygen level during hypoxia condition and/or 
decreased NADPH oxidase activity [33, 184]. Interestingly, activity of cytosolic antioxidant 
enzyme superoxide dismutase was not significantly changed after hypoxia, indicating that 
this cytosolic antioxidant enzyme may not play a major role in cell injury and death pathway 
during chronic hypoxia. On the other hand, there was significant increase of hydrogen 
peroxide/peroxinitrite production, as indicated by DCFH-DA fluorescence probe, suggesting 
a non-cytosolic ROS component may be involved.   
In contrast to the finding of cytosolic superoxide production, mitochondrial superoxide level 
was significantly increased, indicating involving mitochondrial electron transport chain 
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(Figure 3.17B). This is further supported by the finding of Complex I and III inhibitors.  It is 
possible that the increase in mitochondrial superoxide may involve obstructed complex I and 
III (peroxinitrite and NO involvement respectively) and inhibition of mitochondrial 
superoxide dismutase activity. The present result is in line with a previous report showing 
that increased NO and ONOO
-
 generations resulted in enhanced mitochondrial superoxide 
generation by blocking mitochondrial electron transport chain [185]. NO can act as a 
physiological regulator of respiration by reversibly inhibiting cytochrome c oxidase at the 
low concentrations (nanomolar). However, at higher concentrations NO can oxidize 
ubiquinol of ubiquinol-cytochrome c reductase (Complex III) to increase unstable 
ubisemiquinone, which produces the superoxide by univalent electron transfer to O2, [83]. 
Additionally, exposure to higher concentrations of NO can increase in peroxinitrite formation 
which causes an inhibition of mitochondrial respiration at multiple sites (complex I, complex 
II, cytochrome c oxidase, the ATP synthase, aconitase, MnSOD and creatine kinase) [38]. 
This implies that restoring electron transport chain functions, in addition to antioxidant 
enzyme activity, may help to reduce mitochondrial superoxide production. 
 
4.4.3  Chronic hypoxia on intracellular NO production 
As mentioned in Section 1.6.4, NO is produced by NO synthases, and involved cofactors and 
regulators. The findings from the present study that chronic hypoxia increased Hsp90 
expression, eNOS phosphorylation and intracellular calcium level indicates that NO pathway 
is activated by hypoxia. This is consistent with previous studies showing an increase in NO 
production via upregulations of Hsp90 and eNOS phosphorylation [164] and Ca
2+
/calmodulin 
[77].  In addition, cell damages by peroxinitrite though increased eNOS phosphorylation have 
been demonstrated via inhibition of electron transport chain [78, 80].  
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Excess production of NO by hypoxia is also associated with HIF-1α accumulation [186]. 
Quantitatively, it has been shown that when NO levels were higher (> 1 μM), it stabilized 
HIF-1α and resulted in cell damage. On the contrary, when NO levels were lower  (< 0.4 μM), 
it inhibited HIF-1α stabilization and increased cell survival [186]. In the present study, 
although NO levels in cells were not quantitatively determined, it was found that chronic 
hypoxia induced a significant HIF-1α activation (Figure 3.2), excess NO production (Figure 
3.21B) and cell apoptosis (Figure 3.4D). This indicates that higher level of NO may be 
produced by 8 hr hypoxia condition. It is possible that NO may be involved in cell apoptosis 
via HIF-1α stabilization which subsequently accelerates cell death signalling pathway (e.g. 
activation of p-53 and Bnip3 proteins or increase mitochondrial superoxide generation by 
interrupting ETC function) [95, 98]. Finally, mitochondrial complex IV inhibition by NO can 
also reduce oxygen consumption [82]. Thus, increased NO and hydrogen 
peroxide/peroxinitrite productions as observed in this study may result in inhibition of 
electron transport chain function as supported by the finding of decreased cellular ATP level 
(Figure 3.24).  
 
4.4.4  Chronic hypoxia on intracellular calcium production 
Changes in intracellular calcium level during hypoxia are important in MPTP opening[60]. 
Decreased intracellular ATP by hypoxia can decrease cellular pH by glycolysis activation and 
this elicits imbalancing in intracellular ion exchange, and subsequently, increases in 
intracellular calcium level [187]. This is supported by the finding from this study that 
increased intracellular calcium level by hypoxia. Additionally, studies have shown that 
increased intracellular calcium may influence mitochondrial ROS production [188-189]. 
Therefore, there may be interactions between NOS cofactor, Ca
2+
/calmodulin and ROS [77].  
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In summary, chronic hypoxia in H9c2 cells induced apoptosis by activation of mitochondrial 
death pathway, which involves regulation of anti- and pro-apoptotic proteins in Bcl-2 family 
proteins, mitochondria membrane hyperpolarization, cytochrome c translocation and caspase 
3 activity as well as HIF-1α activation. Additionally, hypoxia also causes excess production 
of mitochondrial ROS, NO production and intracellular calcium. These findings highlight the 
importance of intrinsic pathway in hypoxia induced cell injury in H9c2 cells.  
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5 Chapter 4   EFFECTS OF 
TANSHINONES ON CHRONIC 
HYPOXIA INDUCED APOPTOSIS IN 
H9C2 CELLS 
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5.1 Introduction 
Tanshinones are a group of bioactive compounds isolated from Salvia miltiorrhiza (Danshen), 
a traditionally medicinal plant used for treating angina pectoris, atherosclerosis and 
myocardial infarction [190]. Tanshinone IIA (TIIA) and cryptotanshinone (CT) are two major 
bioactive tanshinone [102] . They have been reported with actions against inflammation, 
oxidative stress, myocardial infarction, and myocardial ischemia reperfusion injury [107]. For 
example, studies in neonatal cardiomyocytes have revealed vasodilatation action and anti-
apoptosis effects of TIIA [121, 191] by attenuating ROS level and enhancing Bcl-2 protein 
expression. TIIA has also been shown with anti-inflammatory effects, by reducing monocyte 
chemoattractant protein-1 (MCP-1) expression in cardiac fibroblasts [113].  In vivo studies 
have demonstrated that TIIA reduced MI size, an effect was associated with inhibition of 
expression of tumor necrosis factor-α (TNF-α), MCP-1, and nuclear transcription factor-
kappa B (NF-kB)[113]. Similarly, CT has been shown with anti-inflammatory actions by 
inhibition of expressions of NF-kB and matrix metalloproteinases-9 (MMP-9) and vasodilator 
actions by reduction of calcium influx or attenuating expressions of I/R injuries via 
suppressing TNF-α and interleukin1β in cultured cells or in vivo [116-118]. However, the 
actions of TIIA and CT on chronic hypoxia induced cardiac cell injury have still not been 
fully understood, especially on the mechanisms involving in MPTP and mitochondrial 
apoptosis pathway. Furthermore, the actions of these compounds on ROS and NO pathways 
under chronic hypoxia conditions are still not clearly elucidated.  
Thus, there is a need to evaluate using the established hypoxia cell model, the effects of TIIA 
and CT on chronic hypoxia induced cardiac cell injury and apoptosis as well as their 
associations with ROS and NO generations and intracellular calcium in H9c2 cells.  
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5.2 Methods 
See Chapter 2. 
 
5.3 Results 
5.3.1 Cell viability  
Cells were incubated with TIIA and CT (concentration 0.01 μM to 10 μΜ) for 24 hr after 2 
days culture. TIIA and CT in all concentration did not significantly affect cell viability in 
H9c2 cells (p > 0.05) (Figure 4.1). 
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Figure 5.1 Effects of TIIA and CT on cell viability in H9c2 cells. TIIA and CT 
(concentration 0.01 μM to 10 μΜ) were added and incubated for 24 hr. Cell viability was 
determined by MTT assay as described in materials and methods. The cell viability of normal 
cells was set as 100%. Values are mean ± SE from n=3, ns: not significant compared to 
normal. 
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5.3.2 Effects of TIIA and CT on HIF-1α accumulation 
Figure 4.2 shows a representative western blot of nuclear extract probed for HIF-1α and 
corresponding β-actin. 3 μΜ TIIA groups significantly reduced the HIF-1α protein 
accumulation by 95.7% compared to hypoxia group. 0.3 μΜ and 3 μΜ CT groups also 
inhibited the HIF-1α accumulation by 74.3% and 68.9% compared to hypoxia, but these 
values did not reach to statistical significance level.  
- 106 - 
 
Hypoxia + Treatments 
A.                              Normoxia          Hypoxia            TIIA 0.3         TIIA 3                CT 0.3            CT 3 
                  HIF-1α   
                  β-actin    
 
 
 
 
B.  
R
el
at
iv
e 
ex
p
re
ss
io
n
 (
b
y
 N
o
rm
o
x
ia
)
N
or
m
ox
ia
H
yp
ox
ia M
TI
IA
 0
.3
 
M
TI
IA
 3
 
M
C
T 
0.
3 
M
C
T 
3 
0.0
0.5
1.0
1.5
2.0 *
#
Hypoxia + Treatments
 
Figure 5.2 Effects of TIIA and CT on chronic hypoxia induced HIF-1α accumulation. (A) 
H9c2 cells were cultured and exposed to hypoxia for 8 hr either absence or presence of TIIA 
and CT (0.3 and 3 μM).  Nuclear fractions were prepared from cardiomyocytes after exposed 
to 8 hr hypoxia. Equal amounts (25 μg) of the lysates were used for western blotting as 
described in materials and methods. (B) Quantitative western blot band intensity. The HIF-1α 
protein expression of normoxia control cells was set as 1. Values shown are mean ± SEM 
from n=4. Statistical analysis was performed using a One way ANOVA where significance 
was recorded * P < 0.05 vs. normoxia, # P < 0.05 vs. hypoxia. 
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5.3.3 Effects of TIIA and CT on chronic hypoxia induced cell death 
0.3 μM of TIIA and CT significantly increased the cell viability to 81.9 ± 3.4% and 82.5 ± 
9.7%, presenting 22.5% and 25.4% increase compared to hypoxia group respectively (Figure 
4.3).  
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Figure 5.3 Effects of TIIA and CT on chronic hypoxia induced cell death. After 8 hr hypoxia, 
cell viability was determined by MTT assay as described in materials and methods. The cell 
viability of normoxia cells was set as 100%. Values are mean ± SE from n=5. Statistical 
analysis was performed using a One way ANOVA where significance was recorded # P < 
0.05 vs. hypoxia, ** P < 0.001 vs. normoxia.  
 
5.3.4 Effects of TIIA and CT on lactate dehydrogenase release 
3 μΜ of TIIA and CT significantly decreased the LDH release to 125.1 ± 26.4% and 159.6 ± 
21.6%, presenting 79.2% and 50.4% reduction compared to hypoxia group respectively 
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(Figure 4.4). In the presence of 3 μΜ TIIA, the level of LHD release was similar to that of 
normoxia group.  On the other hand, 3 μΜ CT produced similar but slightly less inhibition 
than TIIA.  
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Figure 5.4 Effects of TIIA and CT on hypoxia induced LDH release. After 8 hr hypoxia, cell 
media was collected and used for measuring LDH release content by colorimetric assay as 
described in materials and methods. The LDH release of normoxia control cells was set as 
100%. Values shown are mean ± SEM from n=3. Statistical analysis was performed using a 
One way ANOVA where significance was recorded * P < 0.05 vs. normoxia, # P < 0.05 vs. 
hypoxia, *** P < 0.001 vs. normoxia, ### P < 0.001 vs. hypoxia. 
 
5.3.5 Effects of TIIA and CT on apoptosis and necrosis 
Figure 4.5A illustrates cells staining with Hoechst 33342, YO-PRO-1and PI as well as 
analysed images. Pre-treatment with TIIA and CT (0.3 and 3 μM) as well as 1 hr pre-
treatment of 0.1 μM cyclosporin A (CsA), an inhibitor of MPTP opening and used for 
positive control of membrane potential, significantly increased the cell viability (Figure 
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4.5B). 0.3 μΜ and 3 μM TIIA significantly reduced late apoptosis rate to 6.05 ± 3.6% and 
7.44 ± 5.4% respectively (77.9% and 68.5% decrease compared to hypoxia group). 0.3 μΜ 
and 3 μM CT also significantly decreased the late apoptosis rate to 9.85 ± 7.9% and 10.06 ± 
5.4%, which presenting 52.9% and 51.5% reduction compared to hypoxia group (Figure 
4.5D). No significant changes were observed in the early apoptosis or necrosis rate in all drug 
treated groups (Figure. 4.5C and 4.5E). 
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A. Morphological changes in hypoxia induced H9c2 cells 
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Figure 5.5 Effects of TIIA, CT and cyclosporin A (CsA; an inhibitor of MPTP opening) on 
chronic hypoxia induced apoptosis. (A) Cell images stained with Hoechst 33342(HC), YO-
PRO-1 and PI probes as well as analysed images. The analysed images show viable (green), 
early apoptosis (blue), late apoptosis (pink) and necrosis (red) cells respectively. (B-E) Mean 
data show subpopulations of viable cells (HC+), early apoptotic cells (HC+ and YO-PRO-
1+), late apoptotic cells (HC+, YO-PRO-1+, PI+) and necrotic cells (HC+ and PI+) 
respectively. Values shown are mean ± SEM from n=5. Statistical analysis was performed 
using a One way ANOVA where significance was recorded * P < 0.05 vs. normoxia, # P < 
0.05 vs. hypoxia, ## P < 0.01 vs. hypoxia, *** P < 0.001 vs. normoxia, ### P < 0.001 vs. 
hypoxia. 
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5.3.6 Effects of TIIA and CT on caspase 3 activity 
As shown in Figure 3.5, TIIA (0.3 μΜ and 3 μM) significantly inhibited the caspase 3 
activity by 88.1% and 79.8% compared to hypoxia group respectively.  Pre-treatment with 
CT (0.3 μΜ and 3 μM) also significantly reduced chronic hypoxia induced caspase 3 activity 
by 65.6% and 108.4% respectively.  
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Figure 5.6 Effects of TIIA, CT and a caspase 3 inhibitor (Ac-DEVD-CHO (20 μΜ)) on 
hypoxia induced caspase 3 activation. Changes of caspase 3 activity were determined by 
colorimetric assay as described in materials and method. The caspase 3 activity of normoxia 
control cells was set as 1. Values are mean ± SE from n=4. Statistical analysis was performed 
using a One way ANOVA where significance was recorded * P < 0.05 vs. normoxia, # P < 
0.05 vs. hypoxia, ** P < 0.01 vs. normoxia ### P < 0.001 vs. hypoxia. 
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5.3.7 Effects of TIIA and CT on cytochrome c translocation 
Figure 4.7A illustrates images of cells stained with three combined fluorescence probes, 
MitoTracker (for mitochondria localization: red), cytochrome c (green) and DAPI (for viable 
cells staining: blue). In TIIA treated cells, punctuate cytochrome c staining was observed 
which agrees intact mitochondria integrity. Hypoxia induced cytochrome c release was 
significantly inhibited by TIIA and CsA but not by CT. TIIA (0.3 μΜ and 3 μM) groups 
reduced the cytochrome c release to 6.8 ± 2.57% and 7.54 ± 1.94%, presenting 120.3% and 
107.5% reduction compared to hypoxia group. CT 0.3 μΜ and 3 μΜ groups reduced hypoxia 
induced cytochrome c release to 8.6 ± 1.26% and 10.6 ± 3.50% (86.3% and 54.1% decrease 
compared to hypoxia) without statistical significance (Figure 4.7B). 
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A. Images of cytochrome c translocation 
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Figure 5.7 Effects of TIIA, CT and cyclosporin A (CsA) on hypoxia induced cytochrome c 
translocation. After hypoxia, cells were stained and visualized as described in material and 
methods. (A) Cell images stained with cytochrome c (green) and MitoTracker (for 
mitochondria localization, red) and DAPI (for viable cell staining, blue). Cytochrome c 
translocation in cytosolic after hypoxia distinguished by prominent cytochrome c (green) 
staining (overtaken mitochondrial staining) as results of losing mitochondrial integrity. (B) 
H9c2 cells were scored as having cytochrome c in mitochondria defined by punctuate (no 
cytochrome c release) or cytochrome c release to cytosolic distinguished by diffused staining 
and overtaking mitochondrial staining. Mean data from 500 cells per group in 3 independent 
experiments. Statistical analysis was performed using a One way ANOVA where significance 
was recorded* P < 0.05 vs. normoxia, # P < 0.05 vs. hypoxia, ## P < 0.01 vs. hypoxia.  
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5.3.8 Effects of TIIA and CT on mitochondria membrane potential 
Hypoxia induced hyperpolarization was significantly reduced when the cells treated with 0.3 
μM and 3 μM TIIA to 2.94 ± 0.64 a.u and 2.25 ± 0.14 a.u (38.9% and 74.4% reduction 
compared to hypoxia respectively). 0.3 μΜ and 3 μM CT also significantly reduced the 
hyperpolarization to 2.58 ± 0.29 a.u and 2.39 ± 0.37 a.u (57.2% and 67.1% reduction 
compared to hypoxia respectively). In the presence of 3 μM TIIA, the level of TMRM 
fluorescence intensity was similar to normoxia group.  
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Figure 5.8 Effects of TIIA, CT and CsA on mitochondria membrane potential. After 8 hr 
hypoxia, cells were loaded with 150 nM TMRM for 30 mins and measured changes in 
fluorescence intensity as described in materials and methods.  Values shown are mean ± SEM 
from n=3. Statistical analysis was performed using a One way ANOVA where significance 
was recorded # P < 0.05 vs. hypoxia, ** P < 0.01 vs. normoxia, ## P < 0.01 vs. hypoxia, *** 
P < 0.01 vs. normoxia, ### P < 0.001 vs. hypoxia. 
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5.3.9 Effects of TIIA and CT on Bcl-2 proteins expression  
5.3.9.1 Anti-apoptosis proteins  
Figure 4.9A shows a representative western blot of whole cell extract probed for Bcl-2 and 
corresponding β-actin. Hypoxia induced reduction in Bcl-2 protein expression (Figure 4.9B) 
was significantly elevated by TIIA (3 μM) and CT (0.3 μΜ and 3 μM) by 41.8%, 49.2% and 
44.6% compare to hypoxia group respectively (Figure 4.9 B).   
Figure 4.10A shows a representative western blot of whole cell extract probed for Bcl-xl and 
corresponding β-actin. No change of Bcl-xl protein expression was observed after hypoxia 
exposure. TIIA group (3 μΜ) significantly increased Bcl-xl protein expression by 29.3% 
compared to hypoxia group. Cell treated with 0.3 μM and 3 μM of CT significantly enhanced 
Bcl-xl protein expression by 36.3% and 35.8% compared to hypoxia group (Figure 4.10B).  
  
- 118 - 
 
Hypoxia + Treatments 
A.                              Normoxia           Hypoxia            TIIA 0.3         TIIA 3                CT 0.3            CT 3 
Bcl-2      
β-actin    
 
 
 
 
 
B.  
 
 
 
R
el
at
iv
e 
ex
p
re
ss
io
n
 (
b
y
 N
o
rm
o
x
ia
)
N
or
m
ox
ia
H
yp
ox
ia M
TI
IA
 0
.3
 
M
TI
IA
 3
 
M
C
T 
0.
3 
M
C
T 
3 
0.0
0.5
1.0
1.5
# ##
Hypoxia+Treatments
 
Figure 5.9 Effects of TIIA and CT on Bcl-2 protein expression in hypoxia cells. Whole cell 
lysates were isolated and used for western blot assay as described in materials and methods. 
(A) Protein (50 μg) was loaded to evaluate Bcl-2 protein expression. (B) Quantitative western 
blot band intensity. The Bcl-2 protein expression of normoxia control cells was set as 1. 
Values shown are mean ± SEM from n=4. Statistical analysis was performed using a One 
way ANOVA where significance was recorded # P < 0.05 vs. hypoxia. 
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Figure 5.10 Effects of TIIA and CT on Bcl-xl protein expression in hypoxia cells. Whole cell 
lysates were isolated and used for western blot assay as described in materials and methods. 
(A) Protein (20 μg) was loaded to evaluate Bcl-xl protein expression. (B) Quantitative 
western blot band intensity. The Bcl-2 protein expression of normoxia control cells was set as 
1.Values shown are mean ± SEM from n=4. Statistical analysis was performed using a One 
way ANOVA where significance was recorded # P < 0.05 vs. hypoxia. 
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5.3.9.2  Pro-apoptotic proteins  
Figure 4.11A shows a representative western blot of whole cell extract probed for Bak and 
corresponding β-actin. The significant increase of Bak protein activation by hypoxia was 
significantly decreased by 0.3 μM CT treatment, presenting 113.6% reduction compared to 
hypoxia group. TIIA (0.3 μΜ and 3 μM) and CT (3 μΜ) treated group also did reduced Bak 
protein activation by 79.2%, 83.8% and 63.4% respectively, but the values did not reach to 
statistical significance level (Figure 4.11B).  
Figure 4.12A shows a representative western blot of whole cell extract probed for Bax and 
corresponding β-actin. TIIA (0.3 μΜ and 3 μM) significantly inhibited Bax over expression 
by 89.9% and 103.4% compared to hypoxia group. Also CT (0.3 μΜ and 3 μM) group 
significantly reduced Bax over expression by 95.5% and 109.3% compared to hypoxia group. 
(Figure.4.12 B).   
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Figure 5.11 Effects of TIIA and CT on hypoxia induced over expressions of Bak protein. 
Whole cell lysates were isolated and used for western blot assay as described in materials and 
methods. (A) Protein (80 μg) was loaded to test Bak protein level. (B) Quantitative western 
blot band intensity. The Bak protein expression of normoxia control cells was set as 1. Data 
shown are representative of mean ± SEM from n=5. Statistical analysis was performed using 
a One way ANOVA where significance was recorded * P < 0.05 vs. normoxia, # P < 0.05 vs. 
hypoxia. 
  
- 122 - 
 
Hypoxia + Treatments 
A.                                   Normoxia          Hypoxia            TIIA 0.3         TIIA 3                CT 0.3            CT 3 
         Bax         
          β-actin    
 
 
 
B.  
R
el
at
iv
e 
ex
p
re
ss
io
n
 (
b
y
 N
o
rm
o
x
ia
)
N
or
m
ox
ia
H
yp
ox
ia M
TI
IA
 0
.3
 
M
TI
IA
 3
 
M
C
T 
0.
3 
M
C
T 
3 
0.0
0.5
1.0
1.5
2.0
2.5
#
*
#
#
#
Hypoxia+Treatments
 
Figure 5.12 Effects of TIIA and CT on hypoxia induced over expressions of Bax protein. 
Whole cell lysates were isolated and used for western blot assay as described in materials and 
methods. (A) Protein (80 μg) was loaded to test Bax protein levels. (B) Quantitative western 
blot band intensity. The Bax protein expression of normoxia control cells was set as 1. Data 
shown are representative of mean ± SEM from n=4. Statistical analysis was performed using 
a One way ANOVA where significance was recorded * P < 0.05 vs. normoxia, # P < 0.05 vs. 
hypoxia. 
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5.3.9.3  Effects of TIIA and CT on Bax/Bcl-2 ratio 
TIIA (0.3 μΜ and 3 μM) significantly reduced hypoxia induced increase in the ratio of 
Bax/Bcl-2 proteins by 86.7% and 107.1% compared to hypoxia group. CT (0.3 μΜ and 3 
μM) group also significantly decreased Bax/Bcl-2 ratio by 106.9% and 108.4% compared to 
hypoxia group (Figure 4.13). 
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Figure 5.13 Effects of TIIA and CT on hypoxia induced increase in Bax/Bcl-2 proteins ratio. 
The Bax/Bcl-2 ratio of normoxia control cells was set as 1. Data shown are representative of 
mean ± SEM from n=4. Statistical analysis was performed using a One way ANOVA where 
significance was recorded *** P < 0.001 vs. normoxia, ### P < 0.001 vs. hypoxia.  
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5.3.10 Effects of TIIA and CT on cytosolic ROS production 
5.3.10.1  NADPH oxidase activity  
TIIA (0.3 μΜ and 3 μM) treatments significantly decreased NADPH oxidase activity by 
25.1% and 38.9% compared to normoxia group, but the values did not show statistical 
difference when it compared to hypoxia group. In 3 μM CT group, NADPH oxidase activity 
was significantly reduced by 34 % compared to normoxia group and no statistical difference 
was observed compared to hypoxia group (Figure 4.14). 
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Figure 5.14 Effects of TIIA and CT on hypoxia induced decrease in cytosolic NADPH 
oxidase activity. After hypoxia, whole cell lysates were collected and used for 
chemiluminoscence assay as described in materials and methods. Diphenyliodonium (DPI, 5 
μΜ) was used as an inhibitor of NADPH oxidase. Data shown are representative of mean ± 
SEM from n=4. Statistical analysis was performed using a One way ANOVA where 
significance was recorded * P < 0.05 vs. normoxia, ** P < 0.01 vs. normoxia, *** P < 0.001 
vs. normoxia. 
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5.3.10.2  Cytosolic superoxide production and SOD activity 
The quantitative values of the DHE florescence intensity were presented in Figure 4.15. TIIA 
(0.3 μΜ and 3 μM) reduced the DHE fluorescence intensity by 40% and 55% compared to 
normoxia group. CT (0.3 μΜ and 3 μM) also decreased DHE fluorescence intensity by 56% 
and 37% compared to normoxia group. These tanshinones did not show statistical difference 
when it compared to hypoxia group (Figure 4.15).  
Figure 4.16 shows the quantitative value of cytosolic SOD activity. TIIA and CT (0.3 μΜ and 
3 μM) treatment showed not significant effects on SOD activity (p > 0.05).  
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Figure 5.15 Effects of TIIA and CT on hypoxia induced reduction in cytosolic superoxide 
production. H9c2 cells were incubated with 5 μΜ DPI for 1hr before hypoxia and treated 
with TIIA and CT for 2hr and during hypoxia. Then cells were labelled with dihydroethidium 
(DHE) and visualized as described in material and methods. (B) The quantified value of 
fluorescence intensity were calculated per image and averaged. Data shown are representative 
of mean ± SEM from n=4. Statistical analysis was performed using a One way ANOVA 
where significance was recorded ** P < 0.05 vs. normoxia, *** P < 0.001 vs. normoxia.  
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Figure 5.16 Effects of TIIA and CT on cytosolic SOD enzyme activity in hypoxia cells. 
After hypoxia, cytosolic fractions were lysated and 20 μg of proteins was used to determine 
colorimetric SOD activity as described in materials and methods. Data shown are 
representative of mean ± SEM from n=4. Statistical analysis was performed using a One way 
ANOVA. 
  
5.3.11 Effects of TIIA and CT on hydrogen peroxide/peroxinitrite levels 
Figure 4.17 presents the quantitative values of DCFH-DA fluorescence intensity. When 
compared to hypoxia, cells treated with TIIA and CT (0.3 μM and 3 μM) showed not 
statistical reduction of ONOO
-
/H2O2 production.  
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Figure 5.17 Effects of TIIA and CT on hypoxia induced increase in ONOO
-
 and H2O2 
production. Cells were treated with 1 μM MnTBAP (ONOO- inhibitor), 10 μM rotenone 
(Complex I inhibitor), and 10 μM antimycinA (AA: Complex III inhibitor) for 1 hr before 
hypoxia. TIIA and CT were treated 2 hr before and during hypoxia. After hypoxia, H9c2 cells 
were stained with 20 μM DCFH-DA and read fluorescence intensity as described in materials 
and methods. Fluorescence was normalized to total protein content and expressed as arbitrary 
units per mg protein. Data shown are representative of mean ± SEM from n=4. Statistical 
analysis was performed using a One way ANOVA where significance was recorded * P < 
0.05 vs. normoxia, # P< 0.05 vs. hypoxia, ** P < 0.01 vs. normoxia. 
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5.3.12 Effects of TIIA and CT on mitochondrial ROS production 
5.3.12.1 Mitochondria superoxide production and SOD activity 
Figure 4.18A illustrates the images of MitoSOX labelled in H9c2 cells. TIIA and CT groups 
present weaker MitoSOX fluorescence intensity than hypoxia group. Figure 4.18B shows the 
quantitative values of the MitoSOX florescence intensity. In the presence of TIIA (0.3 μM 
and 3 μM), chronic hypoxia induced overproduction of mitochondrial superoxide was 
significantly reduced by 66.0% and 65.0% compared to hypoxia group. Cells pre-treated with 
CT (0.3 μM and 3 μM) also significantly inhibited the excess of mitochondrial superoxide 
production by 69.2% and 48.1% compared to hypoxia group.  
Figure 4.19 presents the quantitative values of mitochondrial SOD activity. TIIA (0.3 μΜ and 
3 μM) and CT (0.3 μM) significantly increased the mitochondrial SOD activity by 31.9%, 
18.7%, and 34.6% compared to hypoxia group respectively. 0.3 μM TIIA and 0.3 μM CT 
significantly increased mitochondrial SOD activity compared to normoxia group by 15.4% 
and 17.7% respectively.  
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A. Images of cells staining with DAPI and MitoSOX 
DAPI                               MitoSox                            Merge 
          Normoxia       
            Hypoxia       
            TIIA 0.3                   
               TIIA 3            
                CT0.3       
                  CT 3       
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Figure 5.18 Effects of TIIA and CT on hypoxia induced increase in mitochondrial 
superoxide production. 1 hr before inducing hypoxia, cells were pre-treated with 10 mM 
TEMPOL (SOD mimic), 10 μM rotenone (Complex I inhibitor), and 1 mM L-NAME (NO 
synthase inhibitor). TIIA and CT were treated 2hr before and during hypoxia.  After hypoxia 
cells labelled with 2 μM MitoSOX and visualised as described in materials and methods. (A) 
Images of cells stained with MitoSOX and effects of TIIA, CT and inhibitors (B) The 
quantified values of fluorescence intensity were calculated per image and averaged. 
Represented data are mean value of 500 each cells with 5 independent experiments. 
Statistical analysis was performed using a One way ANOVA where significance was 
recorded # P < 0.05 vs. hypoxia, ## P < 0.01 vs. hypoxia, ### P < 0.001 vs. hypoxia, *** P 
< 0.001 vs. normoxia 
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Figure 5.19 Effects of TIIA and CT on hypoxia induced decrease in mitochondrial SOD 
activity. After hypoxia, mitochondria fractions were lysated and 20 μg of proteins was used 
to determine colorimetric SOD activity as described in materials and methods. Data shown 
are representative of mean ± SEM from n=4. Statistical analysis was performed using a One 
way ANOVA where significance was recorded * P < 0.05 vs. normoxia, *** P < 0.001 vs. 
normoxia, ### P < 0.001 vs. hypoxia. 
  
5.3.13 Effects of TIIA and CT on intracellular nitric oxide production 
Figure 4.20A illustrate the fluorescence images of cells stained with DAF-2. TIIA and CT 
groups show distinctively low DAF-2 fluorescence intensity compared to hypoxia group. The 
quantitative values of the DAF-2 florescence intensity of images are presented in Figure 
4.20B. Pre-treatment with TIIA (0.3 μΜ and 3 μM) significantly decreased the DAF-2 
fluorescence intensity to 109.6 ± 41.6 a.u and 97.9 ± 10.1 a.u respectively (62.0% and 77.6% 
reduction compared to hypoxia group). 0.3 μΜ and 3 μM CT groups also significantly 
reduced the DAF-2 fluorescence intensity to 103.4 ± 17.7 a.u and 97.5 ± 25.6 a.u (70.4% and 
78.2% decrease compared to hypoxia group). The levels of NO in TIIA and CT showed 
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approximate with normoxia group. Additionally, cells 1 hr pre-treated with L-NAME (1 mM, 
NOS inhibitor) significantly reduced the elevated NO generation compared to hypoxia group. 
 
A. Images of cells stained with DAPI and DAF-2 probes 
                                       DAPI                              DAF-2                           Merge 
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Figure 5.20 Effects of TIIA and CT on hypoxia induced increase in intracellular nitric oxide 
production. (A) H9c2 cells were treated 1 hr before hypoxia with 1 mM L-NAME and treated 
2hr before and during hypoxia with TIIA and CT. Then, 5 μM DAF-2 was labelled and 
images were visualized as described in materials and methods. (B) Quantitative fluorescence 
image intensity. Represented data are mean value of 500 each cells with 3 independent 
experiments (n=3). Statistical analysis was performed using a One way ANOVA where 
significance was recorded ** P < 0.01 vs. normoxia, # P < 0.05 vs. hypoxia. 
 
5.3.14 Effects of TIIA and CT on Hsp90 and eNOS proteins expression  
Figure 4.21A shows a representative western blot of whole cell extract probed for Hsp90 and 
corresponding β-actin. TIIA (0.3 μΜ and 3 μM) and CT (3 μΜ) significantly increased 
Hsp90 protein expression by 2.1, 2.1 and 2.2 fold compared to normoxia group (Figure 
4.21B). 
Figure 4.22A shows a representative western blot of whole cell extract probed for p-eNOS 
and corresponding t-eNOS. Cells treated with TIIA (0.3 μΜ and 3 μM) and 0.3 μM CT 
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significantly increased eNOS phosphorylation by 2.0, 2.1, 2.2 fold elevation compared to 
normoxia (Figure 4.22B). 
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Figure 5.21 Effects of TIIA and CT on Hsp90 expression in hypoxia cells. After hypoxia, 
whole cell lysates were prepared and used for western blot as described in materials and 
methods. (A) Protein (50 μg) was loaded to evaluate Hsp90 expression. (B) Quantitative 
western blot band intensity. The Hsp90 protein expression of normoxia control cells was set 
as 1. Data shown are representative of mean ± SEM from n=4. Statistical analysis was 
performed using a One way ANOVA where significance was recorded* P < 0.05 vs. 
normoxia.  
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Figure 5.22 Effects of TIIA and CT on eNOS phosphorylation in hypoxia cells. After 
hypoxia, whole cell lysates were prepared and used for western blot as described in materials 
and methods. (A) Protein (50 μg) was loaded to evaluate p-eNOS expression and t-eNOS. (B) 
Quantitative western blot band intensity. The p-eNOS/ t-eNOS ratio of normoxia control cells 
was set as 1. Data shown are representative of mean ± SEM from n=4. Statistical analysis 
was performed using a One way ANOVA where significance was recorded* P < 0.05 vs. 
normoxia. 
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5.3.15 Effects of TIIA and CT on intracellular calcium level 
Pre-treatment with 3 μM TIIA significantly reduced the [Ca2+]i elevation to 104.8 ± 13.4 nM, 
presenting 59.4% reduction compared to hypoxia group. Similar effects was shown in 3 μM 
CT group by reducing [Ca
2+
]i increase to 113.0 ± 8.3 nM (47.1% decrease compared to 
hypoxia group)  without statistical significance (Figure.4.23). 
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Figure 5.23 Effects of TIIA and CT on hypoxia induced increase in intracellular calcium 
production. After hypoxia, cells were loaded with 2 μM of Fura-2AM. The fluorescence 
intensity was measured by microplate reader as described in materials and methods. The data 
shown is calculated by equation described in appendix (Appendix A.3). Value shown are 
representative of mean ± SEM from n=4. Statistical analysis was performed using a One way 
ANOVA where significance was recorded* P < 0.05 vs. normoxia, # P < 0.05 vs. hypoxia, 
** P < 0.01 vs. normoxia *** P<0.001 vs. normoxia. 
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5.3.16 Effects of TIIA and CT on cellular ATP content  
The hypoxia induced ATP depletion was restored by pre-treatment with TIIA (0.3 μΜ and 3 
μM) by 21.1% and 22.8% compared to hypoxia group respectively. 0.3 μM CT group also 
increased the ATP reduction by 23.5% compared to hypoxia group (Figure 4.25). 
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Figure 5.24 Effects of TIIA and CT on hypoxia induced decrease in cellular ATP content. 
After hypoxia, cell lysates were collected and 10 μg of protein used for ATP contents. 
Cellular ATP contents were measured by luminescence assay as described in materials and 
methods. Data shown are representative of mean ± SEM from n=5. Statistical analysis was 
performed using a One way ANOVA where significance was recorded* P < 0.05 vs. 
normoxia, # P < 0.05 vs. hypoxia. 
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5.4 Discussion 
5.4.1 Effects of TIIA and CT on H9c2 cells injury 
Tanshinones have been shown with cardioprotective effects on atherosclerosis, and 
myocardial infarction (see Chapter 1). The main mechanisms involved in the protective 
actions of tanshinones include anti-inflammatory, antioxidant and anti-apoptotic activities 
[109]. In the present study, TIIA and CT showed clear cytoprotective effects against hypoxia 
induced cell death and LDH enzyme release. The results obtained in the present study 
indicate that the cytoprotective actions of tanshinones may involve the following mechanisms 
1) reducing mitochondrial membrane damages, 2) inhibiting apoptosis rate, 3) regulating 
intrinsic signalling pathway, and 4) regulating ROS, NO and intracellular calcium. These 
findings are similar to previous studies on cell apoptosis induced by doxorubicin and I/R 
injuries [112, 116, 191]. 
It was noted that there was difference between effects of TIIA and CT on MTT and LDH 
assays. 0.3 μM TIIA and CT exhibited significant protection of the decrease of cell viability 
by hypoxia, while only 3 μM TIIA and CT showed significant reduction in LDH release. This 
difference may be due to different mechanisms involved in these two assays.  It has been 
reported that MTT reduction is more dependent on the reduced pyridine nucleotides NADH 
and NADPH in extra-mitochondria indicating that it is more related to glycolysis than 
respiration [192]. It seems that MTT assay is more sensitive for detecting actions of 
tanshinones. 
 
5.4.2 Effects of TIIA and CT on intrinsic pathway 
The key findings in present study are that TIIA and CT treatments prevented or reduced the 
hypoxia induced mitochondria membrane hyperpolarization, which is related to their effects 
on mitochondria apoptosis signalling pathway (e.g., via cytochrome c release and caspase 3 
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activation and Bax/Bcl-2 proteins). Previous studies have reported anti-apoptotic actions of 
TIIA against I/R injuries and angiotensin II induced apoptosis in PC12 cells [193]  and 
neonatal cardiomyocytes [194]. The mechanisms involved in the anti-apoptotic actions of 
TIIA were suppressing caspase 3 activity and increasing Bcl-2 expression. TIIA has also been 
shown to regulate mitochondrial membrane potential in β-amyloid induced cortical neurons 
apoptosis [195]. Similarly, the anti-apoptotic potency of CT has been shown previously with 
actions of conserving mitochondrial membrane potential, reducing Bax/Bcl-2 ratio and 
inhibiting cytochrome c release in nitric oxide induced neuroblastoma cells apoptosis [196]. 
It is possible that the anti-apoptotic actions of TIIA and CT observed in the present study are 
associated with not only direct action of these compounds on the intrinsic pathway and but 
also the antioxidant actions of tanshinones [112, 121], as there are evidence that the 
hyperpolarization of mitochondria membrane regulates mitochondrial ROS generation [131, 
165].  
Bcl-2 family proteins play an important role in maintaining mitochondrial function and 
mediating cardiac protections of various therapeutic agents [176]. TIIA has been 
demonstrated to decrease Bax/Bcl-2 ratio in a rat model of ischemia reperfusion injuries in 
vivo [110], and to regulate Bax/Bcl-2 ratio in neonatal cardiomyocytes treated with 
doxorubicin [121]. In the present study, both TIIA (3 μM) and CT (0.3 and 3 μM) 
significantly inhibited Bax and Bak expressions, but increased Bcl-2 and Bcl-xl expressions 
under the chronic hypoxia condition, resulting in a reduced Bax/Bcl-2 ratio and increased cell 
survival rate. As discussed in section 3.4.1, the Bak protein could be sequestered not only by 
Bcl-xl protein but also by Mcl-l protein [179]. It is not clear if the change of Bak expressions 
by TIIA and CT in this study was resulted from their actions on Bcl-xl protein or involved 
Mcl-1 protein.  
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Previous studies have reported that increased HIF-1α and HIF-regulated gene expressions by 
hypoxia are associated with cell apoptosis, possibly by activation of p53 and Bnip3 proteins 
which subsequently results in activation of Bax and suppression of Bcl-xl proteins 
respectively [98]. The decreased Bax and HIF-1α expressions by TIIA and CT as observed in 
the present study indicates potential mechanism involvement in anti-apoptotic actions of 
TIIA and CT. Previously, TIIA has been shown to decrease HIF-1α protein translocation 
induced by lipopolysaccharide (LPS) in mice lung [197] and down regulating p53 protein 
expression in PC12 cells [198]. Thus, it is possible that TIIA may act via HIF-1α dependent 
p53 signalling pathway in H9c2 cells. 
 
5.4.3 Effects of TIIA and CT on ROS production  
Previous studies have reported that the cardio-protective effects of TIIA on H2O2 induced cell 
injury [110] and doxorubicin induced cell apoptosis[121] in neonatal cardiomyocytes by 
protecting DNA integrity, mitochondrial proteins and reducing intercellular ROS production. 
Similarly, the anti-apoptotic potency of CT has been shown previously with actions of 
preventing mitochondrial dependent apoptosis in nitric oxide induced neuroblastoma cells 
apoptosis [196].  
Since the cytosolic ROS may not play major role in hypoxia induced cell damages (as 
described in section 3.4.2), it is not surprised to observe the lack of effect of TIIA and CT in 
intracellular ROS and NADPH oxidase activity.  
The important finding in this study is that the mitochondria superoxide generation was 
increased by hypoxia. This increase was significantly inhibited by TIIA and CT treatments, 
indicating that mitochondrial ROS plays major role in cell damage induced hypoxia.  
Interestingly, NO synthase inhibitor L-NAME also significantly inhibited mitochondrial 
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superoxide generation, which suggests endogenous NO may regulate the ROS production in 
hypoxia condition. It is possible that ROS may be generated from mitochondrial nitric oxide 
synthases which may be uncoupled under hypoxia condition [199]. The observation of 
increase in mitochondrial superoxide dismutase activity by TIIA and CT is consistent with 
previous studies on changes of NO and SOD activity in H2O2 induced cell injury and 
inflammation induced cell death in endothelial cells [118, 124].  
As a consequence of excess NO generation and mitochondrial superoxide generation in 
chronic hypoxia, intracellular peroxinitrite/hydrogen peroxide level was significantly 
increased as shown by DCF-DH fluorescence assay. TIIA and CT showed significant effects 
on decreasing NO and mitochondrial superoxide levels, but they did not show significant 
reduction in peroxinitrite/hydrogen peroxide levels (labelled with DCF-DH probe). Previous 
studies using the same DCF-DH probe found that TIIA significantly inhibited ROS 
generation induced by doxorubicin [112, 151]. However, it is not clear if the ROS in those 
studies are peroxinitrite/hydrogen peroxide specific as no specific inhibitors were used to 
validate the species of ROS observed. One possible explanation is that ROS labelled with 
DCF-DH may mainly be peroxinitrite as specific peroxinitrite inhibitor MnTBAP markedly 
reduced ROS generation (about 70%), while TIIA and CT may have a capacity to direct ROS 
production toward hydrogen peroxide, as both compounds showed no effects on 
peroxinitrite/hydrogen peroxide production, even they significantly reduced NO and 
superoxide productions which result in less formation of peroxinitrite. Partial supporting 
evidence is that TIIA and CT increased mitochondrial SOD activity, which may result in 
increase in hydrogen peroxide formation. Further study is required to confirm this hypothesis. 
The effects of tanshinones on other antioxidant enzymes such as glutathione peroxidase and 
catalyse was not examined in this study which also requires further investigation.  
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5.4.4 Effects of TIIA and CT on intracellular NO and calcium level  
Previous studies have shown the vasodilator action of TIIA and CT by regulating NO 
production in endothelial cells [117, 123, 147]. In the present study, tanshinones reduced NO 
production and increased eNOS/Hsp90 proteins expression indicating that NO decrease is not 
due to reduction of eNOS/Hsp90 proteins expression. Further study is necessary to 
investigate if tanshinones can affect other mechanism of NO synthesis such as L-arginine 
uptake (substrate of eNOS), activity of eNOS and the actions of other cofactor of eNOS such 
as BH4.  
 
The finding of inhibition of intracellular calcium by TIIA and CT in the present study is 
consistent with previous report in neonatal cardiomyocytes and rat coronary artery [117, 125]. 
Increased intracellular calcium level is likely due to ATP depletion during hypoxia as 
described in Section 1.6.3.  Thus, it is possible that TIIA may regulate intracellular calcium 
through affecting ATP level (see below). However, CT reduced intracellular calcium without 
affecting ATP levels. This suggests that other mechanisms such as endoplasmic reticulum 
related stress [200] may also be involved.  
The increase of ATP level by TIIA may be related to mitochondrial electron transport chain 
(ETC) function as ATP is majorly generated by oxidative phosphorylation, a process 
translocation of protons by complex I/III/IV and subsequently uptake of the protons by ATP 
synthase accompanying the synthesis of ATP, in mitochondria ETC [92]. 
The finding of higher concentration of CT (3 µM) was less effective in restoring cellular ATP 
contents is consistent with a previous study showing this concentration of CT (but not 0.3 µM 
CT) enhanced AMP-activated protein kinase (AMPK), which is associated with energy 
homeostasis, mitochondrial function and cell survival, as a result of intracellular ATP 
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depletion [201-202]. It will be interesting to investigate further the effects of tanshinones on 
AMPK activity in chronic hypoxia condition. 
In summary, the findings from these series of experiments indicate that TIIA and CT protect 
H9c2 cells against chronic hypoxia-induced apoptosis by targeting mitochondrial death 
pathway via reducing HIF-1α expression, balancing in anti- and pro-apoptotic proteins in 
Bcl-2 family proteins and inhibition of mitochondria membrane hyperpolarisation, 
cytochrome c translocation and caspase 3 activity. Moreover, TIIA and CT are also able to 
prevent H9c2 cells damages by reducing excess production of mitochondrial superoxide, 
NO, intracellular calcium level, and restoring ATP generation. These molecular mechanisms 
may be involved in the cardioprotective actions of TIIA and CT.  
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6 Chapter 5 EFFECTS OF COMPOUND 
1 ON CHRONIC HYPOXIA INDUCED 
APOPTOSIS IN H9C2 CELLS 
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6.1 Introduction 
Understanding mechanisms of actions of tanshinones (as described in Chapter 4) may help to 
screening and developing new agents for treating ischemia/hypoxia-induced injury. In this 
regard, it will be interesting to test new compounds using the hypoxia cell model established. 
 Compound 1(Com1) is a newly synthesized analog of TIIA (Structure not shown due to IP 
reason). Its pharmacological effects have not yet been investigated. Therefore, the aim of 
studies as described in this chapter is to investigate the effects of Com1 on chronic hypoxia 
induced cell apoptosis and its actions on mitochondrial death pathway, as well as ROS, NO 
and calcium mechanisms.   
 
6.2 Methods 
See Chapter 2. 
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6.3 Results 
6.3.1  Cell viability 
Cells were incubated with Com1 (concentration 0.01 μM to 10 μΜ) for 24 hr after 2 days 
culture. Com1 increased cell viability in all concentration (Figure 5.1). 
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Figure 6.1 Effects of Com1 on cell viability in H9c2 cells. Concentration of Compound 1 
(0.01 μM to 10 μΜ) were added and incubated for 24 hr. Cell viability was determined by 
MTT assay as described in materials and methods. The cell viability of normal control cells 
was set as 100%. Values are mean ± SE from n=4. Statistical analysis was performed using a 
One way ANOVA where significance was recorded *** P < 0.001 vs. normal. 
 
6.3.2  Effects of Com1 on HIF-1α accumulation 
Figure 5.2A shows a representative western blot of nuclear extract probed for HIF-1α and 
corresponding β-actin. Com1 (0.3 μM and 3 μM) significantly reduced HIF-1α accumulation 
by 50.3% and 97.8% compared to hypoxia group (Figure 5.2B).  
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Figure 6.2 Effects of Com1 on hypoxia induced HIF-1α accumulation in H9c2 cells.  (A) 
H9c2 cells were cultured and exposed to hypoxia for 8 hr either absence or presence of Com1 
(0.3 and 3 μM).  Nuclear fractions were prepared from cardiomyocytes after exposed to 8 hr 
hypoxia. Equal amounts (25 μg) of the lysates were used for western blot for HIF-1α 
antibody as described in materials and methods. (B) Quantitative western blot band intensity. 
The HIF-1α protein expression of normoxia control cells was set as 1. Data shown are 
representative of 4 independent experiments. Statistical analysis was performed using a One 
way ANOVA where significance was recorded # P < 0.05 vs. hypoxia, ** P < 0.01 vs. 
normoxia, ## P < 0.01 vs. hypoxia. 
Hypoxia +Treatments 
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6.3.3  Effects of Com1 on hypoxia induced cell death and LHD release 
Figure 5.3 shows quantitative results of cell viability. Com1 (0.3 μM and 3 μM) was 
significantly increased cell viability to 84.4 ± 3.5% and 86.0 ± 4.3%, which presenting 30.4% 
and 32.9% increase compared to hypoxia group respectively. 
Figure 5.4 presents quantitative values of LDH release. Cell treated with Com1 3 μΜ showed 
significant decrease in LHD release to 166.4 ± 14.2%, which presenting 44.7% decrease 
compared to hypoxia group.  
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Figure 6.3 Effects of Com1 on hypoxia induced cell death. After hypoxia, cell viability was 
determined by MTT assay as described in materials and methods. The cell viability of 
normoxia control cells was set as 100%. Values shown are mean ± SE from n=3. Statistical 
analysis was performed using a One way ANOVA where significance was recorded * P < 
0.05 vs. normoxia, ## P < 0.01 vs. hypoxia, *** P < 0.001 vs. normoxia.  
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Figure 6.4 Effects of Com1 on hypoxia induced LDH release. H9c2 cells were treated with 
Com1 (0.3 and 3 μM) for 2 hr before and during hypoxia. After hypoxia, cell media collected 
to measured LDH release content by colorimetric assay as described in materials and 
methods. The percentage of LDH release of normoxia control cells was set as 100%. The data 
shown are representative of mean ± SEM from n=3. Statistical analysis was performed using 
a One way ANOVA where significance was recorded ## P < 0.01 vs. hypoxia, *** P < 0.001 
vs. normoxia. 
 
6.3.4  Effects of Com1 on apoptosis and necrosis 
Figure 5.6A shows cells images stained with Hochest33342, YO-PRO1 and PI as well as 
analysed images. Hypoxia induced decrease in cell viability was significantly increased by 
Com1 (0.3 and 3 μM) (Figure 5.5B). Com1 (0.3 and 3 μM) treatments also significantly 
reduced late apoptosis rate to 6.33 ± 2.00% and 7.37 ± 1.89%, which presenting 76.1% and 
69.3% reduction compared to hypoxia group respectively (Figure 5.5D). No significant 
change was observed in the early apoptosis or necrosis rate in all drug treated groups (Figure. 
5.5 C and 5.5E. 
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A. Morphological changes in hypoxia induced H9c2 cells 
                       Hochest33342               YO-PRO-1                    PI                        Analysed 
 Normoxia     
   Hypoxia        
   CsA 0.1    
Com1 0.3               
   Com1 3     
 
  
- 151 - 
 
V
ia
b
le
 (
%
)
(p
er
c
en
ta
g
e 
o
f 
to
ta
l 
c
el
ls
)
N
or
m
ox
ia
H
yp
ox
ia M
C
sA
 0
.1
 
M
C
om
1 
0.
3 
M
C
om
1 
3 
0
20
40
60
80
100
***
### ######
B.
Hypoxia + treatments
    
E
ar
ly
 a
p
o
p
to
si
s 
(%
)
(p
er
c
en
ta
g
e 
o
f 
to
ta
l 
c
el
ls
)
N
or
m
ox
ia
H
yp
ox
ia M
C
sA
 0
.1
 
M
C
om
1 
0.
3 
M
C
om
1 
3 
0
5
10
15
20
Hypoxia + treatments
C.
 
 
L
at
e 
ap
o
p
to
si
s 
(%
)
(p
er
c
en
ta
g
e 
o
f 
to
to
al
 c
el
ls
)
N
or
m
ox
ia
H
yp
ox
ia M
C
sA
 0
.1
 
M
C
om
1 
0.
3 
M
C
om
1 
3 
0
5
10
15
20
25
30
***
### /######
Hypoxia + treatments
D.
*
 
N
ec
ro
si
s 
(%
)
 (
p
er
c
en
ta
g
e 
o
f 
to
ta
l 
c
el
ls
)
N
or
m
ox
ia
H
yp
ox
ia M
C
sA
 0
.1
 
M
C
om
1 
0.
3 
M
C
om
1 
3 
0.0
0.2
0.4
0.6
0.8
1.0
Hypoxia + treatments
E.
 
 
Figure 6.5 Effects of Com1 and cyclosporin A on hypoxia induced apoptosis. (A) Cell 
images stained with Hoechst 33342(HC), YO-PRO-1 and PI as described in method with 
analysed images. The analysed images show viable (green), early apoptosis (blue), late 
apoptosis (pink) and necrosis (red) cells respectively. (B-E) Mean data show subpopulations 
of viable cells (HC+), early apoptotic cells (HC+ and YO-PRO-1+), late apoptotic cells 
(HC+, YO-PRO-1+, PI+) and necrotic cells (HC+ and PI+) respectively. The percentage of 
viable, early, late apoptosis and necrosis was calculated as a percentage of total cells. Data 
are representative of five independent experiments. Statistical analysis was performed using a 
One way ANOVA where significance was recorded * P < 0.05 vs. normoxia, *** P < 0.001 
vs. normoxia, ### P < 0.001 vs. hypoxia. 
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6.3.5  Effects of Com1 on caspase 3 activity 
Figure 5.6 shows the quantitative values of caspase 3 activity. Com1 (0.3 and 3 μM) 
significantly reduced caspase 3 activity by 95.8% and 97.4% compared to hypoxia group. 
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Figure 6.6 Effects of Com1 and a caspase 3 inhibitor (Ac-DEVD-CHO (20 μΜ)) in hypoxia 
induced caspase 3 activation. Changes of caspase 3 activity were determined by colorimetric 
method as described in method. The values of caspase 3 activity of normoxia cells were set as 
1. Values are mean ± SE from n=4. Statistical analysis was performed using a One way 
ANOVA where significance was recorded ** P < 0.01 vs. normoxia, ## P < 0.01 vs. hypoxia, 
*** P < 0.001 vs. normoxia, ### P < 0.001 vs. hypoxia. 
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6.3.6  Effects of Com1 on mitochondrial membrane potential 
Hypoxia induced hyperpolarization was significantly reduced when cells were treated with 
Com1 (0.3 and 3 μM) by 52.2% and 97.8% respectively. The mitochondrial membrane 
potential in the presence of 3 μM Com1 was similar to normoxia control.  
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Figure 6.7 Effects of Com1 and CsA on mitochondria membrane potential.  H9c2 cells were 
treated with 0.1 μM CsA (Cyclosporin A: inhibitor of MPTP opening) for 1 hr before 
hypoxia and treated with Com1 for 2 hr before and during hypoxia. After hypoxia, cells were 
loaded with 150 nM TMRM probe and measured changes in fluorescence intensity as 
described in materials and methods. The quantitative results are from fluorescence intensity 
over cell number. Data are representative of three independent experiments. Statistical 
analysis was performed using a One way ANOVA where significance was recorded ** P < 
0.01 vs. normoxia, *** P < 0.001 vs. normoxia, ### P < 0.001 vs. hypoxia. 
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6.3.7  Effects of Com1 on cytochrome c translocation 
Figure 5.8A illustrates image of three combined fluorescence probes, MitoTracker (for 
mitochondria localization: red), cytochrome c (green) and DAPI (for viable cell staining: 
blue). The hypoxia induced cytochrome c translocation was significantly inhibited by Com1 
(0.3 and 3 μM) groups by 84.0% and 102.1% respectively (Figure 5.8B). 
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Figure 6.8 Effects of Com1 and CsA on hypoxia induced cytochrome c translocation. H9c2 
cells were treated with 0.1 μM CsA for 1 hr before hypoxia and treated with Com1 for 2 hr 
before and during hypoxia.  After hypoxia, cells were stained and visualised as described in 
materials and methods. (A) Cell images illustrate cytochrome c (green) and MitoTracker (for 
mitochondria localization, red) and DAPI (for viable cell staining, blue). Cytochrome c 
translocation in cytosolic was distinguished by diffused cytochrome c (green) staining as 
results of mitochondrial integrity loss. (B) Mean data from 500 cells per group in 3 
independent experiments. Statistical analysis was performed using a One way ANOVA 
where significance was recorded * P < 0.05 vs. normoxia, # P < 0.05 vs. hypoxia, ### P < 
0.001 vs. hypoxia. 
 
6.3.8  Effects of Com1 in Bcl-2 proteins expression  
6.3.8.1 Anti-apoptosis proteins  
Figure 5.9A shows a representative western blot of whole cell extract probed for Bcl-2 and 
corresponding β-actin. Com1 (0.3 and 3 μM) significantly increased Bcl-2 protein expression 
by 75.0% and 131.9 % compared to hypoxia group respectively. In fact, the protein 
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expression in Com1 treated groups (0.3 and 3 μM) was significantly higher than that of 
normoxia control (Figure 5.9B).  
Figure 5.10A shows a representative western blot of whole cell extract probed for Bcl-xl and 
corresponding β-actin. Com1 treatment did not significantly affect in Bcl-xl protein 
expression compared to hypoxia group (p > 0.05) (Figure 5.10B).   
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Figure 6.9 Effects of Com1 on Bcl-2 protein expression in hypoxia cells. After 8 hr hypoxia, 
whole cell lysate isolated and used for western blot as described in materials and methods. 
(A) Protein (50 μg) was loaded to evaluate Bcl-2 protein expression. (B) Quantitative western 
blot band intensity. The Bcl-2 protein expression of normoxia control cells was set as 1. Data 
shown are representative of 4 independent experiments. Statistical analysis was performed 
using a One way ANOVA where significance was recorded Δ P < 0.05 vs. Com1 0.3 μM, ** 
P < 0.01 vs. normoxia, *** P < 0.001 vs. normoxia, ### P < 0.001 vs. hypoxia. 
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Figure 6.10 Effects of Com1 on Bcl-xl protein expression in hypoxia cells. After 8 hr 
hypoxia, whole cell lysate isolated and used for western blot as described in materials and 
methods. (A) Protein (20 μg) was loaded to evaluate Bcl-xl protein expression. (B) 
Quantitative western blot band intensity. The Bcl-x protein expression of normoxia control 
cells was set as 1. Data shown are representative of 4 independent experiments. Statistical 
analysis was performed using a One way ANOVA.  
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6.3.8.2 Pro-apoptotic proteins 
Figure 5.11A shows a representative western blot of whole cell extract probed for Bak and 
corresponding β-actin. 0.3 μM Com1 treatment significantly decreased the Bak protein 
activation by 61.7% compared to hypoxia group, but the protein expression in 3 μM Com1 
treated group did not show significant difference compared to hypoxia group (Figure 5.11B) 
Fig 5.12A shows a representative western blot of whole cell extract probed for Bax and 
corresponding β-actin. Com1 (0.3 μM and 3 μM) groups significantly attenuated Bax protein 
expression by 105.0% and 97.1% compared to hypoxia group respectively (Figure 5.12B).  
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Figure 6.11 Effects of Com1 on Bak protein expression in hypoxia cells. After 8 hr hypoxia, 
whole cell lysate isolated and used for western blot as described in materials and methods. 
(A) Protein (80 μg) was loaded to test Bak protein expression. (B) Quantitative western blot 
band intensity. The Bak protein expression of normoxia control cells was set as 1. Data 
shown are representative of 5 independent experiments. Statistical analysis was performed 
using a One way ANOVA where significance was recorded # P < 0.05 vs. hypoxia, ** P < 
0.01 vs. normoxia, *** P < 0.001 vs. normoxia. 
.  
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Figure 6.12 Effects of Com1 on Bax protein expression in hypoxia cells. After 8 hr hypoxia, 
whole cell lysate isolated and used for western blot as described in materials and methods. 
(A) Protein (80 μg) was loaded to test Bax protein levels. (B) Quantitative western blot band 
intensity. The Bax protein expression of normoxia control cells was set as 1. Data shown are 
representative of 4 independent experiments. Statistical analysis was performed using a One 
way ANOVA where significance was recorded ** P < 0.01 vs. normoxia, ## P < 0.01 vs. 
hypoxia. 
 
  
Hypoxia+Treatments 
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6.3.8.3 Bax/Bcl-2 ratio 
Com1 (0.3 μM and 3 μM) treatments significantly decreased Bax/Bcl-2 ratio by 116.8% and 
123.6 % compared to hypoxia group respectively (Figure 5.13).  
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Figure 6.13 Effects of Com1 on hypoxia induced increase in Bax/Bcl-2 proteins ratio. The 
Bax/Bcl-2 ratio of normoxia control cells was set as 1. Data shown are representative of 4 
independent experiments. Statistical analysis was performed using a One way ANOVA 
where significance was recorded *** P<0.001 vs. normoxia, ### P < 0.001 vs. hypoxia. 
 
6.3.9  Effects of Com1 on cytosolic ROS production  
6.3.9.1 NADPH oxidase activity 
3 μM Com1 decreased NADPH oxidase activity to 5969.6 ± 2527.1 RLU, presenting 47.6% 
decrease compared normoxia group. The level of NADPH oxidase activity in 3 μΜ Com1 did 
not show statistical difference compared to hypoxia group. 
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Figure 6.14 Effects of Com1 on hypoxia induced decrease in cytosolic NADPH oxidase 
activity. H9c2 cells were incubated with 5 μΜ DPI for 1 hr before hypoxia and treated with 
Com1 for 2 hr before and during hypoxia. After 8 hr hypoxia, whole cell lysates were 
collected to measure NADPH oxidase activity by chemiluminoscence assay as described in 
materials and methods. Diphenyliodonium (DPI, 5 μΜ) was used as an inhibitor of NADPH 
oxidase. Data shown are representative of 4 independent experiments. Statistical analysis was 
performed using a One way ANOVA where significance was recorded * P < 0.05 vs. 
normoxia, ** P < 0.01 vs. normoxia. 
 
6.3.9.2  Cytosolic superoxide production and SOD activity 
Figure 5.15 presents the quantitative mean values of DHE fluorescence intensity.  Com1 (0.3 
μM and 3 μM) significantly decreased cytosolic superoxide production to 154.4 ± 71.5 a.u 
and 143.7 ± 42.4 a.u, presenting 36.6% and 39.8% reduction compared to normoxia group.  
The levels of cytosolic superoxide production in Com1 (0.3 μM and 3 μM) did not show 
statistical difference compared to hypoxia group. 
Figure 5.16 shows the quantitative values of cytosolic SOD activity. Com1 treatments did not 
show statistical difference compared to hypoxia (p > 0.05). 
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Figure 6.15 Effects of Com1 on hypoxia induced decrease in intracellular superoxide 
production. H9c2 cells were incubated with DPI (5 μΜ) for 1 hr before hypoxia and with 
Com1 (0.3 μM and 3 μM) for 2 hr before and during hypoxia. Then cells were labelled with 
DHE and visualised as described in materials and methods. The quantified value of 
fluorescence intensity were calculated per image and averaged. Data shown are representative 
of 4 independent experiments. Statistical analysis was performed using a One way ANOVA 
where significance was recorded* P < 0.05 vs. normoxia, ** P < 0.01 vs. normoxia, *** P < 
0.001 vs. normoxia. 
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Figure 6.16 Effects of Com1 on cytosolic SOD enzyme activity in hypoxia cells. Com1 
treated 2 hr before and during hypoxia. Cytosolic fractions were lysated and 20 μg of proteins 
was used to determine colorimetric SOD activity as described in materials and methods. Data 
shown are representative of 4 independent experiments. Statistical analysis was performed 
using a One way ANOVA. 
 
6.3.10 Effects of Com1 on hydrogen peroxide/peroxinitrite production  
3 μM Com1 significantly inhibited the H2O2/ONOO
-
 production to 7.6 ± 0.8 a.u/mg protein, 
presenting 66.3% compared to hypoxia group (Figure 5.17).  
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Figure 6.17 Effects of Com1 on hypoxia induced increase in ONOO- and H2O2 production. 
Cells were 1 hr pre-treated with 1 μM MnTBAP (ONOO- inhibitor but not nitric oxide), 10 
μM rotenone (Complex I inhibitor) and 10 μM antimycinA (AA: Complex III inhibitor). 
Com1 (0.3 and 3 μM) were treated 2 hr before and during hypoxia. After hypoxia, H9c2 cells 
were stained with 20 μM DCFH-DA and read fluorescence intensity as described in materials 
and methods. The quantitative data shown are calculated by fluorescence intensity over 
protein amount. Data shown are representative of mean ± SEM from n=4. Statistical analysis 
was performed using a One way ANOVA where significance was recorded * P < 0.05 vs. 
normoxia, # P < 0.05 vs. hypoxia, ** P < 0.01 vs. normoxia. 
 
6.3.11 Effects of Com1 on mitochondrial ROS production 
6.3.11.1 Mitochondrial superoxide production and SOD activity 
Figure 5.18A illustrates the images of MitoSOX labelled H9c2 cells in normoxia, hypoxia, 
and Com1. In the presence of Com1 (0.3 μM and 3 μM), superoxide production was 
significantly reduced by 71.4% and 57.4% compared to hypoxia group (Figure 5.18B). 
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Figure 5.19 shows the quantitative values of mitochondrial SOD activity. Com1 (0.3 μM and 
3 μM) significantly increased the mitochondrial SOD activity to 80.0 ± 3.4% and 78.4 ± 3.5%, 
presenting 13% and 10% increase compared to hypoxia group. 
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Figure 6.18 Effects of Com1 on hypoxia induced increase in mitochondrial superoxide 
production. 1 hr before inducing hypoxia, cells were pre-treated with 10 mM TEMPOL (SOD 
mimic), 10 μM rotenone (Complex III inhibitor), and 1 mM L-NAME (Nitric oxide synthases 
inhibitor). Com1 were treated 2hr before and during hypoxia. After hypoxia, cells were 
labelled with 2 μM MitoSOX and visualised as described in materials and methods. (A) 
Images of cells labelled with MitoSOX (for mitochondrial superoxide staining), DAPI (for 
viable cells staining).  (B) The quantified value of fluorescence intensity were calculated per 
image and averaged. Represented data are mean value of 500 each cells with 4 independent 
experiments. Statistical analysis was performed using a One way ANOVA where significance 
was recorded ## P < 0.01 vs. hypoxia, ### P < 0.001 vs. hypoxia, *** P < 0.001 vs. 
normoxia. 
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Figure 6.19 Effects of Com1 on hypoxia induced decrease in mitochondrial SOD enzyme 
activity. After hypoxia, mitochondria fractions were lysated and 20 μg of proteins was used 
to determine colorimetric SOD activity as described in materials and methods. Data shown 
are representative of 4 independent experiments. Statistical analysis was performed using a 
One way ANOVA where significance was recorded * P < 0.05 vs. normoxia, # P < 0.05 vs. 
hypoxia. 
 
6.3.12 Effects of Com1 on intracellular NO production  
Figure 5.20A illustrates the DAF-2 fluorescence images of each group. Pre-treatment with 3 
μM Com1 significantly decreased the DAF-2 fluorescence intensity to 105.9 ± 20.7 a.u which 
presenting 66.9% decrease compared to hypoxia group. Additionally, cells 1 hr pre-treated 
with L-NAME (1 mM, NOS inhibitor) reduced the NO generation to approximate with 
normoxia group. 
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A. Images of intracellular nitric oxide staining with DAF-2 
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Figure 6.20 Effects of Com1 on hypoxia induced increase in intracellular nitric oxide 
production. (A) H9c2 cells were treated with 1 mM L-NAME (NO synthase inhibitor) for 1 
hr before hypoxia and treated with Com1 for 2hr before and during hypoxia. After hypoxia, 5 
μM DAF-2 were labelled and images were taken as described in materials and methods. (B) 
Quantitative fluorescence image intensity. Represented data are mean value of 500 each cells 
with 3 independent experiments. Statistical analysis was performed using a One way 
ANOVA where significance was recorded ** P < 0.01 vs. normoxia, ## P < 0.01 vs. hypoxia, 
*** P < 0.001 vs. normoxia. 
 
6.3.13  Effects of Com1 on Hsp90 and eNOS proteins expression         
Figure 5.21A shows a representative western blot of whole cell extract probed for Hsp90 and 
corresponding β-actin. Com1 did not affect on hypoxia-induced increase in Hsp90 protein 
expression (p > 0.05) (Figure 5.21B).   
Figure 5.22A shows a representative western blot of whole cell extract probed for p-eNOS 
and corresponding t-eNOS. Com1 (0.3 and 3 μM) decreased hypoxia induced increase in 
eNOS phosphorylation without statistical significance level (p > 0.05) (Figure 5.22B)   
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Figure 6.21 Effects of Com1 on Hsp90 expression in hypoxia cells. After hypoxia, whole 
cell lysate were prepared and used for western blot as described in materials and methods. 
(A) Protein (50 μg) was loaded to evaluate Hsp90 expression. (B) Quantitative western blot 
band intensity. The Hsp90 protein expression of normoxia control cells was set as 1. Data 
shown are representative of 4 independent experiments. Statistical analysis was performed 
using a One way ANOVA. 
 
 
 
 
  
Hypoxia+Treatments 
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Figure 6.22 Effects of Com1 on p-eNOS expression in hypoxia cells. After hypoxia, whole 
cell lysate were prepared and used for western blot as described in materials and methods. 
(A) Protein (50 μg) was loaded to evaluate p-eNOS and t-eNOS expression. (B) Quantitative 
western blot band intensity. The expression of the p-eNOS/ t-eNOS of normoxia control cells 
were set as 1. Data shown are representative of 4 independent experiments. Statistical 
analysis was performed using a One way ANOVA. 
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6.3.14 Effects of Com1 on intracellular calcium level 
Pre-treatment with 0.3 μM and 3 μM of Com1 significantly decreased [Ca2+]i elevation to 
107.7 ± 5.1 nM and 119.3 ± 9.2 1 nM, presenting 55.1% and 37.7 % reduction compared to 
hypoxia group respectively (Figure 5.23).  
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Figure 6.23 Effects of Com1 on hypoxia induced increase in intracellular calcium level. 
After hypoxia, H9c2 cells were loaded with 2 μM of Fura-2AM and measured fluorescence 
intensity as described in materials and methods. The data shown are calculated by equation 
described in appendix (Appendix A.3). The quantitative results are representative of mean ± 
SEM from n=4. Statistical analysis was performed using a One way ANOVA where 
significance was recorded as # P < 0.05 vs. hypoxia, ## P<0.01 vs. hypoxia, ** P < 0.0 vs. 
normoxia, *** P < 0.001 vs. normoxia. 
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6.3.15 Effects of Com1 on cellular ATP contents 
Com1(0.3 μM and 3 μΜ) significantly increased cellular ATP contents by 22.4% and 17.8% 
compared to hypoxia respectively (Figure 5.24).   
R
el
at
iv
e 
A
T
P
 l
ev
el
 (
b
y
 N
o
rm
o
x
ia
)
N
or
m
ox
ia
H
yp
ox
ia M
C
om
1 
0.
3 
M
C
om
1 
3 
0.0
0.4
0.8
1.2
*
# #
Hypoxia + Treatments
 
Figure 6.24 Effects of Com1 on hypoxia induced decrease in cellular ATP content. After 8 hr 
hypoxia, cell lysates were collected and 10 μg of protein used for ATP contents. Cellular 
ATP contents were measured by luminescence assay as described in materials and methods. 
The cellular ATP contents of normoxia control cells were set as 1. Data shown are 
representative of 5 independent experiments. Statistical analysis was performed using a One 
way ANOVA where significance was recorded * P < 0.05 vs. normoxia, # P < 0.05 vs. 
hypoxia. 
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6.4 Discussion 
The most important finding described in this chapter is the discovery of protective actions of 
Com 1 on hypoxia induced cell injury and apoptosis, which are similar to TIIA and CT (see 
Chapter 3 and 4).              
 
6.4.1  Effects of Com1 on H9c2 cells injury  
In the present study, Com 1 exhibited significant inhibition of hypoxia-induced increase in 
LDH release and cell viability, similar to TIIA and CT.  However, Com 1 differs from TIIA 
and CT in that it significantly increased the cell viability in cells under normoxia condition. 
The reason for this action of Com 1 is not clear. As mentioned in Chapter 4.4.1, the MTT cell 
viability assay is largely associated with cell glycolysis activity. It is possible that Com 1 may 
regulate cell glycolysis, thus affect the MTT assay result (or cell growth). The finding that 
Com1 enhanced the cellular ATP content in hypoxia condition seems to support this 
possibility. However, it is also noted that both TIIA and CT increased the ATP content in 
hypoxia condition without affecting cell viability under normoxia condition (Figure 4.1 and 
4.24). Thus, it is also possible that Com1 may affect the ATP content by a similar mechanism 
as TIIA and CT.   Further studies are necessary to elucidate the exact mechanism of Com 1 
on cell growth or glycolysis in normal conditions, or some unknown affect that interfere with 
the MTT assay. Nevertheless, under the hypoxia condition, it is unlikely that such action of 
Com1 play a major role in its protective action against hypoxia-induced LDH release and 
apoptosis markers, since if Com 1 only increased cell growth without affecting relevant 
mechanisms for these markers it would enhance rather than inhibit the release of LDH 
induced by hypoxia (note that the apoptosis protein expressions were determined with a 
normalization of proteins content, thus the results were less influenced by cell numbers).   
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6.4.2  Effects of Com1 on intrinsic pathway 
It is interesting to note that Com1 showed a similar effect as TIIA and CT on the hypoxia-
induced apoptosis and changes of intrinsic apoptosis markers, including inhibitions of the late 
apoptosis rate, mitochondria membrane potential, cytochrome c release, caspase 3 activity 
and balance of Bcl-2 family proteins. The prevention of mitochondrial membrane potential 
by Com1 may be associated with its inhibition of intracellular calcium levels and 
mitochondrial ROS generation, as there is a link between mitochondria membrane 
hyperpolarization and mitochondrial ROS generation [131]. Figure 5.25 illustrates a possible 
link of the actions of Com1.  
 
Figure 6.25 Potential mechanisms involved in cardioprotective actions of Com1 in hypoxia 
cells. The cardioprotective effects of Com1 may be associated with reducing mitochondrial 
ROS as results of preserving mitochondrial membrane potential in which regulated by 
intracellular calcium level. For further information on each figure please refer to Figure 5.8, 
5.18 and 5.23. 
 
A differential effect of Com1 on expressions of Bcl-2 protein was also observed in the 
present study, which is similar to that of TIIA.  As discussed in Chapter 3 (section 3.4.2), 
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overexpression of anti-apoptotic Bcl-2 protein plays an important role in cell survival under 
hypoxia condition as these proteins can inhibit cytochrome c release and subsequent 
apoptosis. In this regard, Com1 showed a more potent effect in enhancing Bcl-2 protein 
expression (which results in a lower Bax/Bcl-2 ratio) than TIIA (compare Figure 4.9 and 
Figure 5.9). This may explain the higher cell viability in Com1 treated group than TIIA 
group. On the other hand, no difference in Bax and Bak protein expressions was observed for 
Com1 and TIIA groups.  Similarly, the significant inhibition of Bak expression but not Bcl-xl 
by Com1 indicates that another protein (e.g., Mcl-1) may be involved in regulation of Bak 
protein expression under the experimental condition, as discussed in Chapter 3 (section 
3.4.2), although further work is needed to explore such possibility.   
 
It has been known that Bax protein can be activated by HIF-1α dependent p53 protein 
activation [98]. Since Com1 produced a significant inhibition of HIF-1α expression, it is 
possible that Com1 may down regulate Bax protein through increasing HIF-1α degradation 
and subsequent inactivation of its related down-stream cell death signalling, i.e. p53 and 
iNOS (see section 1.6.6).  It has been shown that HIF-1α accumulation is associated with not 
only Bcl-2 family proteins, but also high NO content in hypoxia [186]. High NO levels (over 
1 μM) can stabilize HIF-1α which in turn to cause cell damage (see section 1.6.4). In the 
present study, Com1 significantly inhibited the increase of NO by hypoxia, thus, it is possible 
that Com1 may act by inhibiting NO which leads to an inhibition of HIF-1α accumulation. 
However, it is not clear if the action of Com1 on HIF-1α accumulation is a subsequent or 
independent event of NO generation. Further study is necessary to establish the interaction or 
link between NO pathway and HIF-1α accumulation in H9C2 cells under the hypoxia 
condition. Figure 5.26 illustrate a possible link between the actions of Com1 on NO, HIF-1α 
and Bax. 
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Figure 6.26 Possible link of Com1’s effects on NO production, HIF-1α expression and Bax 
expression in hypoxia H9c2 cells. For further information on each figure please see Figure 
5.2, 5.12 and 5.20. 
 
6.4.3  Effects of Com1 on ROS production   
As demonstrated in the studies as described Chapter 3, the major source of ROS during the 
chronic hypoxia condition is mitochondria. The finding that Com1 significantly inhibited the 
mitochondria superoxide generation indicates that such action may be related to its 
cytoprotective action in a similar way to TIIA and CT as discussed in Chapter 3.  The 
inhibition of Com1 in mitochondria ROS production may be resulted from its inhibitory 
action on NO production and stimulatory action on mitochondrial SOD activity. There is no 
significant difference between inhibitory actions of Com1 and TIIA on mitochondrial 
superoxide production, although for the MnSOD activity, 0.3 μM Com1 seems less potent 
than 0.3 μM TIIA (Figure 4.19 and 5.19).  On the other hand, Com1 3 μM seems to have a 
slightly more potent action in scavenging hydrogen peroxide/peroxynitrite than TIIA (see 
Figure 4.17 and 5.17). It is not clear if Com1 affect other anti-oxidative enzymes such as 
glutathione peroxidase, or it has a better antioxidant capacity than TIIA.  Further studies are 
required to examine the anti-oxidant actions of Com1.  
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6.4.4 Effects of Com1 on intracellular NO and calcium production 
Interestingly, Com1 has a similar inhibitory action as TIIA on hypoxia induced increase in 
NO production and intracellular calcium levels. However, there is a difference. Com1 
decreased, while TIIA and CT increased, the expression of Hsp90/eNOS proteins. The down-
regulation of Hsp90/eNOS mechanism may contribute to the overall inhibition by Com1 on 
NO production, although as discussed in Chapter 4, the extent of such contribution may be 
limited. Thus, similar to TIIA, Com1 may have additional actions, such as those on NOS 
activity, NOS substrate or co-factors to regulate NO production (see 4.4.4). The increase in 
expression of Hsp90/eNOS protein by TIIA and CT may be associated PI3K/Akt cell survival 
pathway [164, 203], as studies have shown links of these proteins in hypoxia condition, thus, 
it seems that Com1 may not affect this pathway, so further study is necessary to elucidate the 
mechanism involved.  
As described earlier in section 1.6.3, ATP depletion during hypoxia can result in increased 
intracellular calcium level. Com1 may act through improving ATP levels to regulate the 
intracellular calcium level as discussed in section 4.4.4. It is possible that the reduction of 
intracellular calcium by Com1 may lead to regulation of mitochondrial calcium level, which 
results in MPTP opening. Thus, it is likely that the cytoprotective action of Com1 may 
mediate through the preventing MPTP opening as results of reduction of intracellular calcium 
level which is regulated by restored ATP contents. The increase of ATP level by Com1 may 
be related to mitochondrial electron transport chain (ETC) function as ATP is predominantly 
generated by oxidative phosphorylation as discussed in section 3.4.4 [92]. 
 In summary, the findings as described in this chapter clearly show that the synthetic 
compound Com1 has a capacity of preventing hypoxia-induced H9c2 cells apoptosis in a 
similar way to TIIA and CT, by targeting mitochondrial intrinsic pathway via reduction of 
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mitochondria membrane hyperpolarisation, balancing of anti- and pro-apoptotic proteins in 
Bcl-2 family proteins, inhibition of cytochrome c release and caspase 3 activity. It also 
regulate endogenous NO production, intracellular calcium level and mitochondrial ROS 
production. This provides the first evidence for cytoprotective action of Com1 on hypoxia 
induced cell injury and also the molecular mechanisms involved. In addition, Com1 seems to 
have a better action than TIIA in enhancing anti-apoptotic Bcl-2 protein expression and 
inhibiting hydrogen peroxide production. This indicates that Com1 may be a promising lead 
molecule for future studies on identifying new tanshinone-like agents (e.g., through studying 
series Com1 based analogues) for the development of new therapeutic drugs with a better 
(improved) efficacy and less toxicity than natural tanshinones for treating ischemia/hypoxia 
and reperfusion injury.  
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7 Chapter 6 GENERAL DISCUSSION   
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7.1 Effects of chronic hypoxia on H9c2 cells injury 
The overall objective of this thesis is to examine the molecular mechanisms of tashinones in 
protection of chronic hypoxia induced cell injury in H9c2 cells, with a particular focus on cell 
apoptosis via intrinsic pathways. 
By using a cell based hypoxia model, series experiments have been planned and conducted to 
evaluate the effects of two major tanshiones (TIIA and CT) and a synthetic compound (Com1) 
on these mechanisms.   
In general, all proposed research aims of the study have been successfully achieved. A 
number of important findings have been obtained which provide some important insights into 
the mechanism of cytoprotective actions of tanshinones in H9c2 cells.      
 
In order to achieve the specific research aims, it is fundamentally important to establish a 
proper cell model first. Based on various previous studies, H9c2 cells line was selected as this 
cell line has been shown with the same characteristics as isolated primary cardiomyocytes 
[204-205]. It provides a fast, reliable way and also relatively simple to maintain for screening 
potential compounds in further studies.  
Previous studies have established that a prolonged hypoxia exposure to cardiac cells can 
cause significant changes of cell functions (in particular the mitochondrial function) and 
stimulate intrinsic apoptotic pathway which may result in cell death (see section 1.6.1). This 
study has been focused on examination of mitochondrial mediated cell death due to its 
important role in cell apoptosis (see Chapter 1).  Based on preliminary experiments, a 8 hr 
hypoxia period was selected as the standard condition for the subsequent experiments.  The 
overall changes of mitochondrial function (in terms of mitochondria membrane potential) and 
makers for apoptosis and oxidative stress in H9c2 cells exposed to the hypoxia are 
- 184 - 
 
summarised in Table 6.1 and Figure 6.1.  The main characteristics of this hypoxia cell model 
include late apoptosis, that indicates DNA fragmentation and severe membrane damages, 
activation of intrinsic apoptosis markers (e.g. Bcl-2, Bax, caspase 3 activation and 
cytochrome c release), and increase in mitochondrial ROS, intracellular NO and calcium 
levels. The selection of this experimental condition has turned out to be a right choice as it 
exhibited the same degree of cell damage as that reported by other researchers using the same 
cell line [168, 206].   
It should be pointed out that hypoxia stimulates a significant change in cellular signalling, 
which may result in a complex interaction among various signalling molecules (see section 
1.4). For instance, HIF-1α protein is highly active in hypoxia condition. It can activate a 
number of other proteins including Bax [98]. HIF-1α is also activated by excess NO [207] 
and other factors. The observation of hypoxia-induced concurrent activations of Bax protein, 
HIF-1α and NO production in the present study highlights possibility of such interactions. 
Additionally, it has been shown that overproduction of NO can stimulate mitochondrial ROS 
production and induces cell death [208]. Such interactions may make the analysis of cause-
effect relationship difficult. It also indicates a multiple-target approach may be necessary for 
effectively protecting the cell from damages induced by ischemia/hypoxia. One way to 
identify the involvement of particular mechanisms is to use certain specific inhibitors (as in 
the present study) to serve as positive controls for particular assays.        
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Table 7.1 Summary of changes of cellular mechanisms induced by chronic hypoxia in H9c2 
cells 
 
Mechanism/Target 
Change 
HIF-1α protein expression + Figure 3.2B 
Cell viability (MTT assay) + Figure 3.1 
LDH release + Figure 3.3 
Cell apoptosis 
Early apoptosis - Figure 3.4C 
Late apoptosis + Figure 3.4D 
Necrosis - Figure 3.4E 
Caspase 3 activity + Figure 3.5 
Cytochrome c release + Figure 3.6 
Mitochondria membrane potential + Figure 3.7 
Bcl-2 
family 
proteins 
expression 
Anti 
Apoptotic 
proteins 
Bcl-2 + Figure 3.8 
Bcl-xl - Figure 3.9 
Pro 
Apoptotic 
proteins 
Bak + Figure 3.10 
Bax + Figure 3.11 
Bax/Bcl-2 ratio + Figure 3.12 
Cytosolic 
ROS 
NADPH oxidase activity + Figure 3.13 
Superoxide production + Figure 3.14 
Cytosolic SOD - Figure 3.15 
Mitochondrial 
ROS 
H2O2 and ONOO
-
 production + Figure 3.16 
Superoxide production + Figure 3.17 
Mitochondrial SOD + Figure 3.18 
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NO 
Intracellular NO production + Figure 3.19B 
eNOS expression + Figure 3.20B 
Hsp90 protein expression + Figure 3.21B 
Intracellular calcium level + Figure 3.22 
Cellular ATP contents + Figure 3.23 
       +: significant change compared to normoxia, -: no changes compared to normoxia 
  
 
 
Figure 7.1 A diagram summarizing 8 hr hypoxia induced apoptosis signalling in H9c2 cells.  
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7.2  Effects of TIIA and CT on hypoxia induced cell injury and signalling 
mechanisms in H9c2 cells  
TIIA and CT are major active compounds of Danshen. Although the pharmacological actions 
of these compounds have been extensively studied (see Chapter 1), their actions on hypoxia 
induced cell injury and signalling mechanisms in H9c2 cells are largely unknown. The 
findings from the present study, as summarised in Table 6.2 and Figure 6.2, clearly 
demonstrated that TIIA and CT significantly inhibited hypoxia induced cell injury and 
signalling mechanisms in H9c2 cells via multiple mechanisms.  
In most aspects, the actions of TIIA and CT are similar. Their cardioprotective effects are 
associated with a significant inhibition of mitochondrial death pathway. In some aspects (e.g. 
cytochrome c release), however, TIIA seems more effective than CT. However, cautions 
should be taken to explain these differences, since the CT treatment group showed no 
statistical difference compared with the normoxia control, while the hypoxia group showed a 
significant difference from the normoxia control. The relative small sample size of testing 
groups may affect the statistical analysis, thus further increasing the sample size may improve 
the statistical levels of the CT group. Another puzzling point is the lack a concentration-
dependent effect of these compounds for certain mechanisms studied. For example, TIIA and 
CT at 0.3 μM presented better effects in inhibiting ROS production than those at higher 
concentrations. It may be possible that higher concentrations of tanshinones may have other 
actions, which mask the actions of these compounds on ROS production. Further studies are 
necessary to elucidate the exact mechanisms involved. In addition, as discussed above, the 
complex interaction of cell signalling molecules induced by hypoxia may also affect the 
action of tanshinones.  This seems to be the reason for the observed lack of effect of TIIA on 
Bak protein expression (see chapter 4). The multiple actions of tanshinones on the hypoxia 
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induced cell injury and signalling mechanisms, as demonstrated in this study, may contribute 
to the cardioprotective actions of these compounds (see chapter 1). 
 
Table 7.2 Summary of the effects of TIIA and CT on hypoxia induced cell injury and   
signalling mechanisms in H9c2 cells 
Mechanism/Target 
Effect 
 
TIIA CT 
0.3 
μM 
3  
μM 
0.3 
μM 
3  
μM 
HIF-1α protein expression - + - - Figure 4.2B 
Cell viability (MTT assay) + + + + Figure 4.3B 
LDH release - + - + Figure 4.4 
Cell apoptosis Late apoptosis + + + + Figure 4.5D 
Caspase 3 activity + + + + Figure 4.6 
Cytochrome c release + + - - Figure 4.7 
Mitochondria membrane potential + + + + Figure 4.8 
Bcl-2 
family proteins 
expression 
Anti 
Apoptotic 
proteins 
Bcl-2 - + + + Figure 4.9 
Bcl-xl - + + + Figure 4.10 
Pro 
Apoptotic 
proteins 
Bak - - + - Figure 4.11 
Bax + + + + Figure 4.12 
Bax/Bcl-2 ratio + + + + Figure 4.13 
Cytosolic 
ROS 
NADPH oxidase activity - - - - Figure 4.14 
Superoxide production - - - - Figure 4.15 
Cytosolic SOD activity - - - - Figure 4.16 
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Mitochondrial 
ROS 
H2O2 and ONOO
-
 level - - - - Figure 4.17 
Superoxide production + + + + Figure 4.18 
Mitochondrial SOD activity +, * + +, * - Figure 4.19 
NO 
Intracellular NO production + + + + Figure 4.20 
Hsp90 protein expression -, * -, * -, * - Figure 4.21 
eNOS expression -, * -, * -, * - Figure 4.22 
Intracellular Calcium level - + - - Figure 4.23 
Cellular ATP contents + + + - Figure 4.24 
  +: significant decrease compared to hypoxia, -: no changes compared to hypoxia 
        *: significant increase compared to normoxia 
 
 
 
 
Figure 7.2 A diagram summarizing the mechanisms involved in the cytoprotective effects of 
TIIA and CT against chronic hypoxia in H9c2 cells  
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7.3  Effects of Com1 on hypoxia induced cell injury and signalling 
mechanisms in H9c2 cells 
One of the interesting findings of the present study is the discovery of cytoprotective actions 
of Com1, a synthetic analogue of TIIA.  As discussed in Chapter 5, Com1 showed a similar 
action as TIIA and CT in inhibiting chronic hypoxia induced cell injury and apoptosis by 
regulating signalling mechanisms in intrinsic pathways in H9c2 cells, as summarised in Table 
6.3 and Figure 6.3.    
There are some differences between the actions of Com1 and TIIA. Firstly, Com1 seems to 
have a better capacity in protection of hypoxia-induced cell injury. For example, Com1 
showed a 1.3 fold higher action than TIIA in improving Bcl-2 protein expressions. The over 
expression of Bcl-2 protein has been highly associated with preventing cell death by 
inhibiting cytochrome c release [177]. Secondly, Com1 significantly inhibited the 
mitochondrial derived hydrogen peroxide/peroxinitrite production, while TIIA did not 
showed such effect. This suggests that Com1 may be a better antioxidant than TIIA. Such 
actions of Com1 make it potentially useful for further research to study Com1 based 
analogues to identify more portent agent than natural tanshinones to target the intrinsic 
pathway and oxidative stress mechanisms.  
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Table 7.3 Summary of the effects of Com1 on hypoxia induced cell injury and signalling 
mechanisms in H9c2 cells 
Mechanism/Target 
Effect 
 Com1 
0.3 μM 3 μM 
HIF-1α protein expression + + Figure 5.2B 
Cell viability (MTT assay) + + Figure 5.3B 
LDH release - + Figure 5.4 
Cell apoptosis Late apoptosis + + Figure 5.5D 
Caspase 3 activity + + Figure 5.6 
Membrane potential + + Figure 5.7 
Cytochrome c release + + Figure 5.8 
Bcl-2 
family proteins 
expression 
Anti 
Apoptotic 
proteins 
Bcl-2 +, * +, * Figure 5.9 
Bcl-xl - - Figure 5.10 
Pro 
Apoptotic 
proteins 
Bak + - Figure 5.11 
Bax + + Figure 5.12 
Bax/Bcl-2 ratio + + Figure 5.13 
Cytosolic  
ROS 
NADPH oxidase activity - - Figure 5.14 
Superoxide production - - Figure 5.16B 
Cytosolic SOD activity - - Figure 5.17 
Mitochondrial 
ROS 
H2O2 and ONOO
-
 levels - + Figure 5.18 
Superoxide production + + Figure 5.19B 
Mitochondrial SOD activity + + Figure 5.20 
NO Intracellular NO production - + Figure 5.21B 
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   +: significant decrease compared to hypoxia, -: no changes compared to hypoxia 
   *: significant increase compared to normoxia 
 
 
 
Figure 7.3 A diagram summarizing the mechanisms involved in the cytoprotective effects of 
Com1 against chronic hypoxia. (Pink box represent stronger effects in Com1 than TIIA) 
  
Hsp90 protein expression - - Figure 5.22B 
eNOS expression - - Figure 5.23B 
Intracellular Calcium level + + Figure 5.24 
Cellular ATP contents + - Figure 5.25 
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In summary, H9c2 cells under chronic hypoxia showed significant cell injury and apoptosis 
which are marked by change of mitochondria function, activation of mitochondrial death 
pathway, and elevated levels of endogenous ROS, NO and intracellular calcium. The test 
compounds, TIIA, CT and Com1, all significantly inhibited the chronic hypoxia induced cell 
injury and apoptosis by regulating intrinsic pathway, including inhibition of caspase 3 
activity and promotion of the balance anti- and pro-apoptotic proteins, and reducing excess 
productions of mitochondrial superoxide and NO, inhibiting the elevation of intracellular 
calcium level, and restoring ATP generation. These findings provide strong evidence, some 
for the first time, for the mechanism of cytoprotective actions of these compounds against 
hypoxia in H9c2 cells, and also may also help to understand the  clinical application of 
tanshinones and Danshen. As mentioned in Chapter 1, ischemia reperfusion injury is an 
important mechanism for IHD, to identify and develop more effective agents to treat I/R 
injury will be important for future treatment of IHD. 
 
7.4 Limitations of the present study 
There are certain limitations of the present study. Firstly the cell model used is not a human 
cell line, thus the results obtained need to be further confirmed in human cells/tissue and in 
vivo. Secondly, the conclusion of the effects of test compounds on the relevant mechanisms 
are based on their effects at selected concentrations, the relevance of these concentrations in 
vivo is not clear and needs to be established.             
 
7.5 Future directions  
Clearly, as most other research projects, the findings obtained in this project can lead to more 
research questions and possible new directions for future research. Due to the time limit in 
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this project, only key mechanisms have been studied. Some of related mechanisms, however, 
can be further investigated in future studies, as described below.  
 
7.5.1 Upstream of HIF-1α 
HIF-1α protein is a critical transcription factor and key regulator responsible for the induction 
of genes involved in energy metabolism and vascular homeostasis that facilitate adaptation 
and survival of cell during low oxygen condition [209-210]. The action of test compounds on 
HIF-1α protein, as observed in the present study, is an important new finding. Since HIF-1α 
stabilization is an initiator of chronic hypoxia induced mitochondrial apoptosis and regulation 
of Bcl-2 family proteins, it will be interesting to identify the possible upstream targets by 
TIIA CT and Com1. In this regards, the effects of these compounds on the expression of 
upstream genes of HIF-1α such as related transcriptional enhancer factor-1 (RTEF-1) [211] 
should be studied.  In addition, the link between HIF-1α protein and other mediators such as 
NO should also be investigated.  
 
7.5.2 NO and NO synthesis 
NO is another important cell mediator and regulator. Excess NO generation in hypoxia can 
cause cell damage by interrupting mitochondrial electron transport chain, resulting in ATP 
depletion and increased oxidant stress as well as stabilizing HIF-1α protein. The source and 
level of NO is important in determination of the actions of NO.  For example, iNOS-derived 
NO is largely responsible for cell damages associated with NO. It has been shown that NO 
regulated cell apoptosis at concentrations above 1 μM, while it inhibited cytochrome c 
oxidase at nanomolar concentrations [82, 212]. Thus, further research may be directed to 
investigate the role of different isoforms of NOS (eNOS, nNOS and iNOS), including their 
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cofactors and substrate, in cell injury and apoptosis in hypoxia conditions and the effects of 
tnashinones on these mechanisms. A detailed quantitative analysis of NO production and 
studies of the effects of specific NOS inhibitors may also help to clarify the link between NO 
and apoptosis signaling mechanisms.    
 
7.5.3 Endoplasmic reticulum (ER) stress and mitochondrial dysfunction 
One finding of the present study is the elevation of intracellular calcium level induced by 
hypoxia. Previously studies have demonstrated that the main source of intracellular calcium 
is sarcoplasmic reticulum in smooth endoplasmic reticulum [158, 213], thus, impairment of 
ER mechanism in chronic hypoxia may cause a change of intracellular calcium levels. In a 
preliminary experiment, it was observed that the expression of eukaryotic initiation factor 2α 
(elf2α) protein phosphorylation was increased by hypoxia (see below). elf2α protein is 
phosphorylated by pancreatic ER kinase (PKR)-like ER kinase PERK protein as result of ER 
stress [101]. Moreover, ER stress can cause mitochondrial dysfunction by indirectly 
activating JNK, (define JNK), resulting in Bcl-2 protein inhibition [214]. Thus, further 
studies of the effects of TIIA, CT and Com1 on the expression of elf2α and other ER stress 
markers may help to understand the role of these proteins in hypoxia-induced cell injury and 
also the cytoprotective actions of tanshinones.    
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               Normoxia       Hypoxia 
p-elf2α  
 t-elf2α  
Figure 7.4 Expression of elf2α proteins (total and phosphorylated) after 8 hr hypoxia in H9c2 
cells.  Cell lysates were prepared and used for western blot. 50 μg of proteins were loaded 
and performed western blot to determine phosphorylation of elf2α protein. 
 
7.5.4 Antioxidant activity 
The effects of tanshinones on other antioxidant enzymes (e.g. glutathione peroxidase and 
catalase) have not been investigated in the present study. These enzymes could also be 
targeted by tanshinones [120, 122]. The future studies may be directed to investigate the 
effects of tanshinones and Com1 on these enzymes in hypoxia conditions, which may help to 
understand the reason for lack of effects of TIIA and CT on mitochondria-derived hydrogen 
peroxide/peroxynitrite production in hypoxia. . 
 
7.5.5 Extrinsic apoptosis pathway  
The present study has focused on the intrinsic apoptosis pathway, although there is evidence 
that the extrinsic apoptosis pathway (apoptosis mediated by tumor necrosis factor family 
receptors and Fas receptors) can also stimulate intrinsic pathway by Bid (a BH3- only protein 
in Bcl-2 family proteins) cleave by caspase-8 [50-51]. Once Bid is activated by caspase-8, it 
can be translocated into mitochondria and lead to imbalance of anti-and pro-apoptotic 
proteins, change of membrane permeability transition pore opening and apoptosis [159].  Bid 
protein can also be activated by p-53 dependent caspase 8 activation. p53 protein, can induce 
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cell death indirectly by activating Bax protein or directly by translocation to mitochondria 
[215]. Thus, further studies of the role of these proteins may help to understand the 
relationship of these pathways in hypoxia and the actions of tanshinones.   
 
7.5.6  Ischemia and reperfusion injury  
In order to establish the efficacy and mechanism of actions of tanshinones in human, further 
studies using various in vitro and in vivo animal models on ischemia reperfusion injury is 
necessary. These studies should include examinations of the effects of tanshinones and Com1 
at different dosage and treatment periods, as well as the role of particular signaling molecules 
or markers to establish possible cause-effect relationships. Ischemia and reperfusion injury 
models in animal can be used as described previously [216-217], to confirm the in vitro 
findings.  These studies should include assessment of myocardial functions and mechanistic 
investigation on mitochondrial apoptosis and oxidative stress pathways, in comparison with 
tanshinones. Especially, further study on Com1 based analogues may help to develop 
potential new therapeutic agents for treating ischemia reperfusion injury related diseases. 
In conclusion, the findings presented in this thesis provide new scientific evidence for 
molecular mechanisms of cytoprotective actions of tanshinones and related compounds. This 
evidence may be important for understanding pharmacological actions of Danshen and 
tanshinones in general. But in a broad sense, it paves the way for more research in the future.      
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A.1 Solutions 
 
A.1.1 Cell culture solutions (Chapter 2, Section 2.3) 
 1% (v/v) Penicillin-Streptomycin 
10,000 units/ml penicillin G sodium and 10,000 μg/ml streptomycin sulphate 
 
 Trypsin-EDTA solution 
2.5 g/l trypsin, 0.2 g/l EDTA•4Na, 0.85 g/l NaCl 
 
 1% (v/v) Trypsin Neutraliser or 5% (v/v) Trypsin Neutraliser 
[1% (v/v) FBS in PBS] or [5% (v/v) FBS in PBS] 
 
A.1.2  Caspase 3 activity solutions 
 Lysis buffer 
10mM HEPES, 2mM EDTA, 0.1% 3-((3-Cholamidopropyl)dimethylammonium)-1-
propanesulfonate (CHAPS), 5 mM DTT (DL-Dithiothreitol) and protease inhibitor 
cocktails) 
 
 Assay buffer 
100 mM HEPES, pH 7.4, 0.1% CHAPS, 5 mM DTT, 2 mM EDTA 
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A.1.3  Cell protein lysate preparation solutions (Chapter 2, Sections2.8.1  
and 2.8.2) 
 Lysis buffer 
150 mM NaCl, 1% Nonider P-40, 0.5% deoxycholate, 0.1% sodium dodecylsulfate, 50 
mM Tris-hydrochloric acid, 2 mM phenylmethylsulfonylfluoride, and proteinase 
inhibitor cocktail, pH 7.4 
 
 Laemmli’s sample buffer  
250 mM Tris (pH6.8), 40% (v/v) Glycerol, 5% (w/v) SDS (Sodium Dodecyl Sulfate) , 
0.1% (w/v) Bromophenol Blue and 0.1 M DTT 
 
A.1.4  Western blotting solutions (Chapter 2, Sections 2.8.4 - 2.8.5) 
 7% Running gel 
2.3 ml of 30% (v/v) Acrylamide Bis solution, 5.1 ml H2O, 2.5 ml 1.5 M Tris 
solution (pH8.8), 0.1 ml 10% (w/v) SDS, 0.050 ml 10% (w/v) Ammonium Persulfate 
and 0.005 ml TEMED 
 
 12 % Running gel 
3.4 ml of 30% (v/v) Acrylamide Bis solution, 4 ml H2O, 2.5 ml 1.5 M Tris 
solution (pH8.8), 0.1 ml 10% (w/v) SDS, 0.030 ml 10% (w/v) Ammonium Persulfate 
and 0.0042 ml TEMED 
 
 Stacking gel 
0.67 ml 30% (v/v) Acrylamide Bis solution, 3.075 ml H2O, 1.25 ml 1.5 M Tris 
solution (pH8.8), 0.025 ml 10% (w/v) SDS, 0.025 ml 10% (w/v) Ammonium 
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Persulfate and 0.0005 ml of TEMED 
 
A.1.5 NADPH oxidase assay solutions (Chapter 2, Sections 2.11.2) 
 Lysis buffer  
50 mM KH2PO4 (pH 7.0), 1 mM EGTA, 10 μg/ml aprotinin, 0.5 μg/ml leupeptin, 1 
μg/ml pepstatin and 0.5 mM PMSF  
 
 Assay buffer  
50 mM KH2PO4 (pH 7.0), 150 mM Sucrose, 100 μΜ NADPH, and 1 mM EGTA 
 
A.1.6  Intracellular calcium measurement solutions 
 ECM buffer with Calcium 
10 mM HEPES, 121 mM NaCl, 4.7 mM KCl, 1 mM CaCl2, 1.2 mM MgSO4, 5 mM 
NaHCO3, 1.2 mM KH2PO4, 10 mM glucose and 0.25% bovine serum albumin, pH 7.4 
 
 ECM buffer with EGTA 
10 mM HEPES, 121 mM NaCl, 4.7 mM KCl, 2.2 mM EGTA, 1.2 mM MgSO4, 5 mM 
NaHCO3, 1.2 mM KH2PO4, 10 mM glucose and 0.25% bovine serum albumin, pH 7.4 
 
Protein determination 
An equation of the protein standard graph was generated from the BCA and Bradford Assay 
to determine the amount of protein per sample. 
 
Example: 
Equation of protein standard graph: y = 0.0998x 
Where, y = absorbance of protein sample per well 
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x = mass of protein sample per well (μg) 
 
Calculation: 
Absorbance of protein sample per well = 0.745 
Mass of protein sample per well is, 
y = 0.0992x 
0.745 = 0.0992x 
x = 7.51 μg/ml of protein  
If the sample diluted before protein assay, dilution factor multiples by the protein. 
 
For Western blotting, Laemmli’s sample buffer is added to the protein sample in a 1:4 
dilution. For example, 1.25 μl of Laemmli’s buffer is added to a 5 μl protein sample making 
it a total volume of 6.25 μl. Allowing for Laemmli’s sample buffer this would be 7.51 μg of 
protein in 6.25 μl of sample plus buffer solution. Therefore to add 50 μg cell lysate, 41.6 μl 
of sample plus buffer solution would need to be added to a lane in a SDS PAGE gel. 
 
Intracellular calcium concentration 
Following equation was adapted to calculate calcium concentration. 
[Ca
2+
]I = Kd [(R −Rmin)/(Rmax − R)] × β 
R is the ratio at any time (340nm/380nm) 
Kd is the Ca
2+
 dissociation constant of fura-2 (Kd = 140 nM) 
Rmin is the minimum ratio in Ca
2+
 depleting conditions (addition of 40 mM EGTA) 
Rmax is the maximum ratio in Ca
2+
 saturating condition (0.1% detergent in normal bathing 
media containing approx. 1 mM Ca
2+
) 
β is the ratio of the fluorescence emission intensity at 380 nm excitation in Ca2+ depleting 
and Ca
2+
 saturating conditions 
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Example: 
Absorbance 
after 1hr incubation 
Absorbance with  
0.2% Triton X-100 
Absorbance with 
40 mM EGTA 
340nm 380nm 340nm 380nm 340nm 380nm 
74.015  33.145 
 
110.418 6.111 51.849 46.015 
  
  Calculation: 
   R = (74.015/33.145) = 2.23 
  Rmax = (110.418/6.111) = 18.1 
  Rmin = (51.849/46.015) = 1.13 
β = (46.015/6.111) = 7.52         
[Ca
2+
]I = 224nM [(2.23 −1.13)/(18.1 – 2.23)] × 7.52 
Intracellular calcium concentration is 117.8 nM 
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